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Soft tissue sarcomas:  
long-term aspects of combined modality treatment 
 
Introduction and aim of the study 
Soft tissue sarcomas are aggressive tumors that arise from mesenchymal tissues. The 
incidence is low and accounts for 3.6 per 100,000 per annum.
1 Mortality, on the other hand, is 
high; the average five-year survival rate is only 60%.
2,3 Although fewer than 1% of the 
malignant tumors in adults are soft tissue sarcomas, they are nevertheless responsible for 2% 
of all deaths caused by cancer.
1 The prognosis of poorly differentiated soft tissue sarcomas is 
in particular caused by frequent hematogenic metastases (30-40%) and not so much by 
locoregional recurrence (10-15%).
3 
In the past three decades, the combined modality treatment of soft tissue sarcomas has 
advanced considerably. Although surgery is the cornerstone of the sarcoma treatment, there is 
overwhelming evidence supporting adjuvant radiotherapy after narrow surgical excision of 
the tumor. On the other hand, there is no indication for (neo) adjuvant chemotherapy after 
surgical treatment of soft tissue sarcomas, with the exception of rhabdomyosarcoma, 
extraosseous Ewing’s sarcoma / primitive neuroectodermal tumor (PNET), and extraosseous 
osteosarcoma.
3 Combined treatments have mainly contributed to improved locoregional 
tumor control and only to a lesser degree to survival. Conversely, the ‘aggressive’ surgical 
approach in the treatment of metastasized tumors has contributed to improved disease-free 
and overall survival.
3 
Surgery is the ‘central discipline’ in the multimodality treatment of the disease – which 
involves various disciplines including pathology, radiotherapy, medical oncology, 
rehabilitation medicine, genetics, and psychology. 
Isolated limb perfusion (ILP) is a technique introduced in 1958 by Creech and colleagues.
4 
Their aim with this regional cancer treatment was the local administration of a cytostatic 
agent at the highest dosage without introducing systemic side effects. The extracorporeal 
circulation system used was similar to the one employed in open heart surgery. The technique 
was first applied to patients with in-transit metastases of melanoma of the lower extremities 
who refused amputation. The cytostatic agent administered was melphalan. In 1961, the 
technique of isolated limb perfusion was introduced in the Netherlands by Zwaveling in 
Leiden. In 1964, Oldhoff and Schraffordt Koops successfully initiated the Groningen 
perfusion program in the Algemeen Provinciaal Stads en Academisch Ziekenhuis (APSAZ).
5 Introduction and aim of the thesis 
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The cancer centers in Rotterdam and Amsterdam soon followed. Hyperthermia was 
introduced in 1967 in the perfusion treatment by Cavalière.
6 At present, mild hyperthermia 
(39-40 °C) is widely used, since this causes less local toxicity than higher temperatures.
7 As 
the search for the optimum perfusion technique continued, other cytostatics such as 
dacarbazine (DTIC), adriamycin and cisplatinum were studied, but melphalan remained the 
most used and effective drug.
8 The early 1990s witnessed a breakthrough in this regional 
cancer treatment, when Lejeune and colleagues added Tumor Necrosis Factor alpha (TNFα) 
to melphalan as a perfusion agent in the isolated regional perfusion for locoregional advanced 
soft tissue sarcomas and melanomas.
9,10 This resulted in a high local response rate with 
acceptable locoregional and systemic toxicity and a high percentage of limb salvage. The 
results of the first multicenter trial of limb perfusion in the limb saving treatment of primarily 
irresectable soft tissue sarcomas of the extremities were reported in 1996. Medical centers in 
Lausanne, Amsterdam, Rotterdam, Berlin, Brussels, Tel Aviv, and Groningen participated in 
this trial. Use was made of a high dose of TNFα (3 or 4 mg) in combination with interferon 
gamma and melphalan. The technique allowed the salvage of the affected extremity in 84% of 
the cases.
10 The perfused tumors were extremely large, 20 cm on average. Resection was 
performed several weeks post perfusion. In 87% of the cases, a major tumor response was 
documented. It was then clear that ILP in combination with TNFα , interferon gamma and 
melphalan was safe and highly effective, and constituted a breakthrough in the treatment of 
locally advanced soft tissue sarcomas of the extremities. 
Another aspect of the multimodality treatment is radiotherapy. In the early 1980s, Rosenberg 
was the first to show the value of adjuvant radiotherapy in the limb-saving treatment of 
sarcomas.
11 Yang and colleagues updated the study several years later, with a median follow-
up of almost ten years. They found a significant decrease in locoregional recurrence after 
radiation, without affecting survival.
12 Unfortunately, adjuvant radiation in combination with 
surgery also has side effects, for instance greater stiffness and increased edema of the 
involved extremity.  
Locally advanced soft tissue sarcomas of the extremities can be treated with isolated regional 
limb perfusion with high doses of cytostatics, followed by tumor resection, as outlined before. 
In general, these tumors can only be resected marginally. Adjuvant local radiotherapy might 
be indicated to increase the local tumor control rate.
13  
Radiation can also induce sarcomas, which are then called radiation-induced sarcomas. 
Radiation-induced sarcomas are biologically aggressive tumors.
14 These arise from a previous 
radiation site, usually after a period of around 10 years. In the past radiation was sometimes Chapter 1 
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used in the treatment of ‘benign’ tumors, but radiation sarcoma can also occur after 
radiotherapy for malignant tumors.  
To what extent will a second primary tumor develop in patients treated for a sarcoma? A 
second primary tumor may develop both before and after the onset of the sarcoma. To what 
extent do other primary tumors affect the prognosis of primary non-resectable soft tissue 
sarcomas of the extremities that are being treated with isolated regional perfusion? 
The limb-saving treatment of a ‘primarily’ non-resectable soft tissue sarcoma with isolated 
limb perfusion followed by delayed surgical resection and adjuvant radiation is highly 
intensive and may last for several months. What influence does such an intensive treatment 
have on the patient’s quality of life? 
The aim of this thesis is to gain insight into the various long-term aspects of the combined 
modality treatment of patients with sarcomas that emphasizes isolated limb perfusion, surgical 
resection and radiation therapy. 
 
The aims of the thesis: 
-  Treatment options for radiation-induced sarcoma: what are the challenges in the 
treatment? 
-  What is the role of surgery in the multidisciplinary treatment of soft tissue sarcoma? 
-  During which periods, and through what causes, are patients at risk of losing an extremity 
with a locally advanced soft tissue sarcoma treated with isolated limb perfusion, surgery 
and radiotherapy? 
-  Is adjuvant radiotherapy indicated after isolated limb perfusion and resection for patients 
with a primarily irresectable soft tissue sarcoma in an extremity? 
-  What are the potentials of biological imaging in the prediction of long-term outcome of 
patients with a soft tissue sarcoma of the extremity treated with isolated limb perfusion? 
-  Do STS perfusion survivors differ from the general population in terms of quality of life 
and do post-traumatic stress symptoms occur that should be taken into account in the 
longer term? 
-  Is the incidence of other primary tumors increased in patients with locally advanced soft 
tissue sarcoma of the extremities and does this affect long-term survival? 
 Introduction and aim of the thesis 
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Abstract 
Background: Treatment of a radiation-induced sarcoma (RIS) remains an unsolved problem. 
To provide more insight into the disease process, its characteristics, outcome, and potential 
outcome determinants were defined. 
Methods: Between 1978 and 2003, 27 patients - 20 females (74%) and seven males (26%) 
with a median age 44 years (range, 1-73 years) at the time of diagnosis of the primary -
developed an RIS after a median interval of 8 years (range, 3-41 years). The histology of the 
RIS was 10 (37%) undifferentiated high-grade pleomorphic sarcomas, 7 (26%) 
angiosarcomas, 6 (22%) fibrosarcomas, 2 (7%) osteosarcomas, 1 (4%) pleomorphic 
rhabdomyosarcoma, and 1 (4%) pleomorphic leiomyosarcoma. Surgical resection was 
performed in 21 patients: 13 (62%) R0 (microscopically radical), 4 (19%) R1 
(microscopically irradical), 2 (9.5%) R2 (macroscopically irradical), and 2 (9.5%) RX 
(unknown radicality). Six (22%) patients underwent no resection. 
Results: The 5-year disease-free survival and overall survival rates were 27% and 30 %, 
respectively. The local failure rate after R0 resection was 54%. The distant failure rate for the 
entire group was 41%. Patients with an R0 resection had a significantly better survival rate 
(P<0.05) than patients with an R1, R2, or no resection. 
Conclusions: RISs are aggressive malignancies with a high tendency for local recurrence and 
distant metastases. Previously applied treatment often hampers adequate resection. Therefore, 
radical surgical resection is the only chance to improve disease-free and overall survival, but 
it may also have a palliative role. Still, the overall prognosis remains poor.  Radiation-induced sarcoma 
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Introduction 
In The Netherlands, 69,000 new cases of cancer are diagnosed yearly, and 38,000 patients die 
from their malignancy.
1 The incidence of solid tumors is still increasing. Disease-free (DFS) 
and overall survival (OS) are increasing because of (1) progress in better preoperative staging 
by various imaging techniques, such as spiral computed tomography (CT), magnetic 
resonance imaging (MRI), ultrasound, and positron emission tomography, and (2) appropriate 
surgery in combination with adjuvant therapies such as chemotherapy, radiotherapy, and 
hormonal therapy. Therefore, cancer may now be viewed as a "chronic disease". 
Because more cancer patients survive, there is an increased risk of a new malignancy or a 
secondary treatment-induced malignancy. The number of patients with a second malignancy 
reaches 10% in The Netherlands.
1 Types of treatment-induced malignancies may be 
distinguished between chemotherapy-induced and radiation-induced malignancies. 
Surgical experience with radiation induced sarcoma (RIS) is limited, and the results of 
treatment of RIS are discouraging. With improved preoperative imaging techniques, 
including CT and MRI, and the increased experience in sarcoma surgery, along with plastic 
surgical reconstructions, more radical surgical operations are now possible. Whether this 
aggressive surgical approach has influenced the oncological outcome is yet to be determined. 
Therefore, a retrospective study and review of the literature was performed to investigate the 
short- and long-term outcome of surgical treatment of RIS. 
 
Patients and methods 
From 1978 to 2003, 27 patients - 20 females (74%) and 7 males (26%) with a median age 52 
years (range, 20-83 years) - were diagnosed with RIS at the Groningen University Medical 
Centre. Patient records were retrieved from the sarcoma database of the Division of Surgical 
Oncology. To fill the required criteria, all patients must have received previous radiotherapy 
for a malignant or benign disease. The criteria required to fulfill the definition of RIS were: 
(1) different histopathologic features between primary lesion (i.e., the indication for initial 
radiotherapy) and the sarcoma; (2) sarcoma arising within the irradiated field; and (3) a 
latency period of at least 3 years.
2 The latency period was calculated from initial radiotherapy 
until the diagnosis of RIS. Sarcomas were reviewed on hematoxylin and eosin-stained 
sections with additional immunohistochemistry to evaluate tumor differentiation. They were 
classified with the most recent World Health Organization classification and graded according Chapter 2 
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to the French grading system.
3,4 Additional data reviewed were patient demographics, 
delivered radiation dose, latency period, treatment of RIS, local and distant failure, and 
survival after diagnosis of RIS. 
Treatment for RIS in the absence of distant metastases was surgery. In cases of distant 
metastases, chemotherapy was considered. In cases of local failure after primary treatment for 
RIS, re-excision was preferred. Radiotherapy and chemotherapy were given only in select 
cases. Patient characteristics, tumor data, and treatment schedules are listed in Tables 1 to 3. 
DFS and OS was determined, and a comparison of survival after identifiable resection 
techniques was performed by using Kaplan-Meier survival curves with log-rank test. The 
achieved results were discussed, and the RIS literature was reviewed. 
 
Table 1 Development of distant metastases in patients with RIS 
Variable  n  % 
Total number of patients  11  41 
Anatomic site  Lung  8  73 
 Liver  3  27 
 Lymph  node  4  36 
 Bone  3  27 
  Other soft tissue  3  27 
RIS, radiation-induced sarcoma 
 
Results 
The median age of the 27 patients at the time of diagnosis of the primary lesion was 44 years 
(range, 1-73 years). The median latency period between radiotherapy for the primary lesion 
and RIS was 8 years (range, 3-41 years). The median patient age at diagnosis of RIS was 52 
years (range, 20-83 years). The total delivered irradiation dose could be exactly retrieved in 
24 cases (89%), and the median radiation dose was 50 Gy (range, 16-70 Gy). All three cases 
in which information on the irradiation dose was not retrievable involved a prolonged latency 
period after radiotherapy (>18 years). Eleven patients received adjuvant systemic therapy for 
the primary tumor: seven patients were treated with cytotoxic agents, and five received 
hormonal therapy. The shortest latency period was observed for a patient with a fibrosarcoma 
40 months after irradiation with a dose of 60 Gy for a squamous cell carcinoma of the floor of  Radiation-induced sarcoma 
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Table 2 Primary lesion and presentation of RIS 
Primary lesion  Treatment  Presentation of RIS 
Patient 
no. 
Age 
(y)  Sex PTL  Surgery Chemo  Hormonal 
Radiation 
dose (Gy)  Histology Location 
Latency 
period (y) 
Year of 
diagnosis 
Distant 
disease 
1 47  F  BC  BCT  No  No  50  Ang  Breast  7  1995  No 
2 46  F  BC  BCT  No  No  70  Ang  Breast  4  1995  No 
3 72  F  BC  BCT  No  No  70  Ang  Breast  7  1996  No 
4 64  F  BC  BCT  No  No  50  Ang  Breast  4  1997  No 
5 72  F  BC  BCT  No  No  70  Ang  Breast 
6 
1997 No 
6 63  F  BC  BCT  No  Yes  70  Ang  Breast  4  1999  No 
7 68  F  BC  BCT  No  Yes  70  Ang  Breast  7  2001  No 
8 45  F  BC  BCT  Yes  Yes   70  UHGPS  Breast 5  1992  No 
9 42  F  BC  BCT  Yes  No  70  UHGPS  Breast 7  2003  No 
10 37  F  BC  AMP  Yes  Yes  40  UHGPS  Trunk 16 1997  No 
11 44  F  BC  AMP  No  No  50  UHGPS  Axilla 4  1991  No 
12 64  F  BC  AMP  No  No  50  UHGPS   Trunk 15 2000  Yes 
13 54  F  BC  AMP  No  Yes  50  UHGPS  Trunk 9  2003  No 
14 45  F  BC  AMP  No  No  67  Fib  Trunk  4  1995 Yes 
15 21  F  H  None  No  No  40  UHGPS  Trunk 20 1994  No 
16 28  F  H  None  Yes  No  40  UHGPS  Mediastinum 5  1998  No 
17 16  M  H  None  No  No  60  Fib  Trunk  4  1991 No 
18 18  F  H  None  Yes  No  ?  Os  Trunk  32  1987 No 
19 47  M  RC  APR  Yes  No  50  Fib  Pelvis  9  2002 No 
20 68  M  SQ  RES  No  No  60  Fib  Head  /  Neck  3  1998 No 
21 25  M  MA  RES  Yes  No  45  Fib  Head  /  Neck  36  2000 No 
22 35  M  MY  None  No  No  16  Fib  Upper  leg  17  1978 No 
23 43  F  EN  HYS  No  No  ?  UHGPS  Pelvis 40  1996  No 
24 30  F  VC  None    No  No  30  UHGPS  Pelvis 41  1998  Yes 
25 50  F  EN  HYS  No  No  ?  PL  Pelvis  18  1980 No 
26 1  M  RE  EN No  No  45  PR  Head  /  Neck  21  2000 No 
27 11  M  RH  LR Yes  No  55  Os  Head  /  Neck  21  1997 No 
RIS, radiation-induced sarcoma; F, female; M, male; PTL, primary tumor + localization; BC, breast carcinoma; BCT, breast-
conserving therapy; Ang, angiosarcoma; UHGPS, undifferentiated high-grade pleomorphic sarcoma; AMP, amputation; Fib, 
fibrosarcoma; H, Hodgkin disease; Os, osteosarcoma; RC, rectal carcinoma; APR, abdominoperineal resection; SQ, squamous 
carcinoma, floor of mouth; RES, resection; MA, maxilla osteosarcoma; MY, myositis ossificans, thigh; EC, endometrial 
carcinoma; HYS, hysterectomy; VC, vulvar carcinoma; PL, pleomorphic leiomyosarcoma; RE, retinoblastoma, left and right 
eyes; EN, enucleation; PR, pleomorphic rhabdomyosarcoma; RH, rhabdomyosarcoma, soft palate; LR, local resection. Chapter 2 
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the mouth. The longest latency period was seen for a patient who developed a undifferentiated 
high-grade pleomorphic sarcoma 41 years after a squamous cell carcinoma of the vulva 
(radiation dose, 30 Gy). 
Histology of the RIS was 10 (37%) undifferentiated high-grade pleomorphic sarcomas, 7 
(26%) angiosarcomas, 6 (22%) fibrosarcomas, 2 (7%) osteosarcomas, 1 (4%) pleomorphic 
rhabdomyosarcoma, and 1 (4%) pleomorphic leiomyosarcoma. All patients were staged 
locally and distantly; three (11%) RIS patients had metastatic disease when the RIS was 
diagnosed. 
There were 24 patients (89%) without distant metastases at the time of diagnosis of RIS. 
Thirteen underwent an R0 resection with median survival of 29 month (range, 5-307 months); 
seven of these patients developed a local failure (54%). In patients who did not develop a 
local failure after R0 resection, the median survival was 40.5 month (range 6-88 months). In 
patients who developed a local recurrence, the median survival was 20 month(range, 5-307 
months). Four patients underwent an R1 resection with a survival ranging from 5 to 138 
months. Two patients underwent an R2 resection and survived 4 and 14 months. Three 
patients underwent no resection (two of the three received palliative chemotherapy) and 
survived 7, 7, and 5 months. In two patients, the radicality of the first resection was not 
retrievable. In one patient, a local failure was diagnosed after 13 months, and an R0 resection 
was performed, after which the patient survived 149 months with no evidence of disease. The 
other patient died after 24 months. The three patients with distant metastases at the time of 
diagnosis of RIS survived 1, 6, and 15 months; the one who survived 15 months received 
palliative chemotherapy. During follow-up, eight patients (33%) developed metastases at 
single and multiple locations after a median of 8 months (range, 2-60 months). Details about 
the presentation of RIS, treatment, follow-up, and sites of metastases are listed in Tables 1-3. 
DFS and OS were both 44% at 2 years and were 27% and 30%, respectively, at 5 years (Figs. 
1 and 2). DFS was calculated by using the time period, in the group of patients with primarily 
no evidence of metastatic disease (n = 24), from establishment of the RIS diagnosis until their 
first recurrence (Fig. 1). The median OS after diagnosis of RIS was 15 months (range, 1-307 
months). At the time of this review, nine patients were still alive with no evidence of disease , 
with a median follow-up of 66 months (range, 5-307 months). Seventeen patients (63%) died 
of their RIS, with a median survival of 14 months (range, 1-138 months). In one patient, the 
final cause of death was not retrievable (24 months). The local failure rate after R0 resection 
was 54%, and the overall distant failure rate was 41%. Radiation-induced sarcoma 
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Table 3 Treatment and follow up for radiation-induced sarcoma 
  Primary treatment sarcoma  Local failure     
Patient 
no. 
Surgery 
(radicality) 
Systematic 
therapy  Radiotherapy 
  Treatment  Distant failure (mo + 
location)  Survival (mo) 
 
    
Appearance 
(mo) 
Surgical Other     
1  Excision (R0)  No  No  Yes (6)  No  RT:50Gy  No  DOD   13 
2  Excision (R1)   No  No   Yes (91)  Yes:R0  No  No  NED   96 
3 
Amputation 
(R0) 
No No  Yes 
-LF1 (42) 
-LF2 (56) 
Yes 
-LF1: R0 
-LF2: no 
No No  DOD    60 
4 
Amputation 
(R0) 
No No  Yes 
-LF1 (2)  
-LF2 (6) 
-LF3 (12) 
-LF4 (24)  
Yes: 
-LF1: R0 
-LF2: R0 
-LF3: R0 
-LF4: R1 
Yes: 
-LF1: - 
-LF2: - 
-LF3: - 
-LF4:90 Gy* 
No DOD    38 
5 
Amputation 
(R0) 
No  No  Yes (2)   No  No  Yes (4 lung, 
mediastinal, spleen, 
liver, adrenal, and 
bone) 
DOD   5 
6 Amputation 
(R0) 
 
 
No No  No  No  No  Yes  (19  bone  31 
abdominal lymph 
nodes) 
DOD   40 
 
7 Amputation 
(RX) 
No No  ?  ?  ?  ?  DOUR    24 
8 Amputation 
(R2)  No No 
NA NA  NA Yes  (2  liver) DOD    4 
9 Resection  (R1)  No  No  NA  NA  NA  No  NED    5 
10 Excision:  (R0) 
 
 
 
No No  Yes 
-LF1 (7)  
-LF2 (10) 
-LF3 (12) 
Yes 
-LF1:R0 
-LF2:R0 
No  Yes (12 Lung + soft 
tissue metastases) 
DOD   20 
11  Excision (RX)  No  No  Yes (13)  Yes:R0  No  No  NED  149 
12 No 
 
No  No  NA  NA  NA  Yes (at diagnosis; 
lung) 
DOD 1 
13 Excision  R1 
Re-excision: 
no tumor (R0) 
No No  No  No  No  No  NED    6 
14  No  Yes  No  NA  NA  NA  Yes (at diagnosis; 
lung, bone, lymph-
nodes, mediastinal) 
DOD   15 
15  Excision (R0)  No  No  Yes (5)  Yes  Yes 
60 Gy 
Yes (8 lymph node 
and lung-
metastases) 
DOD   15 
16 No  Yes  No  NA  NA  NA  No  DOD    7 
17 R2 
 
 
No Yes 
 
 
NA NA  NA Yes  (6  sarcomatosis 
peritonei) 
DOD   14 
18 Excision  (R1) 
 
 
No  Yes 56 Gy  NA  NA  NA  Yes ( X lung, lymph 
node, liver) 
DOD 24 
19 Exenteration 
(R0) 
No No  No  No  No  No  NED    16 
20 No  No  No  NA  NA  NA  No  DOD    7 
21 Resection  (R0)  No  No  No  No  No  No  NED    41 
22  Excision (R0)  No  No  Yes (7)  Yes: R0  Yes: chemo  No  NED  307 
23 Hemipel-
vectomy (R0) 
No No  No  No  No  No  NED    88 
24  No  No  No  NA  NA  NA  Yes (at diagnosis; 
lung)  
DOD   6 
25  Excision (R1)  No  No  NA  NA  NA  Yes (60 lung)  DOD   138 
26 No  Yes  No  NA  NA  NA  No  DOD    5 
27 Resection  (R0)  No  No  No  No  No  No  NED  66 
RT, radiotherapy; DOD, dead of disease; NED, no evidence of disease (calculated from the moment radiation-induced 
sarcoma was diagnosed); LF, local failure; DOUR, dead of unknown reason; NA, not applicable; Chemo, chemotherapy; 
R1, macroscopically irradical; R2, X, not retrievable, microscopically radical; R0, microscopically radical. Figure 1 Percentage of disease-free survival (DFS) during follow-up of patients with 
primarily no evidence of metastatic disease (n = 24). 
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Figure 2 Percentage of overall survival during follow-up after radiation-induced sarcoma 
diagnosis of all patients (n = 27). 
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Patients who received an R0 resection had a significantly better survival than the patients 
without metastasis in whom only an R1 or R2 resection, or no resection, could be performed. 
(log-rank, 4.96; df =1, P  = .026; relative risk, 8.6; 95% confidence interval, 8.2-8.9; 
nonradical resection group compared with the radical surgery group. (Fig. 3). 
 
2   2Radiation-induced sarcoma 
  23 
Figure 3 Radicality of resection and survival: a radical resection differs significantly (P = 
.026) from nonradical and no resection with respect to survival. 
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Discussion 
The first RIS was described at the beginning of the 20th century, and the earliest 
comprehensive RIS study was by Cahan et al.
5 Since 1940, 16 studies have been published. 
The number of patients in the studies, latency period, survival time, number of patients dead 
of disease, 2- and 5-year DFS and OS, and percentage of local and distal failure are listed in 
Table 4. 
Until now, RISs have been considered extremely rare, and the current incidence varies from 
.03 to .22%.
6-12 In this study, the median latency period between irradiation and diagnosis of 
RIS was 8 years, which is comparable to the roughly 10 years (range, 3 months to 50 years) 
in the published literature.
8,13-15 The development of RIS may be attributed to ionizing 
radiation, which may induce genomic instability.
16 The precise radiation-induced genetic 
mechanism is still unknown. The prognosis of RIS is poor and worse than the usual prognosis 
of a sarcoma.
11,17-23 The question of whether RIS of the soft tissue differs from RIS of the 
bone with respect to local growth pattern and metastatic potential remains unanswered. 
We noticed an increased number of patients diagnosed with RIS over the last three decades 
(Fig. 4). The increase in RIS of soft tissue might be the result of an intensive cancer treatment 
combining (extensive) surgery with adjuvant or neoadjuvant chemotherapy and preoperative 
or postoperative radiation. Some chemotherapeutic agents, such as doxorubicin, might have 
the potential for causing radiation sensitization. A definitive relationship between latency 
period and radiation dose, with or without chemotherapy, as well as age at the time of RIS Chapter 2 
  24 
diagnosis and survival, could be defined neither in this study nor in the available 
literature.
2,17,24,25 
 
Figure 4 Number of patients diagnosed with radiation-induced sarcoma over the last three 
decades. 
1974 1984 1994 2004 1974 1984 1994 2004
0
2
4
6
8
10
12
14
16
18
20
Year
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
Another problem might be the difficult detection of a second malignancy within a previously 
irradiated area, causing a delay in diagnosis and, therefore, a more advanced stage of disease. 
When alterations occur within a previously irradiated area, the diagnosis of RIS must always 
be considered.
26 
Because of previously performed (intensive) treatment, RIS requires a so-called "tailored" 
cancer treatment with an optimal tumor staging, as well as information with respect to the 
local growth pattern of the RIS and involvement of the surrounding tissues. The current new 
radiodiagnostic imaging modalities of MRI and spiral CT might provide adequate 
information, and three-dimensional reconstruction enables excellent preoperative planning of 
the extent of the surgical resection and the need for reconstruction with plastic surgery, with 
the ultimate goal of achieving an R0 resection with low morbidity, e.g., primary wound 
healing. Adequate radical resection is sometimes difficult or even impossible. The reason for 
this is often the anatomical site of the tumor or extensive ingrowth in surrounding tissue. The 
important role of surgery has been underlined by many authors and confirmed in this 
study.
2,11,20,24 The group of patients with an R0 resection had a significantly longer median 
survival time, even in the group with local failure.  T
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The prognosis for sarcoma patients after radical re-excision for a primary nonradical excision 
has been shown not to differ from that of patients after primary radical excision.
27 This study 
was too small to prove this for RIS as well. 
The results of this study are similar to those in the review by Robinson and associates
25, 
which reported a median survival of 12 months with a survival rate at 2 years of 22% and at 5 
years of 11%. Unfortunately, the overall results have only slightly improved since the 1940s, 
and most published studies provide only limited data; this hampers further insight into the 
described diseases. None of the reviewed studies showed a significantly beneficial effect of 
adjuvant chemotherapy, irradiation, or both.
14,28,29 This is not surprising, because effective 
reirradiation is impossible, and chemotherapy may have a role. However, the numbers of 
patients described in the subsequent studies were small. Recently, there has been evidence 
that most RISs show an extensive expression of the KIT protein. Although treatment with the 
KIT inhibitor imatinib might be considered for patients in whom radical surgery is not 
amenable, it is not likely this will be the final solution to this problem.
30 
As in previous reports, we found a wide variety in histopathological subtypes of RIS. With 
the increasing incidence of angiosarcoma of the breast after breast conserving therapy (BCT), 
this subgroup needs to be explored much more extensively. A cooperative international study 
is required to acquire more fundamental insight in this treatment-induced disease. If more 
information is obtained about these kinds of secondary malignancies and the patients who get 
them, prevention measures might be undertaken in patients who are candidates for BCT. Will 
the reduction of doses of intensity-modulated radiotherapy indeed fulfill the new hope in 
eradicating cancer, or will it, conversely, increase the risk of RIS in the surrounding healthy 
tissue? 
In summary, RISs are aggressive malignancies with a high tendency for local recurrence and 
distant metastases. Previously delivered treatment hampers adequate resection and 
administration of radiotherapy. Therefore, RISs are a challenge for the surgical oncologist. A 
radical surgical approach is the only chance to improve DFS and OS, might offer palliation, 
and it is the only prognostic factor for long-term survival. Because the prognosis is poor, the 
options of new treatment strategies are being studied. More insight into the disease, 
especially angiosarcoma of the breast after BCT, might soon provide preventive measures in 
patients undergoing extensive combined cancer treatment. 
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Introduction 
Soft tissue sarcomas (STS) are a rare group of cancers compromising ~ 1% of all 
malignancies. There has been a slight increase in incidence, and half of STS patients are over 
the age of 65 years.
1 The pathogenesis of most STS remains unknown. Genetic, 
environmental and immunological factors have been identified as risk factors. It is likely that 
the cause of STS is multifactorial. 
STS may arise in any part of the body, predominantly in the extremities (45%; lower limb 
29%, upper limb 16%), trunk (25%), head and neck (13%), and retroperitoneum (8%) [1]. The 
tumors are classified according to the World Health Organization Classification of Tumors, 
dividing STS into 19 categories and >50 subtypes. Some chromosomal abnormalities are 
unique to certain classes of STS. Classification and subtype prediction of adult STS such as 
synovial sarcoma, round-cell/myxoid liposarcoma, clear-cell sarcoma and gastrointestinal 
stromal tumors (GIST) recently became possible by functional genomics.
2 
The tumors are graded according to the French grading system, distinguishing low-, 
intermediate- and high-grade STS, and staged according to the American Joint Committee on 
Cancer staging system. More practical for daily clinical practice is to distinguish between 
low- and high-grade, and between tumor sizes <5, 5–10 and >10 cm, as suggested by 
Brennan.
3 
Insight into the disease and progress achieved with surgical technical skills and combined 
modality approach in these tumors have reduced the local failure rate and improved limb 
salvage figures. One-third to half of patients diagnosed with STS will die of their disease 
because of either metastatic disease or currently infrequently diagnosed locally recurrent 
disease.
4 The high-risk patient with extremity STS for distant metastasis and local recurrence 
is the patient with a large (T2), high-grade, deep lesion. The role of primary surgery as 
primary treatment and intervention in multidisciplinary sarcoma treatment is reviewed.  
 
Landmarks in surgical treatment 
In the past century, STS were simply resected, with local failure rates of 60% to 80%. There 
was a major movement in the late 1940’s and early 1950’s towards more radical surgical 
procedures, such as amputation or radical local resection, as first-line treatment. A sharp 
increase in local control was encountered. Up to the end of the 1970’s, half of all limb 
sarcomas were treated by amputation. Although the local failure rate achieved with this 
surgical approach was only 10% to 15%, a large proportion of patients (30% to 40%) 
continued to die of metastatic disease.
4 Soft tissue sarcoma: role of surgery 
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There have been several breakthroughs in the diagnostic imaging and treatment of STS during 
the last 30 years, resulting in improved limb salvage and survival rate. In the 1970’s, 
computed tomography (CT) became available for local staging of STS and staging for distant 
metastases. Two decades later, magnetic resonance imaging (MRI), with or without 
contrastenhanced sequences, replaced CT in the local staging. Recently, spiral CT was 
introduced, providing the surgeon with optimal three-dimensional images and further 
facilitating preoperative treatment planning. Computer-assisted navigation systems have 
become available, which are extremely useful in the intra-operative treatment planning of 
sarcomas located in or near the pelvic girdle or vertebral column. Improvements in the 
radiodiagnostic of STS had a major impact in staging and in the planning of surgical 
treatment.
5 
In local treatment of STS there have been three successive major breakthroughs. In the 
1970’s, Simon and Enneking
6 developed the concept of compartment excision. At the same 
time, Rosenberg et al.
7 investigated the role of adjuvant radiation in the local treatment of 
limb sarcoma, showing no difference in local control and survival in patients treated with 
amputation compared with patients who received a limbsaving procedure. Compartment 
excision, in the meantime, has been replaced by wide local excision, but 5% to 10% of limb 
sarcomas still require an amputation. The third breakthrough was in the early 1990’s, with the 
introduction of isolated limb perfusion (ILP) with tumor necrosis factor-α (TNF-α) by 
Lejeune in the treatment of primarily unresectable STS of the limb.
8 
Surgical resection of metastatic disease, by example isolated lung metastases, improved the 
disease-free and overall survival of patients.
9 The most recent breakthrough in sarcoma 
treatment was the introduction of the drug targeting therapy with imatinib in the treatment of 
disseminated gastrointestinal stromal tumors.
10 The role of (interval) surgery within drug 
targeting therapy is currently being explored.
11 
 
Surgical approach 
The surgical approach in STS is determined by several factors: tumor location, size of tumor, 
depth of invasion (superficial or deep), involvement of nearby structures, and possibility of 
primary wound closure and/or plastic surgery reconstruction. Beside these factors, patient 
performance and stage of disease are additional important factors in the surgical decision 
process. Although a large proportion of patients receive combined modality treatment, 
patients with localized disease can be treated with surgery alone. However, precise clinical 
pathological criteria for selecting patients for unimodality therapy are currently lacking. Chapter 3 
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Operative procedures in sarcoma surgery have been described excellently by Malawer and 
Sugarbaker.
12 
 
Biopsy 
What kind of biopsy is appropriate in the diagnostic process and treatment of a patient with a 
soft tissue mass? After taking medical history and performing physical examination, the 
tumor is first locally staged with MRI or CT scan before any biopsy.
5 Positron emission 
tomography might allow differentiation between a benign and malignant tumor.
13 Based on 
the results of the imaging techniques, whether the appropriate biopsy technique is incisional, 
excisional, core-needle biopsy (CNB) or fine needle aspiration (FNA) is discussed. 
The diagnostic accuracy of a CNB in referral centers is equivalent to incisional biopsies, 
although it may be difficult to differentiate a low-grade malignancy from a benign tumor 
mass.
14 In the event that a diagnosis is not clarified by CNB, additional CNB samples can be 
obtained without compromising the option to proceed with an incisional biopsy. An open 
biopsy ensures sufficient tissue for extensive immunohistochemistry and molecular 
(cyto)genetic techniques, especially in patients for whom neo-adjuvant treatment is foreseen. 
FNA and CNB are useful in the diagnostic process of a local recurrence or metastatic disease. 
Careful attention should be paid to the biopsy site and the prevention of ecchymosis, e.g. 
tumor cell contamination. An inappropriately planned or poorly performed biopsy might 
seriously compromise subsequent surgical resection and even necessitate amputation. 
Therefore, core-needle and open biopsies should be carefully planned, and performed at the 
sarcoma center where the definitive surgery is to be undertaken. Surgical biopsy tracks are 
excised routinely with the tumor specimen at the time of the definitive resection of the tumor. 
 
Whoops approach 
Sarcomas are still diagnosed after an unplanned excision, the so-called ‘whoops approach’. 
The pathology report will describe an R1 (microscopically involved margin) or R2 
(macroscopically involved margin) resection requiring further therapy. If further surgery may 
render a patient disease-free (R0 resection) or an R2 might become an R1 resection, 
reresection is essential. If this aggressive surgical policy is applied, these patients are not 
apparently at risk for a worse outcome as compared with patients primarily referred to a 
multidisciplinary sarcoma unit.
15 The study from the Memorial Sloan-Kettering Cancer 
Center (MSKCC) even suggests that patients undergoing two operations (excision followed Soft tissue sarcoma: role of surgery 
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by second re-excision) have improved survival compared with patients treated with a single 
definitive operation. 
 
Local resection 
In the late 1970s, compartment excision was advocated, while today the consensus is that in 
sarcoma surgery, a wide local resection, R0 resection with a 2 cm margin, is an adequate 
resection. In the majority of sarcoma resections, a 2 cm margin is impossible to achieve due to 
anatomical structures, and an R1 resection is the best achievable resection margin. R2 
resections should be avoided. Adjuvant radiation after R1 resection improves the local control 
rate (see also radiotherapy and chemotherapy below). Positive microscopic resection margins 
significantly decrease the local recurrence-free survival rate and independently predict distant 
recurrence-free survival and disease-specific survival rates in STS treatment.
16 If local 
resection of a sarcoma of the limb is impossible, amputation or disarticulation of the involved 
limb should be performed to render the patient disease-free. Sometimes extensive ablative 
surgical resections are required. 
Surgical treatment of retroperitoneal STS is a challenge for the surgical oncologist, although 
the majority of these tumors are unresectable. Only radical tumor resection, often with 
resection of nearby organs, can render a patient disease-free.
17 The surgical margins are 
always minimal and the local failure rate is high, especially in high-grade tumors.
18 Palliative 
surgical procedures may be performed to address symptoms (intestinal obstruction, bleeding). 
Chemotherapy is ineffective, post-operative radiotherapy may cause radiation enteritis and 
preoperative radiotherapy is hardly used. Drug targeting therapy with imatinib changed the 
prognosis of GIST. 
 
Ablative surgical procedures 
Forequarter amputation 
Sarcomas of the shoulder girdle are frequently large and deepseated at initial presentation, and 
difficult to manage. For a small group of patients, a forequarter (interscapulothoracic) 
amputation is the only treatment option, and in a few cases a Tikhoff–Lindberg procedure, 
which allows for preservation of the limb, is feasible. On the other hand, for some patients an 
extensive resection with a part of the thoracic wall is necessary to achieve free surgical 
margins. Interthoracoscapular amputation is one of the most major ablative surgical 
procedures, which can be performed with curative or palliative intent, with minimal 
treatment-related morbidity. The prognosis does not differ from STS in general.
19,20 Chapter 3 
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Hindquarter amputation 
The majority of STS of the upper thigh and buttock can potentially be treated with local 
excision, preserving the limb. For a few sarcomas of the lower limb or buttock region, a 
curative or palliative hindquarter amputation is unavoidable. The prognosis of these sarcomas 
after curative surgical treatment is not different from sarcomas in general. Wound healing 
disturbances are a major problem in the treatment of sarcomas in this anatomical region.
21 
 
Buttockectomy 
Locally advanced soft tissue tumors of the buttock region represent a group of tumors with 
specific difficulties common to pelvic tumors, often large and deeply attached at initial 
presentation, and in the past treated with a hemipelvectomy. The majority of patients might 
now be treated with a complete en bloc resection of the gluteus muscles.
22 This procedure can 
be converted into an anterior hemipelvectomy if the tumor penetrates the deep margin of the 
muscle or infiltrates the bone. Involvement of the sciatic nerve is currently not longer an 
indication for a hemipelvectomy, since resection of the sciatic nerve is well tolerated, 
requiring only a brace.
23 
 
Hind foot amputation 
Less than 10% of lower extremity sarcomas arise in the foot. In this location, limb-saving 
surgery is seldom possible and below-knee amputation is indicated. For selected tumors 
located at the forefoot, different hindfoot amputations are available, being excellent 
alternatives to a below-knee amputation.
24 
 
Interval surgery 
Interval surgery is defined as a surgical procedure followed by induction treatment with 
chemotherapy and/or radiation for a solid tumor followed by surgery. The goal of the 
combined treatment strategy in STS is to improve the limb salvage rate, local tumor control 
and/or survival. Interval surgery is applied in the treatment of bone sarcomas, extra-osseous 
Ewing’s sarcoma, primitive neuroectodermal tumor and rhabdomyosarcoma. There is a 
limited experience with interval surgery for STS with isolated limb perfusion, neo-adjuvant 
chemotherapy, intra-arterial chemotherapy and preoperative irradiation. 
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Isolated limb perfusion 
In the first trial of ILP for STS, Krementz
24a showed an early response rate of 83% after 
melphalan; however, complete regression of the tumors was rarely seen. The results achieved 
with ILP were not better than for surgery and adjuvant radiation therapy.
25 Other perfusion 
agents were investigated. Doxorubicin and cisplatin were also ineffective, while doxorubicin 
combined with melphalan was too toxic.
26-28 The resurrection of interest in the ILP technique 
came with the introduction of tumor necrosis factor (TNF)-α and melphalan into the perfusion 
of primarily unresectable STS of the limb [8]. After a so-called TNF perfusion, a remarkable 
shrinkage of the tumor was encountered within 6–12 weeks, and unresectable sarcomas 
became resectable. 
A large European study proved the ILP concept in the limbsalvage procedures for 
unresectable STS with TNF-α and melphalan. The objective response rate was 76%. A limb 
salvage rate of 71% was achieved, with minimal treatment-related morbidity.
8 An 
independent review committee considered that 80% of all enrolled patients in this study met 
the criteria for irresectability.
29 Further analysis showed that ILP patients survived as long as 
matched controlled conventionally treated patients.
29 Since the resection margins in these 
tumors are minimal and viable tumor cells are often encountered at the periphery of the 
tumor, radiation is indicated to ensure local tumor control. Adjuvant radiation is well tolerated 
after ILP and extensive surgical resection.
30 TNF perfusion has now been used for over a 
decade, and in surviving patients the long-term treatment-related morbidity necessitating 
amputation is low.
31 The outcome of the ILP procedure in ‘elderly’ sarcoma patients is in 
general not different from in ‘younger’ sarcoma patients.
32 Perfusions in elderly limb sarcoma 
patients, on the other hand, sometimes cannot be performed due to atherosclerotic changes in 
the main arteries and/or severe comorbidity. 
Why do all perfused sarcomas not respond to a TNF-α ILP? Multidrug resistance (MDR) is a 
major issue in chemotherapy treatment. Two groups investigated the expression of MDR in 
patients undergoing TNF perfusion treatment and showed that temperature and drugs were 
unable to induce MDR-positive sarcomas.
33,34 This is an important finding, since systemic 
doxorubicin-based polychemotherapy is currently being investigated in STS patients after 
TNF perfusion as an adjunct within the European Organization for Research and Treatment of 
Cancer (EORTC) trial 62931. 
ILP with TNF-α provides the ability to avoid amputations and further increase the 
preservation of functional limbs, and is currently available in over 30 centers in Europe. In 
2002, a total of 350 TNF perfusions were performed. Chapter 3 
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Neo-adjuvant chemotherapy 
The idea behind neo-adjuvant chemotherapy for locally advanced STS is: (i) tumor 
cytoreduction to render local surgery less extensive; (ii) early treatment of occult metastatic 
disease; and (iii) in vivo evaluation of the tumor’s chemosensitivity. The EORTC performed a 
randomized phase II trial with doxorubicin 50 mg/m
2 and ifosfamide 5 g/m
2 versus local 
therapy alone. Owing to slow accrual, the trial was not extended to a phase III trial. There was 
no difference in the 5-year survival rate: 64% in the no-chemotherapy arm versus 65% for the 
control arm, and no conclusions could be drawn from the trial.
35 The trial showed no increase 
in surgical morbidity or improved local control. Based on the meta-analysis study, as well as 
recent data from Italy, there is still interest in the use of preoperative chemotherapy in the 
treatment of locally advanced STS.
36,37 The question is whether surgeons and their patients 
are willing to participate in such a trial. 
 
Drug targeting therapy 
Complete surgical resection is the most important prognostic factor for patients with GIST. 
Local recurrences and metastatic disease are frequently encountered after surgery for GIST. 
Recently, a breakthrough in the treatment of disseminated GIST was observed with the 
introduction of imatinib. The preliminary results are impressive. The role of surgery is 
currently unknown for patients treated for metastatic GIST, as well as for patients who are 
unresectable and receive induction imatinib therapy. It is clear that in the near future, the role 
of surgery in locally advanced and metastatic GIST, as well as the role of imatinib, will be 
defined.
11 
 
Intra-arterial chemotherapy 
The idea behind the intra-arterial chemotherapy was the ‘first pass through effect’ of the 
cytostatic agent. In the late 1970’s, Eilber et al. 
38  developed, for locally advanced limb 
sarcoma, a 3-day regimen of continuously intra-arterial doxorubicin with preoperative high-
dose fractionation radiation schedules of different dose levels. The initial results in the early 
1980’s were so promising that the treatment was adopted by the Groningen University 
Hospital. The treatment was indeed effective, but the treatment-related morbidity was too 
high. Severe long-term treatment-related morbidity was encountered; 60% of the survivors 
developed serious functional problems varying from fibrosis to pathological stress fractures 
and invalidating neuropathy.
39 Since 1975, 753 patients have been treated at the University of Soft tissue sarcoma: role of surgery 
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California at Los Angeles for a primary or recurrent sarcoma of the limb; 498 patients 
received neo-adjuvant therapy with intra-arterial doxorubicin and different radiation dose 
schedules. The study showed only a benefit of neo-adjuvant treatment in patients with 
recurrent sarcomas. Three-quarters of all recurrences were diagnosed within 36 months. When 
a local recurrence occurred, an amputation was unavoidable in 38% of cases.
38 Intra-arterial 
chemotherapy has no advantage over systemic drug delivery, and doxorubicin acts in this 
treatment mainly as a radiation sensitizer. 
 
Preoperative radiation therapy 
External beam radiotherapy delivered either pre- or postoperatively is highly effective in 
preventing local recurrences in patients who have a high risk for local failure, without any 
significant change in overall survival.
40 Adjuvant radiation is mostly used after marginal 
resection of STS, with a substantial treatment-related morbidity, especially after extensive 
surgery, such as reduced limb strength, range of motion, fibrosis and edema. Locally 
advanced sarcomas might be treated with preoperative radiotherapy. A retrospective non-
randomized comparison of pre- versus post-operative radiotherapy from the MD Anderson 
Cancer Center suggested that local control might be improved for patients with measurable 
disease treated with preoperative radiation.
41 A randomized trial of pre- versus post-operative 
radiotherapy in STS of the limb showed that preoperative radiotherapy was associated with a 
significant increase in wound healing complications, and did not warrant the further use of 
preoperative radiation in STS.
42 In contrast, preoperative radiotherapy is well accepted in the 
treatment of retroperitoneal sarcoma, to improve the local control rate while reducing the 
radiation induced morbidity, and sophisticated treatment schedules in which preoperative 
radiotherapy is combined with doxorubicin and intraoperative radiotherapy are promising for 
the surgical oncologist and radiation oncologist.
43 To further optimize the effectiveness of 
radiation treatment in locally advanced sarcoma, molecular target agents are currently being 
developed for cytoprotective or cytotoxic pathways, and clinical trials are already under 
way.
44 
 
Surgery for recurrent disease 
Local recurrence 
The most significant independent factor for recurrence is surgical margin, followed by deep 
tumor location and tumor grade.
16 Local control after inadequate resection or recurrent Chapter 3 
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sarcoma is equal to that of primary sarcomas, if negative margins can be obtained by 
surgery.
15 
 
Metastasectomy 
Approximately 30% to 40% of patients with high-grade sarcomas develop hematogenous 
metastases, predominantly to the lungs. Less than 3% of STS patients develop lymphogenic 
metastases. Patients with clear cell sarcoma, embryonal rhandomyosarcoma, epitheloid 
sarcoma and angiosarcoma are especially at risk, and the incidence in these tumors might be 
as high as 20%.
1 Although the lungs might be the primary site for distant failures in three-
quarters of patients, other sites of metastasis include the skin and soft tissues of the head and 
neck, trunk, and extremities. The median survival after the diagnosis of metastatic disease 
from primary extremity sarcoma is ~ 1 year, with no difference between pulmonary and non-
pulmonary metastases.
45 
Pulmonary metastases from STS are in general diagnosed with conventional X-rays and 
further staged with CT. If resection of all metastatic disease seems possible, a unilateral, 
bilateral or median sternotomy is advised. Approximately 60% to 80% of these patients might 
be rendered disease-free after surgical resection of the lung metastases, with a 5-year survival 
ranging from 20% to 40%. Long-term survival is possible in selected patients, but is 
exceedingly rare [46]. The EORTC experience showed a 3-year survival rate of 54% among 
patients undergoing complete resection of metastatic disease confined to the lungs, 
comparable to the MSKCC experience, with a 3-year actuarial survival of 46%.
47 Despite 
successful metastasectomies, a large proportion of patients will recur in one or both lungs. A 
second or even a third thoracotomy might be considered to render the patients disease-free.
48 
Lymphogenic metastases are treated with a radical lymphadenectomy with a 5-year survival 
rate of >30%. Soft tissue masses are generally easy to resect, and resection might improve 
local control and quality of life. The only curative treatment option for metastatic disease is 
surgery, which can be performed with minimal treatment-related morbidity and mortality. 
 
Surgery for complications 
The risk for complications is related to the extent of surgery, the overall and local condition of 
the sarcoma patient and the eventually applied adjuvant treatment. Two different 
complications might be distinguished: short- and long-term. The short-term complications are 
mainly wound infections and wound healing disturbances, and may cause delay in adjuvant 
treatment when indicated. The long-term complications are treatment-related and are mainly Soft tissue sarcoma: role of surgery 
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caused by radiation treatment. Complications are frequently seen after extensive surgery, 
especially fibrosis. Plastic surgery reconstruction should be used liberally in sarcoma surgery. 
The management of late (wound) complications requires much surgical expertise, and 
adequate treatment is seldom possible. 
 
Plastic surgery reconstruction 
The tactical and technical surgical parameters in sarcoma surgery are well defined in order to 
diminish the complication rates during tumor biopsy and definite resection. Reconstructive 
plastic surgery procedures by tissue transfer and microvascular surgical techniques play a key 
role in coverage of major defects and prevention of wound healing problems, and should be 
used more liberally; prevention is better than cure. 
 
Conclusions 
During the last two decades, considerable progress has been made in the diagnostic imaging 
of STS and use of combined modality treatment strategies. The extent of local resection and 
role of adjuvant radiation treatment are well defined. Preoperative radiation treatment in 
locally advanced STS has several advantages, but increased risk for wound complications has 
hampered further implementation. The optimal sequence of radiation and surgery remains 
complex. The reintroduction of ILP with TNF-a and melphalan was a breakthrough in limb 
salvage for primarily unresectable STS. The ILP technique is complex, and is only available 
in a few cancer centers in Europe. In the combined modality treatment, surgery is still the 
cornerstone of successful STS treatment. Further research in STS with new experimental 
approaches in multimodality treatment strategies with new chemotherapeutic agents and drug 
targeting therapies are under way, and may change the role of primary surgery to interval 
surgery in the future. Considering the increased insights in the tumor biology of STS and the 
improved surgical techniques, combined with intensive adjuvant treatment strategies, 
attention should be paid now to minimizing long-term treatment-related complications, as 
well as quality of life issues in these cancer survivors. 
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Abstract 
Background: The aim of this study was to investigate the long-term limb salvage rate and 
overall survival after isolated limb perfusion (ILP) with Tumor Necrosis Factor alpha (TNF) 
and melphalan for locally advanced soft tissue sarcoma (STS). 
Methods: From 1991-2003, 73 patients (36 male, 37 female, median age 54 (range 14 – 80) 
years) years with biopsy proven STS underwent 77 perfusions followed by delayed surgical 
resection, with or without adjuvant radiation. Limb salvage and overall survival curves were 
calculated using the Kaplan-Meier method. 
Results: A total of 21 amputations (28%) were performed. Overall 1, 5 and 10 years limb 
salvage was 80.1 ± 4.8, 68.2 ± 6.5% and 60.6 ± 9.2% respectively. Three time episodes were 
at risk for amputation. The first period was within 1½ year after perfusion mainly due to 
massive necrosis of the tumor and overlying skin resulting in a soft tissue deficit or recurrent 
disease (n=17). The second time period was within 5 years with 2 amputations performed for 
late local recurrence. The third episode occurred ten years after perfusion, 2 amputations 
performed for critical leg ischemia. Another two patients developed a pathological fracture of 
the femur due to radiation osteonecrosis. These 4 patients received adjuvant radiotherapy. 
Overall 1, 5 and 10 years survival was 82.9 ± 9.2%, 58.7 ± 13.1% and 42.5 ± 18.2% 
respectively. 
Conclusions:  ILP with TNF and melphalan followed by delayed surgical resection and 
adjuvant radiation treatment is an effective limb salvage treatment regimen for locally 
advanced STS. However, we observed late morbidity with 2 amputations performed for 
critical leg ischemia and 2 pathological fractures of the femur in patients receiving adjuvant 
radiotherapy. 
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Introduction 
Limb salvage in patients with locally advanced extremity soft tissue sarcomas (STS) 
continues to be a challenge. Survival in these patients is determined by the development of 
distant metastases and is not improved with the amputation of the affected limb.
1,2 Besides 
amputation, an extensive surgical procedure followed by radiation therapy is a treatment 
option.
3 Rosenberg et al. showed the same disease free and overall survival as amputation in 
the early eighties with this treatment regimen.
1 Preoperative therapies to improve limb 
salvage rates have been propagated. Suit et al. reported already in 1981 on the use of 
preoperative radiation therapy.
4 Eilber et al. combined preoperative (intra-arterial or systemic) 
chemotherapy and radiation therapy to improve resectability rates.
2,5 In a randomized trial 
O’Sullivan et al. reported a greater risk of wound complications in the preoperative 
radiotherapy group compared with the postoperative radiotherapy group.
6 The use of 
brachytherapy may also improve local control and avoid amputation.
7 The current treatment 
strategy of high grade limb sarcomas is wide local resection with the goal to achieve a R0 
resection with a 2 cm margin. In case the margin is less than 2 cm, or a R1 resection 
(microscopically involved margin), adjuvant radiation therapy with 50-70 Gy is indicated to 
reduce the risk of local failure.
3 The question whether radiotherapy should be given 
preoperative or postoperative is still unanswered.
6 
Another strategy for limb salvage in locally advanced extremity STS is to perform an isolated 
limb perfusion (ILP) with cystostatic agents. Originally developed for the treatment of 
melanoma of the limb in 1957, the procedure was also applied in the treatment of STS of the 
limb. In their first experience, Krementz et al. showed an early response rate with melphalan 
alone of 83%, however complete regression of the tumor was hardly seen.
8 Other perfusions 
agents in the treatment of limb STS were therefore investigated. Rossi claimed efficacy of 
doxorubicin, while another study proved that doxorubicin alone was ineffective and combined 
with melphalan too toxic.
9,10 Cisplatin showed also to be less effective than melphalan in the 
limb perfusion setting of sarcomas and carboplatin too neurotoxic.
11,12,13 
With the addition of Tumor Necrosis Factor alpha (TNF) to the perfusion circuit, Lejeune et 
al. made a step forward in the treatment of locally advanced extremity soft tissue sarcoma 
(STS).
14 A large European multi-center study proved the ILP concept in the limb salvage 
procedures for locally advanced STS with TNF and melphalan. The objective response rate 
was 75% and a limb salvage rate of 82% was achieved with a minimal treatment related 
morbidity.
15 Since 1991, patients with locally advanced STS of the limbs, have been treated at 
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the University Medical Center Groningen by ILP with TNF, melphalan with or without 
interferon gamma (IFN) as perfusion agents, followed by delayed surgical excision and 
postoperative radiation therapy if a marginal resection or non radical resection was 
performed. Recently we encountered long-term local morbidity and therefore the aim of the 
present study was to analyze the limb salvage rate and survival in patients with locally 
advanced STS of the extremities that were treated in our center and to report the late effects of 
this treatment modality. 
 
Patients and methods 
Patient Characteristics 
From the time period 1991-2003, 73 patients with soft tissue sarcoma of the extremity 
underwent 77 perfusions with a combination of TNF and melphalan, with (19) or without IFN 
(58). Thirty-six males and 37 females, with a median age of 54 (range 14 - 80) years were 
treated. Tumors were considered unresectable because of size, their multicentricity in the 
limb, or fixation to the neurovascular bundle and or bone and therefore amputation was the 
only alternative treatment option. Perfusion was performed at the iliac level in 32 cases 
(42%), at the popliteal level in 23 cases (30%), at the femoral and axillary level in each 11 
cases (14%). There were 60 primary (82%) and 13 recurrent (18%) sarcomas. Sixty two 
sarcomas were located in the leg (85%) and 11 in the arm (15%). All patients were treated 
after informed consent was obtained according to the institutional guidelines. 
Nineteen different histological types of STS were distinguished. The pathological grade of the 
tumor was scored following the criteria of Coindre et al. as well as the stage of the tumor 
according to the American Joint Committee on Cancer (AJCC)
16 (Table 1).
17 Median tumor 
size was 16.2 (range 8.3 – 23) cm. In case of multifocal disease, the largest diameter was 
used. 
 
Perfusion technique 
The perfusion technique employed at the University Medical Center Groningen is based on 
the technique developed by Creech et al.
18and described elsewhere.
19 The major modifications 
during the last thirty years were the use of modern thermal blankets, improvement in leakage 
monitoring, the introduction of a membrane oxygenator and heat exchanger, to ensure an 
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optimal perfusion at 39-40°C. Since an extensive wash out procedure with 6 L of saline is 
used systemic inflammatory response syndrome (SIRS) is hardly seen.
20 Postoperatively 
patients can be monitored on the recovery ward instead of the intensive care unit.  
 
Assessment of Tumor Response, tumor remnant and follow-up 
Responses were assessed by standardized World Health Organization (WHO) criteria and 
based on physical examination, and or MRI/CT investigations.
21 Complete response (CR) was 
defined as the disappearance of all measurable disease in the limb for longer than 4 weeks, 
partial response (PR) as regression of the tumor size by greater than 50% for longer than 4 
weeks, no change (NC) as regression of less than 50% of the tumor in the limb or progression 
of less than 25% for longer than 4 weeks. 
Resection of the tumor remnants was performed between 2 – 15 weeks after perfusion 
(median 8 weeks). After resection, response was also made on pathological examination. The 
tumor remnants were measured in three dimensions and the percentage of necrosis estimated 
in relation to the complete tumor volume. Representative tumor sections were taken, 
encompassing macroscopically different tumor areas, including necrosis. As a general rule, 
one section per centimeter largest diameter with a minimum of three was taken. Based on an 
integration of gross and microscopic findings, a final estimate of the percentages of viable and 
necrotic or regressive tumor was made. 
Excision margins were also evaluated on pathological examination and classified as radical 
when the resection margins were free of tumor cells (complete resection; R0), or as R1 when 
resection margins were microscopically involved or as R2 when resection margins were 
macroscopically positive involved. Postoperative radiotherapy (60 - 70 Gy) was considered 
indicated in case of <95% necrosis on pathological examination of the tumor or with marginal 
or microscopically positive resection margins. All patients were followed after perfusion 
treatment in a standardized protocol. Median follow-up was 27 (range 2 – 138) months. 
 
Statistical Analysis 
Survival and limb salvage curves were calculated according to the Kaplan-Meier method and 
Log-rank test.
22 Values of P ≤ 0.05 were considered to be statistically significant. Graph Pad 
Prism
® version 2.0 for Windows statistical software was used. 
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Results 
Tumor response 
A clinical complete response was observed after 19 ILP’s (25%), a PR after 53 ILP’s (69%) 
and NC after 5 ILP’s (6%) local progression was never observed. Resection of the remnant 
tumor was performed in 68 patients (93%). The pathological response is illustrated in Figure 
1. After 17 ILP’s (23%) no viable tumor cells were found on pathological examination. In 29 
ILP’s (37%) 90% or more necrosis was found on pathological examination. Adding both 
groups together a good response to ILP was found in 60% of the patients. In 17 ILP’s (22%) 
an intermediate response was found on pathological examination (necrosis 50-80%). After 8 
ILP’s (10%) less than 20% of necrosis or no necrosis was found on pathological examination. 
In 5 patients (7%) tumor response was not assessed because of progression of distant 
metastases in 4 patients and a local recurrence in one patient that necessitated a second 
perfusion resulting in 90% necrosis of the tumor. No correlation could be demonstrated 
between grade and percent necrosis of the tumor after perfusion (Pearson’s correlation). Post 
operative radiotherapy (total dose 60-70 Gy, 25 x 2 Gy daily and 10-20 Gy boost) was given 
in 37 patients with microscopically involved or marginally free resection margins. Radiation 
therapy started within 5-6 weeks after tumor resection. Radiation treatment was delivered 
through a multiple-field technique with CT treatment planning on a linear accelerator, 6-15 
MV. 
 
Amputations and limb salvage 
A total of 21 amputations (28%) were performed. Table 2 presents the time interval between 
ILP and amputation and the rationale for amputation. Overall 1, 5 and 10 years limb salvage 
was 80.1 ± 4.8, 68.2 ± 6.5% and 60.6 ± 9.2% respectively (Figure 2). When analyzing the 
limb salvage curve, a distinction in 3 time episodes was observed at risk for amputation. The 
first period was observed within the first one and a halve year after perfusion (17 patients) due 
to a perfusion induced massive necrosis of the tumor and overlying skin resulting in a soft 
tissue deficit (6 patients), tumor recurrence after perfusion (5 patients), wound complications 
after ILP followed by radiotherapy (2 patients), a microscopically involved resection margin 
with the rejection of the patient for adjuvant radiotherapy of the foot (2 patients), one patient 
with an insufficient clinical response and in one patient an arterial trombosis occurred with no 
5   2Amputation after isolated limb perfusion with TNF and melphalan for STS 
 
 
vascular reconstruction possibilities 2 months after resection of a local recurrence in the groin. 
The second time period was within 5 years after ILP, with 2 amputations performed for late 
local recurrent disease (37 and 58 months after perfusion). The third episode occurred around 
ten years after perfusion. Amputation was performed for critical leg ischemia with neuropathy 
due to treatment induced atherosclerosis of the remaining tibial artery which was not suitable 
for arterial reconstruction (110 and 125 months after perfusion). An example of the clinical 
appearance of patient no 21 is shown in Figure 3. In this patient a popliteal ILP was 
performed at the age of 18 years for a chondrosarcoma. After marginal resection this patient 
received 66 Gy adjuvant radiotherapy. Ten years after ILP an amputation was performed 
because of critical leg ischemia. No recurrent disease was found on pathological examination 
of the amputated specimen. Another two patients developed a pathological fracture of the 
femur due to radiation induced osteonecrosis (78 and 129 months after perfusion). All of 
these 4 patients with late post ILP complications received high dose post-perfusion 
radiotherapy (60 - 70 Gy).  
 
Systemic metastases and survival 
Twelve patients presented with distant metastases at time of ILP (16% stage IV AJCC), 50% 
of these patients had lung metastases whereas remarkably the other halve had lymphe node 
metastases. Eleven of these patients died of disease after a median period of 9 (range 2 - 54) 
months), one patient is alive with no evidence of disease after 11 months. During follow-up 
25 patients (36%) developed distant metastases at a median interval of 9 (range 2 - 100) 
months. A significant difference (P < .001) was observed between patients with no distant 
metastases at the time of ILP (mets -) compared with patients with metastases at the time of 
ILP (mets +) (Fig. 4). Overall 1, 5 and 10 year’s survival for all patients was 82.9 ± 9.2%, 
58.7 ± 13.1% and 42.5 ± 18.2% respectively (Figure 4). 
 
Discussion 
The results of an European multi-center trial performed in the nineties, lead to the approval of 
using TNF for ILP in patients with locally advanced extremity sarcomas by the European 
Medicine Evaluation Agency.
15 Currently ILP with TNF is available in more than 30 Centers 
and in 2002, 350 so called TNF-perfusions were performed. As one of the first centers that 
participated in the TNF ILP experience and practice for over a decade we recently 
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encountered long-term treatment related morbidity necessitating amputation of the perfused 
limb 10 years after treatment. For this reason we analyzed our results of ILP with TNF and 
melphalan and describe our results in the present study. 
We observed an overall response rate of 82% which is in the range of the 63 - 91% response 
rates reported in the literature.
15,23-25 Although a suggestion has been made for a relation 
between the grade of a sarcoma and the response to TNF ILP we could not demonstrate a 
correlation between grade and the percent necrosis after ILP with TNF. This is in 
concordance with the results of the Amsterdam group.
23 Various reports have shown that a 
limb salvage rate of 81-86% can be achieved in patients with locally advanced limb 
sarcoma.
15,23-25 An independent review committee reconsidered the unresectability criteria of 
all enrolled patients in the European study. Eighty percent of the patients in this study met 
indeed the criteria for unresectability and survival curves based on a match control study with 
cases of the Scandinavian Soft Tissue Sarcoma Databank showed that TNF ILP had no 
negative effect on survival.
26 
We used the Kaplan-Meier method to calculate limb salvage as this method adjust for 
censored observations, i.e. patients who were alive and well at the time of last contact or 
patients who have died of distant metastases but with preserved limb function. Using this 
method we calculated a 1 year limb salvage rate of 80% with amputations performed mainly 
because of post perfusion related complications or early local recurrence in the first year after 
ILP. A second curve in limb salvage was observed within 5 years after TNF ILP in two 
patients with late local recurrences. A third bent in the limb salvage curve was observed 
around ten years after ILP. This was a new observation in two patients that presented with 
critical leg ischemia with ulceration and continuous pain. Besides ILP with TNF and 
melphalan, both patients received adjuvant radiotherapy (66 and 70 Gy) after marginal tumor 
resection. 
What seems to be the cause of this late morbidity? Analysis of the functional and long-term 
morbidity in 97 patients with stage I melanoma treated with ILP with melphalan as the sole 
perfusion agent in our own center, showed after a median follow up of 36 (range 12-76) 
months, no patients with critical leg ischemia.
27 The Rotterdam and Amsterdam perfusion 
group reported a long-term morbidity consisting of muscle atrophy or fibrosis in 11% of the 
patients after ILP with melphalan, however cases of critical leg ischemia are not described.
28 
The fact that in our series no muscle atrophy or fibrosis was found might be explained by the 
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fact that we always perform a lateral fasciotomy after ILP to prevent a compartment 
syndrome. With a literature search for late morbidity after ILP with TNF and melphalan, no 
studies could be retrieved. 
The clinical importance of late morbidity after radiotherapy has evolved since the publication 
of Eifel et al. who retrospectively reviewed the medical records of 1784 FIGO stage IB 
patients receiving primary radiotherapy at the MD Anderson Cancer Center between 1960 and 
1989.
29 She showed that after 5 years, there was a small but continuous risk of experiencing 
major complications of radiotherapy, i.e. urinary, rectal and small bowel complications, all 
the way to 20 years of follow-up. Johansson et al. described a high occurrence of severe 
neuropathy closely linked to the development of fibrosis around the nerve trunks, after 
aggressive postoperative telecobalt therapy received in 1963-1965 in a group of 71 breast 
cancer patients that were initially treated with modified radical mastectomy.
30 Radiotherapy 
damage to the vascular system was demonstrated by Hopewell in an experimental setting, 
arteries of the hamster cheek pouch, showed localized constrictions after irradiation.
31 These 
constrictions were caused by clones of endothelial cells and may be the predominant factor 
influencing the degeneration of the capillary bed after radiotherapy.
32 Evidence of this 
occlusive effect of vessels by proliferating endothelial cells after radiation have also been 
reported by other investigators.
33  
Another argument to subscribe the observed late morbidity, at least in part, to the radiotherapy 
is the fact that another two patients receiving adjuvant radiotherapy after ILP with TNF and 
melphalan, developed a pathological fracture of the femur (78 and 129 months after ILP with 
TNF and melphalan). Radiotherapy induced osteonecrosis is a well known phenomenon after 
radiotherapy. Lin et al. described 12 fractures of the femur after surgery and irradiation for 
STS of the thigh. Treatment of these fractures was difficult and demanding with only 4 bony 
unions after a mean follow-up of 37 months.
34 When we add up the evidence of developing 
fibrosis after ILP with melphalan and the development of fibrosis after radiotherapy, the 
combination of the two regiments could explain the observed late morbidity rate in the present 
series.  
Overall survival for all patients showed a steadily decline with a ten year percentage of 42%. 
Even after 110 and 120 months patients die of distant metastases. Sixteen percent of the 
patients had metastases at the time of ILP. A significant difference in survival was observed 
comparing these patients with pulmonary or lymphe node metastases with patients lacking 
metastases at time of ILP. Five- year overall survival of 59% in this series is higher than the 
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5  
reported 5 year survival of 48% in the Amsterdam experience and the reported 32% of 
Lejeune et al.
23,24 This in an unexpected observation since selection criteria for ILP with TNF 
between the institutes are comparable. 
Patients with high-grade tumors and diameters greater than 5 centimeter have a great 
tendency to metastasize. These patients could theoretically benefit from neo-adjuvant 
chemotherapy. A quantitative meta-analysis of data from 14 trials of doxorubicin-based 
adjuvant chemotherapy showed indeed a benefit from systemic adjuvant chemotherapy of 6% 
for local relapse-free interval, however there was no overall survival benefit at 10 years.
35 
Delaney et al. developed a regimen of preoperative chemotherapy consisting of mesna, 
adriamycin, ifosfamide, and dacarbazine (MAID) interdigitated with radiotherapy followed 
by resection and postoperative chemotherapy with or without radiotherapy to improve 
outcome in patients with high grade extremity STS. Compared with a historical group of 
control patients, outcome in the MAID group was superior.
36 In an update of 64 patients 5 
required amputation because of disease, 3 had unresectable disease and 1 patient refused 
surgery. Estimated three-year survival and local-regional control were 75.1% and 79.3%, 
respectively. These results are comparable with the results of the present study.
37 However, 
systemic therapy is associated with systemic toxic effects in contrast with the mild systemic 
side effects observed after ILP with TNF and melphalan. 
Since 1992 we have not changed the indication for TNF perfusion. Patients who were 
candidates for amputation of the involved limb, based on the preoperative MRI, were offered 
an ILP with TNF and melphalan with the ultimate goal to preserve the limb with a locally 
advanced soft tissue sarcoma. After ILP patients received a delayed surgical resection and 
adjuvant radiation therapy in those patients with marginal or microscopically positive 
resection margins. This treatment resulted in a high limb salvage rate in patients with locally 
advanced STS, however late morbidity can occur especially when adjuvant postoperative 
radiotherapy is applied. Therefore continuous follow-up of these patients is warranted.  
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Table 1 Histological grade of the tumors according to Coindre et al.
17 and stage of the tumors 
according to AJCC.
16 
Grade Number  % 
I  10 14 
II  23 32 
III  40 54 
Stage    
I  10 14 
II  1 1 
III  50 69 
IV  12 16 
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Table 2 Amputations performed in 21 patients sorted on interval duration. 
N Diagnosis  Age 
(years) 
Interval 
(months) 
Rationale for amputation  Current status 
1 PUS  60  0  Postperfusion  necrosis
38  NED 120 months 
2  Angiosarcoma  74  1  Local recurrence   DOD 11 months 
3  Fibrosarcoma  76  1  Postperfusion necrosis  NED 2 months 
4  PUS  67  2  Postperfusion necrosis  DOD 9 months 
5  Epitheloid sarcoma  21  2  Postperfusion necrosis  DOD 54 months 
6 Leiomyosarcoma 
 
17 
 
2 
 
Insufficient clinical 
response 
DOD 7 months 
 
7 Liposarcoma 
 
60 
 
2 
 
R1 resection, RT not 
possible 
AWD 10 months 
 
8  PNET  62  3  Local recurrence  DOD 17 months 
9  Synovial sarcoma  39  3  Postperfusion necrosis  DOD 50 months 
10  PUS  63  3  Postperfusion necrosis  NED 72 months 
11  Angiosarcoma  80  4  Local recurrence  DOD 10 months 
12  Synovial sarcoma 
 
65 
 
4 
 
R1 resection, RT not 
possible 
NED 6 months 
 
13  Epithelioid sarcoma  22  6  Local recurrence *  DOD 39 months 
14  Haemangiopericytoma 
 
50 
 
8 
 
Wound complications after 
ILP with radiotherapy * 
AWD 65 months 
 
15  PUS 
 
71 
 
12 
 
Wound complications after 
ILP with radiotherapy * 
NED 14 months 
 
16  PUS  61  15  Arterial occlusion  AWD 17 months 
17  Synoviosarcoma  42  18  Local recurrence  NED 20 months 
18  Liposarcoma  53  37  Local recurrence  DOD 110 months 
19  Liposarcoma  39  58  Local recurrence  DOD 120 months 
20  PNET  56  110  Critical leg ischemia  NED 118 months 
21  Chondrosarcoma  18  125  Critical leg ischemia  NED 134 months 
 
NED = no evidence of disease; AWD = alive with disease; DOD = death of disease; PUS = pleomorphic undifferentiated 
sarcoma; PNET = malignant peripheral nerve sheath tumor; R1 resection = microscopically involved resection margin; 
RT = radiotherapy; * patients with a second TNF melphalan ILP 
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Figure 1 Percentage of necrosis estimated on pathological examination of the resected tumor 
remnant in relation to the number of patients. 
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Figure 2 Limb salvage curve in patients with locally advanced soft tissue sarcoma treated 
with TNF and melphalan isolated limb perfusion. 
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6  
Figure 3 Clinical appearance of the lower leg of patient no 21 (Table 3) before amputation for 
critical leg ischaemia. 
 
 
Figure 4 Overall survival in patients with locally advanced soft tissue sarcoma treated with 
ILP, TNF and melphalan. A significant difference was observed between patients with no 
distant metastases at the time of ILP (mets -) compared with patients with metastases at the 
time of ILP (mets +). 
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Abstract 
Background: The aim was to investigate the value of adjuvant radiotherapy for locally 
advanced soft tissue sarcoma (STS) after hyperthermic isolated limb perfusion (ILP) with 
Tumor Necrosis Factor alpha (TNF) and Melphalan followed by limb-saving surgery. 
Methods: From 1991-2003, 73 patients, median age 54 (range 14-80) years underwent 77 
ILP’s followed by resection in 68 patients (93%). Radiotherapy was administrated in case of 
marginally or microscopically positive resection margins. Local recurrences were scored and 
calculated according to the Kaplan-Meier method and Log-rank test. 
Results: After residual tumor mass resection 58% received radiotherapy (EBRT+group) and 
42% did not (EBRT-group). The median follow-up was 28 (range 2-159) months. A 
significant better local control rate was observed in the EBRT+ compared with the EBRT-
group (P<.0001). When only R0 resections in non-metastased patients were considered the 
significance remained between both groups (P=.0003). In the EBRT-group, a R1 or R2 
resection resulted in earlier relapse of local disease compared with R0 resections (P=.0475). 
Conclusions: Adjuvant EBRT reduces the risk for local recurrence after delayed resection in 
STS patients treated with ILP and TNF and is indicated when resection margins are close or 
microscopically positive and seems, also beneficial after a R0 resection. 
 
66Adjuvant radiotherapy after isolated limb perfusion  
 
Introduction 
Soft tissue sarcomas (STS) comprise a heterogeneous group of malignant mesenchymal 
tumors, generally classified according to their resemblance to normal tissue. Currently 19 
histological types and over 50 different subtypes can be recognized. Many histological types 
reveal different biological behavior, but even within a single histological group considerable 
divergence in the malignant potential has been noticed. During the last decade it has become 
evident that the studies in STS provide more insight in tumor behavior, when they were 
specified for histological type and grade.
1 
A major difficulty in the management of STS is the low incidence, as well as their insidious 
presentation. During the last two decades there have been improvements in the 
radiodiagnostic evaluation of these tumors. The development of magnetic resonance imaging 
(MRI) with or without angiography and spiral computer tomography (CT) facilitates the 
surgeon in planning the surgical procedure as well as the radiation oncologist in planning the 
pre or postoperative radiation treatment. More extensive surgical procedures became possible 
with the reconstructive surgical techniques with implants and/or tissue transfer with the 
ultimate goal to improve the outcome, e.g. limb saving operations, decrease local failure rate 
and increase disease free and overall survival, without increasing long-term morbidity. The 
role of (neo)adjuvant chemotherapy in the treatment of soft tissue sarcomas is limited with the 
exception of the Ewing sarcomas, primitive neuro ectodermal tumors (PNETs) and 
rhabdomyosarcomas.
1 
Although limb saving surgical procedures are feasible in the majority of patients with soft 
tissue sarcomas of the limb, a small proportion of patients can only be treated with an 
amputation. Since the early nineties these patients are candidates for the so-called 
hyperthermic isolated limb perfusion (ILP) with Tumor Necrosis Factor alfa (TNFα) and 
Melphalan followed by delayed resection. Eggermont and co-investigators investigated this 
new treatment approach and documented in a large European study an objective response rate 
of 76% and a limb-salvage rate of 71% with minimal treatment related morbidity.
2 This 
treatment approach is also applied at the University Medical Center Groningen since 1991. 
We recently investigated the overall limb salvage rate of these patients and described long 
term morbidity resulting in late amputations years after therapy. The role of adjuvant 
radiotherapy in this late observed morbidity was discussed as a possible contributing factor.
3  
The goal of the present study was to investigate the primary role of the radiotherapy as an 
adjunct to prevent local recurrence after ILP with TNFα and Melphalan. 
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Patients and methods 
During the time period July 1991- December 2003, 73  patients, 36 males (49%) and 37 
females (51%) with a median age of 54 (range 14-80) years with locally advanced primary or 
recurrent STS were eligible for an ILP with TNFα and melphalan, followed by delayed 
resection and adjuvant external beam radiotherapy. The sarcomas were graded according to 
the French grading system and the histology was based on the most recent World Health 
Organization's Classification of Tumors (Table 1).
4,5 All patients had the same preoperative 
workup to stage the disease locally and to detect possible distant metastases: magnetic 
resonance imaging (MRI) of the affected limb and computed tomographic (CT) scans of the 
lungs.
6 Patients without metastatic disease were treated with curative intent, while patients 
with metastatic disease were eligible for a so called ‘palliative perfusion’ when they had a life 
time expectancy of minimum six months and the intention of the treatment was limb salvage.  
 
Table 1 Classification of the locally advanced soft tissue sarcomas in this study: 
Primary/recurrent, grade and histology. 
 
Primary/recurrent soft tissue sarcoma  % 
Primary STS  88 
Recurrent STS  12 
Grade   
Grade I  14 
Grade II  32 
Grade III  43 
Histology  
Pleomorphic undifferentiated sarcoma (non otherwise specified)   32 
Synovial sarcoma   14 
Myxoid liposarcoma   10 
Leiomyosarcoma   8 
   Myxofibrosarcoma   6 
Fibrosarcoma   4 
Malignant peripheral nerve sheath tumor (MPNST)   4 
Epitheloid sarcoma   3 
Myxoid chondrosarcoma   3 
Angiosarcoma   3 
Other*   13 
 
Legend 
Other* = embryonal rhabdomyosarcoma, well differentiated (lipoma like) liposarcoma, pleomorphic liposar-
coma, primitive neuroectodermal tumor (PNET), clear cell sarcoma, malignant solitary fibrous tumor, Ewing 
sarcoma, malignant myoepithelioma of soft tissue, pleomorphic rhabdomyosarcoma. 
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According to the AJCC staging system there were 10 stage I, 1 stage II, 50 stage III and 12 
stage IV tumors.
7 All patients were treated after informed consent was obtained according to 
the institutional guidelines. 
 
Perfusion technique 
 ILP was performed under general anesthesia. The major artery and vein of the limb were 
clamped after heparinization with 3.3 mg heparin/kg body weight (Thrombolique, Organon 
BV, Oss, The Netherlands). Collateral vessels were ligated and a tourniquet was applied to 
compress the remaining minor vessels. The perfused limb was wrapped in a thermal blanket 
to reduce heat loss. The perfusion technique of the axillary, iliacal and popliteal vessels was 
previously extensively described.
8,9  Leakage of the perfusion circuit to the systemic 
circulation was measured with radio labeled iodide and technetium.
10 The extremities were 
perfused for 90 minutes under mild hyperthermia (39-40°C) with TNFα (Beromun®, 
Boehringer, Ingelheim, Austria) and Melphalan (L-phenylalanine mustard; Glaxo- Wellcome 
company, Italy). The following doses were used: 3 mg TNFα (arm), 4 mg TNFα (leg) or 3 
mg TNFα (popliteal perfusion) and 10 mg/l Melphalan (limb volume, leg) to 13 mg/l 
Melphalan (limb volume, arm). In the beginning of the study, 18 patients also received a dose 
of 0.2 mg Interferon  (Boehringer, Ingelheim, Austria) subcutaneously 1 and 2 days before 
perfusion, followed by 0.2 mg INFγ injected into the arterial line at the start of perfusion. At 
the end of the perfusion the heparin was antagonized with prothrombin and a fasciotomy was 
performed. Patients received subcutaneous low-dose molecular heparin until full 
mobilization. 
 
Clinical and pathological response 
Complete clinical response (CR) was defined as disappearance of all measurable disease in 
the limb for longer than 4 weeks; partial response (PR) as regression of the tumor size by 
greater than 50% for longer than 4 weeks, no change (NC) as regression of less than 50% of 
the tumor in the limb or progression of less than 25% for longer than 4 weeks. After resection 
were the tumor remnants measured in three dimensions and based on an integration of gross 
and microscopic findings, the percentage of necrosis was estimated. The histopathological 
response of ILP was standardized and scored according to the World Health Organisation 
(WHO) criteria.
11 The resection margins of the tumor were classified as radical when the 
resection margins were free of tumor cells (complete resection; R0), or as R1  when resection 
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margins were microscopically involved or as R2 when resection margins were 
macroscopically positive involved. Resection margins were perioperatively marked with clips 
to facilitate adjuvant radiotherapy when indicated.  
 
Radiation treatment 
Postoperative radiotherapy (60-70 Gy) was considered indicated in case of <95% necrosis on 
pathological examination of the tumor or with marginal or microscopically positive resection 
margins. EBRT was given with a daily dose 2 Gy (25x2Gy) and an additional boost dose of 
10 Gy (after R0 resection) or 20 Gy (after R1-R2 resection) (2 Gy/day). Radiation therapy 
started within 5-6 weeks after tumor resection. Radiation treatment was delivered through a 
multiple-field technique with CT treatment planning. Radiotherapy was given on a linear 
accelerator, 6-15 MV. When indicated, patients received rehabilitation service as well as 
physiotherapy. 
 
Follow-up 
All patients were clinically followed after treatment according to a standardized protocol at 
three months intervals during the first year, four month intervals during the second year, than 
every six months and after five year once a year. A chest X-ray was performed after each 
visit. Primary end point in this study was local recurrence. Disease free and overall survival 
(DFS and OS), regional and distant metastases were also scored. Analyses of endpoints were 
calculated according to the Kaplan-Meier method and Log-rank test.
12 Values of P < .05 were 
considered statistically significant. Graph Pad Prism® version for Windows statistical 
software was used.
  
 
Results 
Ten perfusions were performed for a sarcoma tumor grade I (14%), 24 perfusions for grade II 
(32%), 43 perfusions for grade III (54%). Sixty perfusions were performed for primary (88%) 
and 17 perfusions for recurrent sarcomas (12%); 61 ‘curative perfusions’ and 12 ‘palliative 
perfusions’. Sixty-two sarcomas were located in the lower limb (85%) and 11 sarcomas in the 
upper limb (15%). Perfusion was performed at the iliac level in 32 patients (42%), at the 
popliteal level in 23 patients (30%), at the femoral level in 11 patients (14%) and axillary 
level in 11 patients (14%). Four patients underwent a second perfusion: in two of these 
patients there was an insufficient response after the first perfusion. In two other patients a 
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complete response was achieved however the tumor recurred for which a second perfusion 
was performed. 
The median tumor size before an ILP was performed was 16.2 (range 8.3-23) cm. Resection 
of the residual tumor was performed after a median post-perfusion time of 8 (range 2-15) 
weeks in 68 patients (93%). After ILP complete clinical response was observed in 19 patients 
(25%), a partial response in 53 patients (69%) and no response in 5 patients (6%). Resection 
of the remnant tumor was performed in 68 patients. In four patients no resection was 
performed due to progression of distant metastasis and one patient with complete response 
refused further surgery.  
The median follow-up of the patients treated with ILP was 28 (range 2-159) months and a 
flowchart of the 73 ILPs is presented in Figure 1.  
 
Local control rate 
From the 68 patients another 4 could not complete the combined modality treatment schedule 
because they were amputated shortly after resection of the STS. This amputation was due to 
vascular disturbances, wound healing disturbances or the tumor did not respond after the 
perfusion treatment. After residual tumor mass resection 37 of the 64 patients (58%) received 
EBRT (EBRT+group) and 27 patients (42%) did not (EBRT-group). The five years local 
control rate was 96.5 ± 3.5% in the EBRT+group and 52 ± 23% in the EBRT-group 
(P<0.0001) (Figure 2). 
When only patients with curative intention, i.e. without distant metastases at the time of 
perfusion, were selected, the local tumor control rate was 96.5 ± 3.5% in the EBRT+group 
(n=35) and 56 ± 25% in the EBRT-group (n=20) (P<0.0001) (Fig. 3). 
When R0 resections were considered in the curative treated group, the local tumor control rate 
was 100% in the EBRT+group (n=29) and 55 ± 31% in the EBRT-group (n=15) (P=0.0003) 
(Figure 4). 
In the EBRT-group of patients treated with a curative intention, a R1 or R2 resection (n=3) 
resulted in an earlier relapse of local disease compared with R0 resections (n=15)(P=0.0475): 
with at 2 years a difference of 57 ± 28% versus 33 ± 33% (Figure 5). 
In the EBRT+group of patients treated with curative intention, a R0 resection (n=29) resulted 
after 5 years in 100% local tumor control rate versus 75 ± 25% in a R1 resection (n=6) 
(P=0.01) (Figure 6).  
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Figure 1 A flowchart of the patients from entry all the way to the final group. 
73 ILPs 
68 tumor resections 
5 not resected due to: 
- progressive disease (4) 
- complete response (1) 
Resection of tumorbed 
64 patients 
limb salvage 
37 
EBRT+ 
27 
EBRT- 
4 amputations 
11 patients with progress of 
distant metastases or 
amputation who are not 
scored for local recurrence 
29 
R0 
6 
R1 
15 
R0 
3 
R1 or R2 
35 EBRT+  18 EBRT- 
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Figure 2 Local tumor control rate in all patients: five years local control rate EBRT+group 
(n=37) 96,5 ± 3,5% versus 52 ± 23% EBRT- group (n=20) (P<0.0001). 
 
 
Figure 3 Local control rate in patients treated with curative intent: five years local control rate 
EBRT+group (n=35) 96.5 ± 3.5% versus 56 ± 25% EBRT- group (n=20) (P<0.0001). 
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Figure 4 Local control rate in patients treated with curative intention and R0 resections: five 
years local control rate EBRT+ R0 group (n=29) of 100% versus 55 ± 31% EBRT- R0 group 
(n=15) (P=0.0003). 
 
Figure 5 Local control rate in patients treated with curative intention without adjuvant 
radiotherapy: EBRT- R0 (n=15) versus R1 or 2 resections (n=3): 2 years local control rate 57 
± 28% versus 33 ± 33% (P=0.0475). 
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12
0
20
40
60
80
100
EBRT + R0
EBRT - R0
Years
L
o
c
a
l
 
c
o
n
t
r
o
l
e
 
r
a
t
e
0 1 2 3 4 5 6 7 8 9 10 11 12
0
20
40
60
80
100
EBRT - R0
EBRT - R12
Years
L
o
c
a
l
 
c
o
n
t
r
o
l
e
 
r
a
t
e
74Adjuvant radiotherapy after isolated limb perfusion  
 
Figure 6 Local control rate in patients treated with curative intention, EBRT+ R0 (n=29) 
versus EBRT+ R1 resections (n=6): 5 years local control rate 100% versus 75 ±  25% 
(P=0.01). 
 
Metastasis and overall survival 
Twelve patients presented with distant metastasis (Stage IV) at the time of ILP (16%). There 
was a significant difference in survival between the group of patients with and without distant 
metastases at the time of ILP (P< .001). During follow-up 25 patients (36%) developed distant 
metastasis at a median interval of 9 (range 2-100) months. A total of 21 amputations (28%) 
had to be performed in the whole series. The overall 1, 5 and 10 years survival was 83.1 ± 
4.4%, 61.4 ± 6.4% and 47.5 ± 7.5% respectively (Figure 7). 
 
Figure 7 Overall survival in all ILP patients: the overall 1, 5 and 10 years survival was 83.1 ± 
4.4%, 61.4 ± 6.4% and 47.5 ± 7.5% respectively. 
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Discussion 
The goal of adjuvant radiotherapy in this combined limb saving treatment modality was to 
decrease the local recurrence rate. From previous studies we know that survival figures in 
extremity sarcoma patients are not influenced by limb saving procedures.
13,14,15 Adjuvant 
radiation treatment improves local tumor control in limb saving treatment of STS.
16,17 The 
first goal of the applied combined modality treatment of ILP was to increase the limb salvage 
rate in patients with extremity sarcomas, who were locally irresectable by standard surgical 
treatment. Indeed we were able to achieve a limb salvage rate of 72%. Tumors with 
microscopically or macroscopically involved margins received adjuvant radiation as well as 
marginal resected tumors with less than 95% necrosis on pathological examination. From an 
earlier study we know that adjuvant radiation after ILP and delayed tumor resection of locally 
advanced extremity STS was feasible.
18 In this study we demonstrated unequivocally that 
adjuvant radiation treatment should be used in this combined modality treatment, even after 
radical resections.Radiation can improve local control after marginal resection (R1 or R2). 
Trovik showed a local failure rate in R1 and R2 resection of 39% without irradiation 
compared to 24% with irradiation.
19 There is also a relation between the delivered radiation 
doses and local tumor control in sarcoma treatment. Fein et al demonstrated that boost therapy 
with a total dose >62.5Gy resulted in a 5-year local control rate of 95% compared to 78% for 
patients receiving less than 62.5Gy (p=0.008).
17  
The value of adjuvant radiotherapy in limb saving sarcoma surgery was first demonstrated by 
Rosenberg et al. in the early eighties.
15 Yang et al updated their initial experience and 
described after a median follow-up of 9.6 years a highly significant decrease in the probability 
of local recurrence after irradiation (p=0.0028), without difference in overall survival. 
Adjuvant irradiation resulted in significantly worse limb strength, oedema, and range of 
motion. But these deficits were often transient and had few measurable effects on activities of 
daily life or global quality of life.
16  
Despite the advantage of decreasing the local recurrence rate, the clinical importance of acute 
and late morbidity after radiotherapy may not be underestimated. Two patients in our series 
developed late radiation induced complications after ILP and adjuvant radiotherapy. A 
pathological fracture of the femur at 78 months and 129 months and in both patients this 
resulted in pseudarthrosis. Treatment of these fractures might be difficult.
20 Therefore a study 
was designed by Sullivan and co-workers in the nineties to overcome the postoperative 
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radiation morbidity. Postoperative radiotherapy was compared with preoperative radiotherapy 
and a disadvantage of the preoperative radiotherapy with increased risk of wound 
complications was shown.
21 Recently, Eggermont and co-workers demonstrated that ILP can 
also be safely applied in pre-irradiated limbs.
22 There is often a discussion with respect to 
‘unresectability’ of these kind of extensive sarcomas and the type of treatment to be 
performed. Instead of ILP, preoperative radiotherapy might be an option, to reduce ‘tumor 
volume’and ‘tumor aggressiveness’ and to render a patient resectable for cure. A disadvantage 
of this treatment option is the increased risk for woundcomplications.
21  Another point of 
discussion might be if ILP patients with a good clinical/pathological response (>95% 
necrosis) and ‘good’ surgical margins need adjuvant radiation. We showed that indeed these 
patients need adjuvant radiation, since the local control rate in this group was only 56% 
without adjuvant radiation. Our PET studies in sarcomas after ILP showed in these tumors 
often an active rim on the outside of the tumor.
23 This was the rim with viable tumor, inside 
full necrosis, outside viable tumor cells. It is well known that a ‘good’ surgical margin in 
sarcoma surgery is often an inadequate margin for local tumor control.
15,16 
Therefore ‘wide’ local tumor resections are advocated, but these ‘wide’ local resections were 
impossible in these perfused patients. The results of this study emphasize the key role of 
adjuvant radiation in reducing the risk of local recurrences in the combined modality 
treatment of ILP for locally advanced STS of the extremities. Although we observed in an 
earlier publication about the risks of late morbidity of radiation in a perfused limb, the 
contributing effect of radiotherapy should outweigh this risk since patients with locally 
advanced soft tissue sarcoma are at a high risk of dying of distant metastases. 
 
Conclusion 
ILP followed by delayed surgical resection is an effective limb salvage treatment regimen for 
locally advanced extremity STS. Adjuvant EBRT reduces the risk for local recurrence 
significantly and is indicated when resection margins are close or microscopically positive 
and seems, also beneficial after a R0 resection. 
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Abstract  
Background: Evaluating the potential role of standardized uptake value (SUV) in patients 
with locally advanced, non-metastased, high-grade, extremity soft tissue sarcoma.  
Methods: Thirteen patients scheduled for hyperthermic isolated limb perfusion (ILP), referred 
for a 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)-scan were 
eligible. The SUV in the sarcoma lesion was calculated before and six weeks after ILP. After 
the second scan, surgical resection was performed. Survival data were assessed.  
Results: Univariate analysis showed prolonged overall survival in those with a low SUVmax 
value after perfusion (144 ± 8months) compared to those with a high SUVmax (33 ± 
8months) (p=0.004), but SUV max was not an independent prognostic factor (p=0.08).  
Conclusion:  Patients with a high grade locally advanced STS with a high SUVmax 
postperfusion showed a decreased overall survival compared to patients with a low SUVmax. 
The opportunities of SUV measurements in diagnosis and treatment evaluation of STS 
patients needs further exploration. 
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Introduction 
Over the past thirty years there has been a tremendous progress in the local management of 
these malignancies. Improved developments in diagnostic imaging and surgical treatment 
with adjuvant radiotherapy are the cornerstones of this evolution: almost 90% of extremity 
STS can be treated today with limb salvage surgery with or without adjuvant radiation.
1,2 For 
patients with primary irresectable STS, hyperthermic isolated limb perfusion (ILP) with 
Tumor Necrosis Factor alpha (TNF) and Melphalan became available in the early nineties. 
This treatment has resulted in a long term limb salvage rate of 82%.
3 Survival of extremity-
STS-patients is not influenced by these limb salvage procedures.
4 The 5-year survival rate of 
soft tissue sarcomas (STS) of the extremities is 60-70%.
1,2 Identification of prognostic factors 
may allow the development of individualized strategies leading to improved results.  
A possible way to identificate prognostic factors is Positron Emission Tomography (PET). 
PET visualizes the uptake of radiolabeled tracers.
5 18F-Fluorodeoxyglucose (FDG), a 
radiolabeled glucose analogue is a tracer that measures the glucose metabolism which is 
increased in cancer cells.
6 An accelerated rate of glucose transport and an increased rate of 
glycolysis are among the most characteristic biochemical markers of malignant 
transformation.
7 FDG uptake has been found to be associated with cell viability and 
particularly with cell proliferative activity.
8-10 The currently most widely used radiotracer in 
oncology is FDG.
11 A systematic review and meta-analysis indicated that FDG-PET can 
discriminate between benign and malignant soft tissue tumors and low and high-grade 
sarcomas based on the Standardized Uptake Value (SUV).
12 SUV of PET assesses the degree 
of tracer accumulation. In patients with breast cancer, head and neck carcinoma, pancreatic 
cancer and lung cancer, high FDG uptake showed a significantly lower disease-free and 
overall survival. The SUVmean or SUVmax turned out to be significant prognostic factors in 
several univariate and multivariate analyses.
7,13-19 However, studies have also been published 
where the SUV had no prognostic value with respect to disease-free or overall survival.
17,20  
No studies evaluating consecutive values of FDG-uptake prior and after regional 
chemotherapy have been performed in patients with a soft tissue sarcoma of the extremity. 
The potential role of the SUV was analyzed in predicting relevant aspects of long-term 
outcome in patients with STS treated with regional chemotherapy with isolated limb 
perfusion. 
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Patients and Methods 
Patients 
All STS patients with a high grade STS in the extremity, more than 5 cm in diameter and 
without distant metastases, who where referred to Groningen University Medical Center from 
1991 to 1995 and who underwent a hyperthermic iolated limb perfusion (ILP) and FDG-PET 
imaging prior and 6 weeks post ILP were eligible for this study. The SUV in the sarcoma 
lesion was calculated before resection: the first FDG-PET before ILP and the second FDG-
PET after ILP. ILP of the affected limb was performed with TNF alpha and Melphalan and 
followed by delayed surgical resection.
3,21 The histopathological response of ILP was 
standardized and scored according to the World Health Organisation (WHO) criteria.
22 
Complete histopathological response (CR) was defined as disappearance of all measurable 
disease in the limb for longer than 4 weeks; partial response (PR) as regression of the tumor 
size by greater than 50% for longer than 4 weeks, no change (NC) as regression of less than 
50% of the tumor in the limb or progression of less than 25% for longer than 4 weeks. 
Extensive histopathologic examinations of the resected specimens were performed. The 
percentage of necrosis was estimated on the basis of macroscopic evaluation of necrotized 
tissue and histologic examination results of tissue surrounding the necrotic area, tissue 
without identifiable nuclei being considered necrotic. If clinically no tumor was detectable 
anymore (clinical CR) but resection of the tumor bed showed vital tumor cells, the final 
outcome was downgraded to a PR. A clinical PR could only be upgraded to a CR if histologic 
analysis showed 100% necrosis of the tumor remnant. Likewise, a clinical minimal regression 
of <50%, but still rendering the tumor resectable, could be upgraded to a PR if the tumor 
remnant was found to be necrotic for 50% or more. A clinical regression of >50% would 
qualify for a PR even if necrosis in the tumor remnant would be <50%, as >50% of the tumor 
mass had disappeared.
23 The tumor was histopathological classified using the most recent 
World Health Organization's Classification of Tumors and graded according to the French 
grading system.
24,25 In case of marginal resection margins postoperative radiotherapy (60-70 
Gy) was started 5-6 weeks after tumor resection. Patients were included in the study if they 
had a perfusion after the first PET and a resection after the 2nd PET. The medical records of 
these patients were reviewed and the following information was retrieved: age at the time of 
perfusion, sex, FDG-uptake prior to, and after ILP, characteristics of the sarcoma 
(localization, type, grade, percentage of necrosis after perfusion), limb salvage, period of 
follow-up, local recurrence of the tumor, disease free survival, overall survival and 
characteristics of the metastases if they occurred during follow-up (localization, time of 
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appearance). The technique of hyperthermic ILP with TNF ad Melphalan was extended 
described earlier.
26  
 
Positron emission tomography 
FDG was routinely produced by a robotic system with a radiochemical purity of > 98% 
according to the procedure described by Hamacher et al.
27 All PET scans were performed 
using a ECAT 951/31 PET camera (Siemens/CTI, Knoxville, TN). Patients fasted for at least 
6 hours prior to PET scanning. Serum glucose levels (FDG-PET) were measured and were all 
within normal range. After a 20-min transmission scan for attenuation correction, 300-350 
MBq of FDG was injected intravenously and dynamic images were acquired for 16 time 
frames for a total of 50 min (ten 0.5 min, three 5 min and three 10 min). 
 
PET data analysis 
To measure the standardized uptake value (SUV), the last three time frames were summed 
using standard ECAT software. A region of interest (ROI) was drawn around the tumor in all 
planes to establish the plane with maximum FDG. A threshold of 70% of the maximum pixel 
value within the tumor was used. In this plane, SUVmax and SUVmean were determined 
using the injected radioactivity, measured radioactivity and patient weight. (SUV = 
radioactivity concentration in tissue (Bq/kg) / (injected dose (Bq) / patient weight (kg)). In the 
post-ILP PET scans, this procedure was repeated.  
 
Statistics  
The clinical data of the patients were analyzed using the Statistical Package for the Social 
Sciences (SPSS) for Windows (Version 12.0; SPSS INC., Chicago, IL). For the survival 
analysis patients were divided into two groups based on the median SUVmax. The 
relationships between SUV and patients' characteristics were assessed by the Student's t-test 
or analysis of variance as appropriate. Survival data were analyzed using the Kaplan-Meier 
method and the differences in cumulative survival rate were assessed using the log-rank test. 
Univariate and multivariate analysis (Cox proportional hazard model) were performed to 
determine independent prognostic predictors. All variables with p<0.2 in the univariate 
analysis were entered in the multivariate analysis. All p-values are 2-tailed and considered 
significant if p<0.05.  
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Results 
Thirteen patients met the inclusion criteria; eight males and five females with median age of 
53 (range 18-80) years. The STS was located in the upper extremity in 1 patient and in the 
lower extremity in 12 patients. The histology of the sarcomas is presented in Table 1. 
 
 
Table 1 Histology and grade of the soft tissue sarcomas in this study 
 
Histology Grade 
Embryonal rhabdomyosarcoma  3 
Dedifferentiated liposarcoma  2 
Fibrosarcoma 3 
2X Synovial sarcoma  3, 3 
Malignant peripheral nerve sheath tumor 
(MPNST) 
2, 3 
Myxoid Chondrosarcoma  2 
Primitive neuroectodermal tumor (PNET)  3 
Angiosarcoma 3 
3X Pleomorphic undifferentiated sarcoma   2, 3, 3 
 
The median size of the tumor was 16.2 cm. Median pre perfusion SUVmax was 5.6 (range 
2.1-12.2) and median post perfusion SUVmax was 3.1 (range 0.9-12.2). The median follow-
up time after PET scanning was 65 (range 10-152) months. At last follow-up, five patients 
were alive and eight were dead as a result of the disease. During follow-up one patient 
developed a local recurrence and nine patients distant metastases. Characteristics of the 
patients’ sarcomas and SUVmax are summarized in Table 2. There were no significant 
differences in patient and sarcoma characteristics. 
Univariate survival-analysis for various patient characteristics is presented in Table 3. Patients 
with a high SUVmax after perfusion had a significant lower overall survival as compared to 
those with low SUVmax (33±8 months versus 144±8 months; p=0.0004) (Figure 1). We also 
performed a univariate analysis for disease free- and limb-survival but no significant findings 
were retrieved.  
Because of possible interrelation between prognostic factors, multivariate analysis was 
performed. All variables with p<0.2 in the univariate analysis were entered in the multivariate 
analysis: sex, metastases during treatment, local recurrence, pathological response, radicality 
of performed resection (microscopically radical (R0), macroscopically radical but 
microscopically irradical (R1) or macroscopically irradical (R2)), and SUVmax after 
perfusion. Multivariate Cox regression showed that SUVmax after perfusion did not have a 
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significant independent impact on survival (p=0.084), but a trend can be shown towards 
increased survival with lower SUVmax. 
 
 
Table 2 Characteristics and SUVmax in patients with soft tissue sarcoma of the extremities  
 
Characteristic   Patients 
N 
Mean 
SUVmax ±SE 
pre 
perfusion 
p-value  Mean  
SUVmax ±SE 
post 
perfusion 
p-value 
Sex 
 
Male 
Female 
8 
5 
7.0±1.3 
5.2±1.3 
 
0.362 
4.6±1.2 
2.7±0.6 
 
0.226 
Age  <50 y 
>50 y 
6 
7 
5.8±1.1 
6.6±1.4 
 
0.693 
2.7±0.5 
4.9±1.3 
 
0.164 
Location  Arm 
Upper leg 
Lower leg 
1 
5 
7 
5.9 
6.4±1.3 
6.2±1.5 
 
 
0.991 
4.4 
4.8±1.9 
3.2±0.6 
 
 
0.648 
Grade  II 
III 
4 
9 
6.8±2.1 
6.0±1.0 
 
0.709 
4.0±0.8 
3.8±1.1 
 
0.943 
Local recurrent 
disease at start of 
treatment 
No 
Yes 
10 
3 
6.6±1.2 
5.3±1.2 
 
0.584 
4.1±0.9 
3.2±1.5 
 
0.663 
Pathologic 
response rate  
Complete 
Partial 50% 
Partial 90% 
No response 
6 
2 
4 
1 
6.1±1.4 
5.0±0.4 
7.0±2.8 
7.6 
 
 
 
0.910 
2.7±0.5 
7.7±4.5 
3.1±0.4 
6.1 
 
 
 
0.107 
Radiation  No 
Yes 
9 
4 
6.7±1.0 
5.4±1.9 
 
0.509 
4.4±1.1 
2.7±0.2 
 
0.344 
Resection  R0 
R1 
R2 
11 
1 
1 
 
6.3±1.0 
5.3 
 
 
 
0.769 
3.2±0.4 
12.2 
3.3 
 
 
0.0005 
 
 
SE = standard error  
SUV = standard uptake value 
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Table 3 Univariate Kaplan-Meier survival analysis: differences in survival (log-rank test)  
 
Variable   Patients 
N 
Mean survival ±SE 
(months) 
p-value 
Sex 
 
Male 
Female 
8 
5 
60±20 
114±16 
0.119 
Age  <50 y 
>50 y 
6 
7 
104±22 
62±20 
0.282 
Location  Arm 
Upper leg 
Lower leg 
1 
5 
7 
51 
79±28 
91±22 
0.826 
Grade  II 
III 
4 
9 
62±27 
93±19 
0.459 
Local recurrence at start 
of treatment 
No 
Yes 
10 
3 
82±19 
86±29 
0.986 
Pathologic response rate   Complete 
Partial 50% 
Partial 90% 
No response 
6 
2 
4 
1 
103±16 
38±28 
85±34 
17 
0.156 
Radiation  No 
Yes 
9 
4 
62±17 
127±22 
0.117 
Resection  R0 
R1 
R2 
11 
1 
1 
96±17 
10 
18 
0.001 
Development of 
metastases during 
treatment 
No 
Yes 
4 
9 
138±11 
59±18 
0.058 
Median SUVmax  
pre perfusion 
<=5.6 
>5.6 
6 
7 
104±22 
73±23 
0.443 
Median SUVmax  
post perfusion 
<=3.1 
>3.1 
6 
7 
144±8 
33±8 
0.0004 
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Figure 1 Kaplan-Meier overall survival for STS patients with a high post perfusion SUVmax 
or low post perfusion SUVmax after hyperthermic isolated limb perfusion. P= 0.0004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
There i  an increased interest with respect to the potential of SUV-measurements with FDG-
PET in patients treated with combined modality treatment. This pilot study shows that 
SUVmax of FDG-PET after regional chemotherapy with isolated limb perfusion might be a 
predictor for survival in patients with locally advanced high grade soft tissue sarcoma of the 
extremity. Biological studies have shown a correlation between SUVmax and tumor 
cellularity, mitosis and level of Ki-67 (a proliferative marker) and a moderate correlation with 
tissue levels of p53 (a cell growth regulation product).
19 Data in clinical studies suggest SUV 
to be an important prognostic factor, e.g. in patients with pancreatic, prostate, gastric cancer, 
head and neck and non-small-cell lung cancer and melanoma.
5,7,16,28-30  
In a selective group consisting of only high-grade sarcomas of the extremities without 
metastatic disease treated with regional chemotherapy through ILP we found that SUVmax 
was an independent predictor for survival in univariate analysis. A study in patients with bone 
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and soft tissue sarcoma (n=209) showed after a mean follow up of 19 months that SUVmax 
was a statistically significant independent predictor of patient survival.
19 We can support this 
result with our findings reported after a longer period of follow up and in a less heterogeneous 
but smaller group as only high grade soft tissue sarcomas in the extremities were considered 
and the type of treatment was more standardized. Studies with more patients are needed to 
affirm the finding of both biological imaging studies. 
 
Conclusion 
Biological imaging with FDG-PET opens new frontiers in treatment evaluation of cancer 
treatment. In this pilot study patients with a high grade locally advanced STS with a high 
SUVmax postperfusion showed a decreased overall survival in univariate analysis compared 
to patients with a low SUVmax. The opportunities of SUV measurements in diagnosis and 
treatment evaluation of STS patients needs to be further explored. 
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Abstract 
Background: Quality of life (QoL) and post traumatic stress symptoms (PTSS) were studied 
in patients with soft tissue sarcoma (STS) of the extremities treated with isolated limb 
perfusion (ILP), delayed resection with or without adjuvant irradiation.  
Methods: Forty-one patients received a questionnaire including the Rand-36 and Impact of 
Event Scale (IES). 
Results: 39 STS survivors, 16 male (41%) and 23 (59%) female, median age 59 (range 15-78) 
years participated in the questionnaire survey (response rate 95%). Median age at perfusion 
was 49 (range 14-72) years. No significant differences were found in mean scores between 
STS survivors and the reference group with the exception of a worse physical functioning. 
Amputated patients showed significantly worse physical and social functioning, and more role 
limitations than patients whose limbs were saved. Eleven patients (28%) had a PTSS score of 
zero, 8 patients (20.5%) had a score > 26 suggesting the need for psychological counselling. 
None of these 8 patients had lost their limb. Patients who indicated that the choice of 
treatment was made by the surgeon rather than collaboratively showed significantly decreased 
social functioning, more role limitations and intrusion. Greater treatment satisfaction was 
significantly related to better social functioning, more vitality, better general health 
perception, less intrusion, avoidance, and total IES.  
Conclusions: Even though STS-survivors’ QoL was only different from a reference group in 
physical functioning, one fifth of the patients suffered from PTSS. An amputation, the 
physicians’ decision rather than the patients’ decision for the perfusion treatment and a low 
satisfaction with the performed treatment negatively influenced QoL. 
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Introduction  
For decades soft tissue sarcomas (STS) were known for their poor long-term outcome with 
respect to local tumor control, survival as well as functional outcome. Developments in 
diagnostic imaging and surgical treatment with adjuvant radiotherapy are the cornerstones of 
the evolution over the past thirty years. Nowadays, STS patients have 5-year survival rates of 
60-70%.
1,2  For patients with primarily irresectable locally advanced STS, the so-called 
hyperthermic isolated limb perfusion (ILP) with Tumor Necrosis Factor alpha (TNFα) and 
Melphalan, became available in the early nineties with a limb salvage rate of 82%.
3 Survival 
of extremity-STS-patients is not influenced by limb salvage procedures.
4  
The limb salvage treatment of STS with ILP is a combined modality treatment of regional 
chemotherapy followed by delayed extensive surgical resections with or without surgical 
reconstructions and/or adjuvant high dose radiation therapy sometimes followed by systemic 
chemotherapy with curative or palliative intent. ILP treatment is time consuming and has an 
uncertain outcome. The risk of loosing a limb after limb salvage procedure is determined by 
the risk of perioperative complications, local recurrences, and short and long-term treatment 
induced morbidity.  
Patients who are alive after treatment for a potential fatal disease are often analyzed in terms 
of overall and disease free survival. However, less attention is paid to their quality of life 
(QoL) in these years gained. Health is defined by the WHO as a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity. Medical 
oncologists were one of the first physicians to implement QoL measurements into practice as 
the question raised to which extent quantity of life was gained at the expense of quality of 
life.
5 The need to investigate the QoL and the psychological consequences of this combined 
treatment became increasingly clear as more patients with extremity STS became long-term 
survivors. It is often hypothesized that for many people with cancer, the survivor advantages 
of the intensive treatment far outweigh the potential long-term side effects.
6 Findings in the 
literature are inconsistent concerning that matter: worse, equal or even better QoL in cancer 
survivors than in healthy comparison group have been reported.
7,8 However, specific 
subgroups at risk for a worse QoL have been identified such as survivors who are single, less 
educated, less involved in decision making or less satisfied with the received medical 
treatment.
9,10 Little is known about the QoL of patients with locally advanced, primary 
irresectable STS of a limb who underwent a TNF based ILP as an intentional limb saving 
treatment.  
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The present study was conducted to gain insight into the QoL in this intensively treated group 
of patients and into aspects possibly affecting these patients’ QoL. The study investigates if 
STS-survivors differ in QoL from a reference group and evaluates if QoL and stress response 
symptoms in STS-survivors are related to A) socio-demographic aspects (sex, age, education 
level, employment and marital status and to B) disease- (time period since perfusion, limb 
survival, local recurrence, presence of metastases, co-morbidity) and treatment-related aspects 
(i.e., involvement in the choice of treatment, satisfaction with treatment). 
 
Methods 
Procedure and patients 
All patients with locally advanced STS who underwent ILP with TNFα and melphalan and an 
intentional limb salvage treatment during the time period 1991-2003 were eligible for the 
study. None of the patients had metastases at the time of the ILP treatment. Patients who were 
alive received a letter explaining the aim of the study, an invitation to participate in the 
questionnaire survey and a prepaid return envelop. 
All patients underwent a complex diagnostic and therapeutic pathway. Before treatment 
started the option of amputation or an intentional limb saving treatment with ILP was 
discussed. This study focuses on the STS patients who received the intentional limb saving 
tumor treatment. The affected limb received an ILP with TNFα and Melphalan followed by 
delayed resection The technique is described previously.
11 Most patients received adjuvant 
radiotherapy (60-70 Gy).
11 During the whole range of the intentional limb saving procedure it 
was possible that patients still lost their limb due to irresectability, vascular complications, 
wound healing disturbances or radiation induced complications.
3 The TNFα based ILP-
containing treatment and the series of patients were recently extensively described.
3,11 All 
patients were treated following the institutional guidelines. 
 
Measurements 
Socio-demographic (sex, age, education level, employment and marital status) and disease 
related data (time period since perfusion, limb survival, local recurrence, presence of 
metastases at the time of questionnaire completion, co-morbidity) were assessed from all 
patients.  
On a five options scale, patients could fill in their perception of actual involvement in the 
decision for treatment. Answers ranged from the doctor only (1) to the doctor and myself in 
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equal extent (3) to me only (5).
12 In addition patients were asked to score their satisfaction 
with treatment received on a five-point scale from ‘very good’ to ‘very bad’. Patients were 
invited to indicate reasons for satisfaction and for dissatisfaction. 
Health related quality of life was investigated with a Dutch-language version of the Rand 
36
13, a multidimensional self-report questionnaire identical to the Short Form (SF)-36
14 but 
using a different scoring method. The Rand 36 consists of the following domains: physical 
functioning (10 items), social functioning (two items), role impairment due to physical 
problems (four items), role impairment due to emotional problems (three items), mental 
health (five items), vitality (four items), pain (two items), general health perception (five 
items) and health change (one item). After recoding and transformation, scores on the 
subscales could range from 0 to 100. Higher scores indicate a better QoL. Internal consistency 
of the subscales for the respondents in the present study was good (alpha ranged from 0.70 to 
0.92). Normative data are available for the healthy Dutch population. The normative data 
compromise the mean scores of a group of 1063 men (35%) and women (65%) from a 
random sample of the population register of a municipality in the Netherlands (number of 
inhabitants = 108 000). The mean age of the persons in the total random sample was 44 (range 
18-89) years.
13 
Post traumatic stress symptoms (PTSS) were measured with the Dutch version of the Impact 
of Event Scale.
15,16 This scale is often used in studies on cancer patients.
17 In this study 
information was obtained about the degree to which confrontation with the treatment for a 
sarcoma was influencing the current daily life of the respondent. Fifteen items measured 
intrusion (intrusively experienced ideas, images, feelings or bad dreams about the event) (7 
items) and avoidance of unpleasant feelings or memories of the event (8 items) using the 
answer categories: not at all (0), rarely (1), sometimes (3) and often (5). (Intrusion: range 0-
35, avoidance: range 0-40) Items of the two subscales are summed to compute a total score. 
(range 0-75) A total score of more than 26 is a strong indication of clinically significant 
PTSS, for which psychological help is recommended. Internal consistency of this 
questionnaire was good (alpha was 0.84 for intrusion, 0.76 for avoidance, and 0.85 for the 
total IES score). 
 
Statistics 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) for Windows (Version 12.0; SPSS INC., Chicago, IL). Unpaired t-tests were 
computed to compare STS-survivors with the reference group in the domains of quality of 
99Chapter 7 
life. Pearson correlations, unpaired T-tests, and non-parametric Mann-Whitney and Kruskal-
Wallis tests were conducted to examine effects of socio-demographics and treatment- and 
disease related variables on the outcome measures.  
Correlation coefficients < 0.30 indicate a weak association, those between 0.30 and 0.50 a 
moderately strong association and those > 0.50 a strong association.
18 
 
Results 
Forty-one of the 73 patients (57%), who had been treated with intentional limb salvage 
procedure for locally advanced, irresectable STS at the Department of Surgical Oncology at 
the UMCG since 1991 were still alive. Thirty nine patients, 16 male (41%) and 23 (59%) 
female, median age 59 (range 15-78) years participated in the questionnaire survey (response 
rate 95%). Median age at perfusion was 49 (range 14-72) years. Median time since perfusion 
was 7 (range 1-13) years. A fifth of the patients had completed primary school only and only 
one patient had a university degree. The median education level was lower secondary school. 
A little over one third of the patients had a job and one third was retired. Over two third of the 
STS-survivors was married or cohabiting (69%). (Table 1). 
  Successful limb salvage was achieved in 30 patients, while 9 patients underwent an 
amputation of the affected limb. Amputation of the affected limb was due to massive necrosis 
after ILP, local recurrence or critical leg ischemia.
3 The decision to amputate was not 
influenced by the presence of metastases. At the time of the present study, 4 of the 9 patients 
(44%) whose limb was amputated had metastases. Of the 30 patients whose limb was saved, 6 
patients (20%) had metastases at the time of questionnaire completion. Thirty-three patients 
had a sarcoma in the lower limb (31% thigh, 21% knee and 33% lower leg) and 6 in the upper 
limb (15%). Three patients had local recurrence and 10 patients had distant metastases at the 
time of filling in the questionnaire (Table 1). The vast majority did not suffer from 
comorbidity. 
Nine patients responded that the choice was made by the physician alone and two patients 
indicated that the choice was made by themselves. Almost half of the patients judged that the 
physician mainly made the choice of treatment with their participation. Thirty patients were 
very or rather satisfied with the treatment, 3 patients were not, and 6 scored the answer as 
neutral. Involvement in treatment choice and satisfaction with treatment were not significantly 
related. (Table 2). 
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Table 1 Socio-demographic and disease related characteristics  
 
  N % 
Sex    
    Male  16  41 
    Female  23  59 
Age    
    Median 59 years 
    (range 15-78) years 
  
Highest education completed    
    Primary school  8  21 
    Lower vocational degree  3  8 
    Lower secondary school  9  23 
    Middle secondary school  6  15 
    High secondary school  4  10 
    High vocational degree  8  21 
    University  1  2 
Employment    
    Paid job   13   33 
    Voluntary job    2  5 
    Housekeeping  8  21 
    Retired    12  31 
    Student  1  2 
    Unemployed  3  8 
Marital status    
    Single/divorced/widowed  12  31 
    Married/cohabiting  27  69 
Location of STS    
   Upper limb  6  15 
   Lower limb  33  85 
Limb Survival    
    No  9  23 
    Yes  30  77 
Local recurrence    
    No  32  82 
    Yes  3  8 
    Unknown  4  3 
Metastases    
    No  29  74 
    Yes  10  26 
Comorbidity    
    No  35  90 
    Yes  4  10 
 
Independent t-tests showed no significant differences in mean scores between the STS 
survivors and the reference group in most aspects of QoL, except in physical functioning 
(p<0.001) and role limitations due to physical problems (p=0.01). A tendency for a worse 
social functioning was found (p=0.09) (Table 3). Eleven patients (28%) had a total stress 
response symptom score of zero. Eight patients (20.5%) had a score > 26 suggesting that 
psychological counselling was needed. 
No significant differences were found between male and female patients in QoL and PTSS. 
Younger STS-survivors scored better on physical functioning than older ones (r=-0.34, 
p=0.035). Educational level was not significantly related to QoL and PTSS in STS patients.  
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Table 2 Treatment choice and satisfaction and relationship between the two variables. 
 
  Frequency  % 
Choice of treatment made by…    
physician only   9  23 
mainly physcian  19  49 
physician and patient equally   6  15 
mainly patient  3  8 
patient only  2  5 
Satisfaction with treatment    
Very satisfied  20  51 
Rather satisfied  10  26 
Neutral 6  16 
Rather unsatisfied  1  2 
Very unsatisfied  2  5 
Correlation coefficient*  r=-.19 not  significant 
 
* correlation coefficient between the choice of treatment and satisfaction with treatment 
 
Table 3 Quality of life of STS-survivors who underwent ILP and a reference group and 
comparison between the two groups. 
 
QoL STS 
Survivor  
Mean (SD) 
Reference 
group 
Mean (SD) 
t p   
-Physical functioning  55.6 (30.0)  81.9 (23.2)  -5.42  <.001 
-Social functioning  79.8 (25.1)  86.9(20.5)  -1.75  0.09 
-Role limitations- physical   61.6 (41.4)  79.4(35.5)  -2.62  0.01 
-Role limitations- emotional   87.0 (26.8)  84.1(32.3)  0.63  0.53 
-Mental health    76.7 (16.4)  76.8 (18.4)  -0.04  1 
-Vitality  64.6 (18.9)  67.4 (19.9)  -0.90  0.37 
-Pain   82.2 (21.2)  79.5 (25.6)  0.78  0.44 
-General health perception  69.1 (19.1)  72.7 (22.7)  -1.13  0.26 
-Health change  57.1 (25.6)  52.4 (19.4)  1.14  0.26 
Stress response  Mean (SD)      
-Intrusion  6.9 (7.1)       
-Avoidance  5.3 (6.7)      
-Total  12.2 (13.1)      
 
There was a significant difference in only one domain of QoL when patients employed for 
wages were compared with the rest: they suffered from significantly less pain (Mann-Whitney 
U test= -2.47, p= 0.014). Having or not having a partner did not affect functioning in STS 
survivors. A Mann-Whitney test showed that those whose limb was amputated reported 
significantly worse physical (U=-2.41, p=0.016) and social functioning (U=-2.27, p=0.023), 
and they reported more role limitations due to physical (U=-2.39, p=0.017) and emotional 
(U=-2.45, p=0.014) problems than those whose limb could be saved. No significant 
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differences were found in mental health, vitality, pain, general health perception and 
avoidance, intrusion and total IES between the two groups. No significant relationships were 
found between time since initial treatment and the various QoL domains and PTSS.  
If patients had metastases at the time of the survey, they reported significantly worse physical 
functioning (U=-2.13, p=0.034), and more role limitations due to physical (U=-2.14, p=0.032) 
and emotional (U=-2.92, p=0.004) problems. There were no differences in the other areas of 
QoL nor in intrusion, avoidance and total stress response symptoms. None of the nine 
amputated patients had a score > 26 on the total IES. Of the ten patients with metastases two 
had a score > 26. The effects of incidence of local recurrence and chronic diseases on QoL 
and STS could not be examined because only a few patients had experienced local recurrence 
(n=3) or suffered from co-morbidity (n=4). 
Kruskal Wallis tests showed that those who were less involved in the decision for treatment 
had significantly higher scores on intrusion (Chi-square=11.37, p=0.023). Also, they tended to 
report more total IES (Chi-square=9.12, p=0.058) and a worse social functioning (Chi-
square=9.17, p=0.057). Greater treatment satisfaction was related to a better social 
functioning (r=-0.36; p=0.024), more vitality (r=-0.32; p=0.046), and a better general health 
perception (r=-0.36; p=0.028). Higher treatment satisfaction was significantly associated with 
less intrusion (r=0.57; p<0.0001), avoidance (r=0.35; p=0.27) and total IES (r=0.58; 
p<0.0001). These correlation coefficients ranged from moderately strong to strong.  
Fourteen patients (36%) indicated additionally why they were satisfied with the treatment, 18 
(46%) why treatment had discouraged them, and 7 patients (18%) mentioned both positive 
and negative aspects of treatment. Positive experiences mentioned by 16/21 of the patients 
were that they were satisfied with the final result and the fact that the course of treatment was 
as explained and therefore expected. The remaining 5/21 mentioned they experienced the 
treatment positively because they had expected worse and because they had suffered little 
pain. Discouraging arguments mentioned were the intensity of treatment (20/25), long 
recovery period (9/25) and/or the fact that they had been seriously ill as a consequence of the 
treatment (6/25).  
 
Discussion 
The aim of the current study was to gain insight into the QoL and PTSS of patients with 
locally advanced, primary irresectable STS of a limb who underwent an intensive and 
extensive sarcoma treatment that consisted out of a TNFα based ILP followed by delayed 
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surgical resection ± adjuvant high dose external beam radiotherapy as an intentional limb 
saving treatment. 
Physical functioning and role limitations due to physical problems were the only domains in 
which our group of patients scored significantly lower than the reference group. The problems 
perceived in the physical domains could be explained by the resection of a large muscular 
compartment and often adherent structures in the affected part of the limb that the sarcoma 
patients had undergone. Obviously, such invasive surgery affects the physical functioning of 
these sarcoma patients. On the other hand, functioning in the remaining QoL domains in these 
patients was the same as in the reference group. It has been suggested that patients with 
cancer seem to change their internal standards and their expectations about life during 
treatment. Other studies also postulate that cancer patients evaluate QoL according to their 
new expectations and different standards.
5,19 The limitations patients experienced in physical 
functioning do not seem to affect functioning in the other QoL domains.  
The finding of a surprisingly high percentage of 20.5% of the patients having clinically 
elevated PTSS is in contrast to literature showing a prevalence of clinically high PTSS among 
people with cancer varying from 3% to 12% depending on the cancer treatment.
20-23 The 
20.5% PTSS rate found is this study is comparable with more traditional traumatic events 
such as rape, war, disaster and accidents in general samples.
21 
To distinguish those in our group of patients who had more problems concerning QoL and 
PTSS, we investigated the effects of socio-demographic, disease and treatment related 
variables.  
 
Socio-demographics 
Younger STS-survivors scored better on physical functioning than older STS-survivors. Some 
other QoL studies also showed that the physical autonomy score was affected by age.
24,25 In 
the other QoL domains and PTSS we found no associations with age. This is in contrast with 
the literature reporting that younger age is a risk factor for psychosocial distress, anxiety and 
depressive symptoms among cancer survivors.
19,26 
Other socio-demographics such as sex, education level, marital status were not related to QoL 
and PTSS in our studies. This is different from findings in literature that show that women 
tend to develop somatic complaints more quickly after negative life events
24,27; a higher 
educational level is associated with a higher QoL in the general population
19,24; and that 
having a partner has been identified as a predictor of better well-being in the general 
population, in particular in men.
19,26 There was a significant difference in one domain of QoL 
104Quality of life after ILP for sarcoma 
 
when patients employed for wages were compared with the rest: they suffered from 
significantly less pain. This can be a chance finding. Another suggestion is that work distracts 
and reduces pain sensation. More research is needed to evaluate this finding. 
 
Illness related 
Patients with an amputated limb had a worse QoL score in physical and social functioning, 
and in role limitations due to physical and emotional problems. This is in contrast with the 
literature that showed no differences in QoL between patients whose limb was amputated and 
patients treated with conservative surgery and adjuvant radiation treatment.
28-30 These studies, 
however, describe patients who were randomised between amputation and limb saving 
treatment. In our group, all treatments started intentionally with a limb-saving purpose. Our 
results suggest that once the patients are on the pathway where limb-saving treatment seems 
possible, an eventual amputation actually may make a difference resulting in a decreased 
perception in some of the QoL domains.  
Even though more quality of life problems were found in patients whose limb was amputated 
it appeared that none of these patients had a posttraumatic response symptom score indicative 
of need of professional psychosocial care. A hypothesis for this phenomenon may be that the 
loss of a limb has released patients from the insecurity of a possible loss in the future. The 
threat of local recurrence and further damage to the limb due to long-term effects of radiation 
or vascular incompetence may be like a sword above the head that may fall at any moment. 
An equal percentage of patients with metastasised disease had a clinically elevated PTSS 
score as found in the complete study group (20%). Metastasised patients did have problems in 
physical functioning and role limitations due to physical and emotional problems. 
We found no effect of time in relation to QoL suggesting physical functioning problems are 
of a more permanent nature. In Lamperts study patients with lower extremity STS were more 
at risk to become disabled than patients with STS in other areas of the body.
31 In our own data 
the number of upper extremity STS patients (n=3) was too small to detect significant 
differences in QoL and PTSS compared to patients whose affected limb was a lower 
extremity.  
 
Choice of treatment 
This study shows that those patients who indicated that the surgeon made the treatment choice 
rather than they themselves, showed a decreased social functioning, more role limitations due 
to physical problems and higher levels of intrusion. This is in agreement with other studies 
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reporting that patients benefit from participating in medical decision making.
10 Despite all the 
reasonable doubts patients may have, it seems important that the patient is at least involved in 
the final decision for his or her treatment. Other studies also mention that patients who 
perceive that they have decisional control in their treatment may regain control-perception 
over the disease as well, which may ultimately lead to a higher QoL.
32-36 It may be that 
greater attention should be paid to the communication of treatment options and its 
consequences to the patient so that the patient is better able to make an informed decision. 
Our results also showed that patients who were more satisfied with treatment reported less 
PTSS and a better QoL, a finding in line with earlier research.
10,37-40 In contrast to other 
studies no significant relationship was found between decision involvement and treatment 
satisfaction in the current study.
10,39  
In the light of data indicating that 20.5% of the STS survivors experience PTSS symptoms 
even years after treatment and that patients, in particular those whose limb was amputated, 
had problems in the physical QoL domains, identifying ways to prevent or relieve these 
symptoms should be considered. A suggestion would be a multimodal rehabilitation program 
including a physical and a psychosocial program that might help reduce the problems in the 
physical domains and the psychosocial distress in these patients. An intensive multi-focus 
rehabilitation program for cancer patients after completion of their cancer treatment appeared 
to have immediate and longer term beneficial effects on physiological functioning and quality 
of life.
41 Furthermore, attention should be paid to the issue of collaborative decision making 
that may be better achieved with informing the patient more comprehensively about treatment 
options and possible consequences. Attention to communication issues may also increase 
patient satisfaction.  
The inclusion of a validated generic QoL questionnaire and the high response rate (95%) are 
the strengths of this study. On the other hand only 41 patients (57%) of the original study 
population of 73 patients were eligible since the remaining 32 patients were deceased at the 
time of the survey. In addition, the present study is a retrospective cross-sectional study. The 
measurement of quality of life in STS patients is a dynamic rather than a static process that 
requires reassessment. Consecutive quality of life measurements may give insight into change 
over time and causal relationships between variables. 
 
106Quality of life after ILP for sarcoma 
 
References 
1.  Ham SJ, van der Graaf WT, Pras E, Molenaar WM, van den Berg E, Hoekstra HJ. Soft 
tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. 
Cancer Treatment Reviews 1998; 24:373-91. 
2.  Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an 
overview and update. The Lancet Oncology 2000; 1:75-85. 
3.  Van Ginkel R, Thijssens K, Pras E, Suurmeijer A, Hoekstra H. Hyperthermic solated 
limb perfusion with TNFα and Melphalan for primarily irresectable soft tissue sarcoma; 
three time periods at risk for amputation. Ann Surg Oncol 2004; 11:S54. 
4.  Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-
sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 
215:269-75. 
5.  Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life 
research: a theoretical model. Soc Sci Med 1999; 48:1507-15. 
6.  Ahles TA, Saykin AJ, Furstenberg CT, et al. Quality of life of long-term survivors of 
breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J 
Clin Oncol 2005; 23:4399-405. 
7.  Kornblith AB. Psychosocial adaptation of cancer survivors, in Holland J, et al (eds) 
Textbook of Psycho-Oncology. New York, NY: Oxford University Press, 1998, 223-54. 
8.  Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast 
cancer. J Clin Oncol 2005; 23:3322-30. 
9.  Rudberg L, Carlsson M, Nilsson S, Wikblad K. Self-perceived physical, psychologic, and 
general symptoms in survivors of testicular cancer 3 to 13 years after treatment. Cancer 
Nurs. 2002;25:187-95. 
10.  Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in 
medical decision making? Longitudinal follow-up of women with breast cancer. Psycho-
Oncology 2005; in press. [online Januari 2005, epub ahead of print] 
11.  Thijssens K, Van Ginkel R, Pras E, Suurmeijer A, Hoekstra H. Hyperthermic isolated 
limb perfusion with TNF and Melphalan for locally advanced soft tissue sarcoma: the 
value of adjuvant radiotherapy. Ann Surg Oncol 2005; 12:S35. 
12.  Degner LF, Sloan JA. Decision-making during serious illness: What role do patients 
really want to play? Journal of Clinical Epidemiology 1992; 45:941-48. 
107Chapter 7 
13.  van der Zee KI, Sanderman R. The measurement of generic health with the RAND-36. 
Northern Centre for Healthcare Research. Available: http://www.med.rug.nl/nch/ 
[accessed May, 2005] 
14.  Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. Med care 1992; 30:473-83. 
15.  Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective 
stress. Psychosom. Med. 1979; 41:209-18. 
16.  van der Ploeg E, Mooren TT, Kleber RJ, van der Velden PG, Brom D. Construct 
validation of the Dutch version of the impact of event scale. Psychological Assessment 
2004; 16:16-26. 
17.  Gurevich M, Devins GM, Rodin GM. Stress response syndromes and cancer: conceptual 
and assessment issues. Psychosomatics 2002; 43:259-81. 
18.  Cohen J. Statistical power analysis for the behavioral sciences. 2 ed. Hillsdale, New 
York: Lawrence Erlbaum Associates, 1988. 
19.  Parker PA, Baile WF, de Moor C, Cohen L. Psychosocial and demographic predictors of 
quality of life in a large sample of cancer patients. Psycho-Oncology 2003; 12:183-93. 
20.  Cordova MJ, Andrykowski MA, Kenady DE, McGrath PC, Sloan DA, Redd WH. 
Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment 
for breast cancer. Consult Clin Psychol 1995; 63:981-6. 
21.  Green BL, Rowland JH, Krupnick JL, et al. Prevalence of posttraumatic stress disorder in 
women with breast cancer. Psychosomatics 1998; 39:102-11. 
22.  Widows MR, Jacabson PB, Fields KK. Relation of psychological vulnerability factors to 
posttraumatic stress disorder symptomatology in bone marrow transplant recipients. 
Psychosomatic Medicine 2000; 62:873-82. 
23.  Hampton MR, Frombach I. Women's experience of traumatic stress in cancer treatment. 
Health Care Women Int 2000; 21:67-76. 
24.  Nagarajan R, Clohisy DR, Neglia JP, et al. Function and quality of life of survivors of 
pelvic and lower extremity osteosarcoma and Ewing’s sarcoma: the Childhood Cancer 
Survivor Study. Br J Cancer 2004; 91:1858-65. 
25.  Caffo O, Amichetti M, Tomio L, Galligioni E. Quality of life after radiotherapy for early-
stage testicular seminoma. Radiotherapy and Oncology 2001; 59:13-20. 
26.  Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: analyses 
of the National Health Interview Survey. J Clin Oncol 2002; 20:4581-90. 
108Quality of life after ILP for sarcoma 
 
27.  Conger RD, Lorenz FO, Elder GH Jr, Simons RL, Ge X. Husband and wife differences in 
response to undesirable life events. J Health Soc Behav 1993; 34:71-88. 
28.  Sugarbaker PH, Barofsky I, Rosenberg SA, Gianola FJ. Quality of life assessment of 
patients in extremity sarcoma clinical trials. Surgery 1982; 91:17-23. 
29.  Refaat Y, Gunnoe J, Hornicek FJ, Mankin HJ. Comparison of quality of life after 
amputation or limb salvage. Clin Orthop 2002; 397:298-305. 
30.  Zahlten-Hinguranage A, Bernd L, Ewerbeck V, Sabo D. Equal quality of life after limb-
saving or ablative surgery for lower extremity sarcomas. Br J Cancer 2004; 91:1012-4. 
31.  Lampert MH, Gerber LH, Glatstein E, Rosenberg SA, Danoff JV. Soft tissue sarcoma: 
functional outcome after wide local excision and radiation therapy. Arch Phys Med 
Rehabil 1984; 65:477-80. 
32.  Morris J, Royle GT. Offering patients a choice of surgery for early breast cancer: a 
reduction in anxiety and depression in patients and their husbands. Soc Sci Med 1988; 
26:583-85. 
33.  Hack TF, Degner LF, Dyck DG. Relationship between preferences for decisional control 
and illness information among women with breast cancer: a quantitative and qualitative 
analysis. Soc Sci Med 1994; 39:279-89. 
34.  Street RL, Voigt B. Patient participation in deciding breast cancer treatment and 
subsequent quality of life; Med Decis Making 1997; 17:298-306. 
35.  Deadman JM, Leinster SJ, Owens RG, Dewey ME, Slade PD. Taking responsibility for 
cancer treatment. Soc Sci Med 2001; 53:669-77. 
36.  Davison BJ, Parker PA, Goldenberg SL. Patients’ preferences for communicating a 
prostate cancer diagnosis and participating in medical decision-making. BJU Int 2004; 
93:47-51. 
37.  de Bock GH, Bonnema J, Zwaan RE, van de Velde CJ, Kievit J, Stiggelbout AM. 
Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J 
Cancer 2004; 90:1144-50. 
38.  Han WT, Collie K, Koopman C, et al. Breast cancer and problems with medical 
interactions: Relationships with traumatic stress, emotional self-efficacy, and social 
support. Psychooncology 2005; 14:318-30. 
39.  Leighl N, Gattellari M, Butow P, Brown R, Tattersall MH. Discussing adjuvant cancer 
therapy. J Clin Oncol. 2001; 19:1768-78. 
109Chapter 7 
40.  Walker MS, Ristvedt SL, Haughey BH. Patient care in multidisciplinary cancer clinics: 
does attention to psychosocial needs predict patient satisfaction? Psycho-Oncology 2003; 
12:291-300. 
41.  Van Weert E, Hoekstra-Weebers J, Grol B, et al. A multidimensional cancer 
rehabilitation program for cancer survivors. Effectiveness on health-related quality of 
life. J Psychosom Res. 2005; 58:485-96.  
 
110 
 
 
 
 
 
 
 
Chapter 8 
 
Other primary neoplasms in patients with soft tissue sarcomas of 
the extremities treated with isolated limb perfusion  
 
Katja M.J. Thijssens MD
1, Jan C. Oosterwijk MD PhD
2, Esther Bastiaannet MSc
3, Albert J.H. 
Suurmeijer MD PhD
4, Robert J. van Ginkel MD PhD
1, Harald J. Hoekstra MD PhD
1 
Department of Surgical Oncology
1, Department of Clinical Genetics
2, Comprehensive Cancer 
Center Northern Netherlands
3, Department of Pathology
4, University Medical Center 
Groningen and Groningen University, Groningen, The Netherlands 
 
Submitted: Annals of Surgical Oncology. Chapter 8 
Abstract  
Purpose: To investigate the incidence of other primary neoplasms (OPN) in patients with a 
locally advanced soft tissue sarcoma (STS) of the extremities and their effect on survival. 
Patients and methods: A retrospective cohort of 73 patients, median age 54 (range 14-80) 
years diagnosed with locally advanced STS, all treated by isolated limb perfusion and delayed 
surgical resection was studied. Medical records were examined for clinical characteristics of 
the STS and OPN, therapeutic interventions, morbidity and survival. 
Results:  Seventeen patients of the 73 treated with ILP (23%) had an OPN: 8 OPNs before 
STS diagnosis (47%), 1 synchronously, 1 between two OPNs, and 7 OPNs after STS 
diagnosis (41%). The median follow-up period after STS-diagnosis was 48 (4-162) months. 
The 5-year survival of the non-metastasized STS-only group (79 ± 13%) was not significantly 
different from the STS-OPN group (83± 17%) (p=0.46), whereas the 5-year survival rate of 
the OPN-STS group (13 ± 13%) was significantly decreased versus the STS-only group 
(P<0.0001). The most frequent types of OPN were breast cancer, squamouscell carcinoma and 
urinary tract (kidney and bladder) cancer. 
Conclusion:  Patients with locally advanced STS have a high risk to be diagnosed with an 
OPN. The overall survival in non-metastasized STS patients is significantly decreased if 
patients had an OPN before an STS.  
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Introduction 
Soft tissue sarcomas (STS) occur at approximately 3.6 per 100.000 per year in The 
Netherlands. They may arise in any part of the body, but their predominant location are the 
extremities. The incidence increases with age and half of the patients are over 65 years of age, 
but STS are also common among children.
1 The only curative treatment for local and even 
recurrent disease is surgery. For the majority of STS, chemotherapy seems to be ineffective, 
with some exceptions, e.g. Ewing sarcomas/ primitive neuroectoderm tumors (PNET) and 
embryonal rhabdomyosarcomas for which chemotherapy can increase curation rate.
2 
Over the past thirty years, enormous progress has been made in the local management of STS. 
Developments in diagnostic imaging, adjuvant radiotherapy and the introduction of 
hyperthermic isolated limb perfusion (ILP), are the cornerstones of the improved limb salvage 
rate.
3 Nowadays almost 90% of patients with extremity STS can be treated with limb salvage 
treatment, with a 5-year survival rate of 60-70%.
2,4 Tumor size, histology, grade, primary 
tumor site, and presence of metastatic disease are the most important prognostic factors for 
survival.
1 With the improving prognosis of STS patients, long-term follow-up data on local 
recurrences, distant disease and survival are becoming available.
2,3 Several recent studies 
suggested that patients with STS are at increased risk of development of an other primary 
neoplasm (OPN). Genetic tumor syndromes such as neurofibromatosis type 1, familial 
adenomatous polyposis, retinoblastoma and Li-Fraumeni syndrome are known to be 
associated with STS.
2,5-11 But also in STS patients without these well defined genetic 
syndromes, an increased risk of developing other malignancies - either before or after the 
sarcoma diagnosis - has been noted, most notably of the breast and kidney.
12,13  
The aim of the study was to investigate the incidence of OPNs in a patient cohort with locally 
advanced STS of the extremities treated with ILP and resection, as well as the effect of OPNs, 
diagnosed either before or after sarcoma treatment, on the overall survival of these sarcoma 
patients.  
 
Patients and Methods 
Patients 
The incidence of OPN in a retrospective cohort of 73 patients, diagnosed with a locally 
advanced STS of the extremity from January 1991 till December 2003 and referred to the 
University Medical Center Groningen for a combined treatment consisting of ILP and delayed 
surgical resection was studied. 
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These 73 patients, 36 males and 37 females with a median age of 54 (range 14-80) years 
received a treatment that consisted of 60 minutes ILP (39-40 °C) with Tumor Necrosis Factor 
alpha (TNFα) (Beromun®, Boehringer Ingelheim, Austria) (3 mg TNF upper limb or 3-4 mg 
lower limb) and Melphalan (L-phenylalanine mustard; Glaxo-Wellcome Company, Italy) ((10 
mg/l Melphalan (limb volume, leg) to 13 mg/l Melphalan (limb volume, arm)). The perfusion 
technique was described previously.
14  
After ILP, delayed tumor resection was performed after 6-8 weeks, unless there was an 
indication for earlier intervention. The patients included in this study were recently described 
in detail elsewhere with respect to limb salvage and the value of adjuvant radiation in the 
local sarcoma treatment.
3,15 Postoperative radiotherapy (60-70 Gy) was considered indicated 
in case of <95% necrosis on pathological examination of the tumor or with marginally free or 
microscopically positive resection margins. Patients with metastatic disease at time of 
diagnosis of STS were excluded in the overall survival analysis in this study. 
The medical records of all patients were reviewed and the following information was 
retrieved: age at diagnosis of STS, sex, characteristics of the sarcoma (localization, type, 
grade), duration of follow-up, characteristics of the OPN (age at diagnosis, type, location, 
treatment), diagnosed before or after the sarcoma treatment, the characteristics of metastases 
if they occurred during the treatment (localization, age at detection) and overall survival. All 
ILP patients were followed at regular intervals in the outpatient clinic. No patient was lost for 
follow-up.  
The STS’s and OPN’s were histopathologically classified using the most recent World Health 
Organization's Classification of Tumors and the STS were also graded according to the 
French grading system.
16,17  
 
Statistical analysis  
The disease status at the latest follow-up (i.e. death due to the STS, death due to the OPN , 
death to other cause, alive with disease and no evidence of disease) was analyzed. Overall 
survival calculated from STS treatment onwards was scored in the non-metastasized treated 
STS patients grouping those with STS-only and those with STS and an OPN before or after 
the STS. Analyses were performed according to the Kaplan-Meier method and the Log-rank 
test.
18 Endpoints were either death or date of last follow-up. A P-value of less than 0.05 was 
considered statistically significant. Graph Pad Prism® version for Windows statistical 
software was used.
 Differences between groups were assessed by analysis of variance or Chi-
Square as appropriate.
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Results 
Data of seventy-three patients with primary, locally advanced STS of a limb who underwent 
ILP and surgery were analysed. In 17 patients (23%) a total of 19 OPNs were diagnosed: 10 
females (59%) and 7 males (41%). The time interval between the diagnosis of the OPN prior 
or after STS-treatment is represented in Figure 1.  
 
Figure 1 Cancer events depicted chronologically: age related in penetrance in 17 patients with 
soft tis  sue sarcoma (STS) and another primary neoplasm (OPN). Every line indicates one 
patient. 
 
  Age at which STS was diagnosed 
   
  Age of death 
   
∇  Age on which OPN was diagnosed 
 
Eight patients had OPNs before STS diagnosis (47%) with a median time interval of 84 
(range 15-145) months, 1 synchronously, 1 between two OPNs, and there were 7 patients who 
developed a OPN after the STS (41%) with a median time interval of 68 (range 1-273) 
months. We distinguished three groups; those without OPN (=‘STS-only’), those with STS 
followed by OPN (=’STS-OPN group’) and those with OPN followed by STS (‘OPN-STS 
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group’). The patient with an STS between the two OPN’s could not be included in either of 
the two latter groups. The various types of OPNs, their order of appearance and their 
treatment are represented in Table 1, indicating that breast cancer, squamous cell carcinoma, 
renal cancer and colorectal cancer were detected more than once.  
 
Table 1 Types of other primary neoplasms (OPNs) in STS patients and their treatment 
 
First neoplasm  Second neoplasm  Treatment of OPN 
STS adenoca  breast  BCT 
STS adenoca  breast  ablatio 
STS*
pt1 adenoca  breast  ablatio 
STS  renal clear cell cancer  nephrectomy 
STS adenoca  colon  none 
STS *
 pt2   melanoma upper arm as well as 
basocellular carcinoma nose  
local excision 
STS  MPNST neck (C1-C3)  laminectomy and XRT 
STS  adenocarcinoma parotic gland  local excision and 
lymphadectomy 
adenoca breast  STS  BCT 
squamouscell carcinoma mouth  STS  local excision 
squamouscell carcinoma larynx**  STS local  excision 
squamouscell carcinoma mouth  STS  XRT 
renal clear cell cancer  STS  partial nephrectomy 
adenoca rectum  STS  LAR + CT 
Hodgkin's disease  STS  splenectomy, XRT, CT 
endometrial carcinoma*
pt1 STS  hysterectomy 
cervical carcinoma  STS  total exenteration 
bladder cancer   STS  intravesical CT 
 
Legend 
-BCT = breast conserving therapy 
-CT = chemotherapy 
-LAR = low anterior resection 
-MND = modified neck dissection 
-MPNST = malignant peripheral nerve sheath tumor  
-XRT = radiation therapy 
*
pt = indication of the two patients with a double OPN 
** = patient with STS and OPN diagnosed simultaneously  
 
There were more breast cancers in the STS-OPN group and there more skin tumors in the 
OPN-STS group. Renal cell cancer and colon cancer were divided equally in both groups. 
There was one patient who had a second STS as OPN. Since the first tumor was a 
fibrosarcoma in the leg and the second tumor was a malignant peripheral nerve sheath tumor 
(MPNST), diagnosed 15 months later in the cervical vertebrae C1-C3, this last one was 
considered as an OPN. Demographic data and clinical characteristics of the patients are 
summarized in Table 2.  
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Table 2 Demographic and clinical data of 73 patients with a locally advanced soft tissue 
sarcoma (STS) of the extremities: 56 patients with only an STS (A) and 17 patients had an 
STS and another primary neoplasm (OPN) (B).  
 
  All patients   A: Patients with 
only an STS  
B: Patients with STS 
and OPN  
All n=  73 56  17 
Sex      
   males  36 (49%)  29 (52%)  7 (41%) 
   females  37 (51%)  27 (48%)  10 (59%) 
   male: female-ratio  1:1  1:1  2:3 
Median age STS diagnosis   54 (range 14-80) yrs  52 (range 14-78) yrs  60 (range 28-80) yrs 
Overall survival (after 
STS-diagnosis ) in non 
metastasized patients 
    
   1 year  83.0 ± 10.0%  93,3 ± 6,7 %  79,8 ± 20,2 % 
   5 years  63.1 ± 14.1%  78,9 ± 13,3 %  49,7 ± 26,7 % 
   10 years-  48.0 ± 17.2%  60,0 ± 19,6 %  41,5 ± 26,7 % 
Median size of the STS  16.2 (range 8.3-23) cm  14 (range 8.3-20) cm  17.5 (range 10.2-23) cm 
Tumor grade      
   grade I  6 (14%)  4 (7%)  2 (12%) 
   grade II  24 (32%)  18 (32%)  6 (35%) 
   grade III  43 (54%)  34 (61%)  9 (53%) 
Histology in %    
   pleomorphic undifferentiated 
   sarcoma  
   (not otherwise specified) 
24 (33%)  17 (31%)  7 (41%) 
   synovial sarcoma   10 (14%)  9 (17%)  1 (6%) 
   myxoid liposarcoma   7 (9%)  4 (7%)  3 (17%) 
   leiomyosarcoma   6 (8%)  5 (9%)  1 (6%) 
   myxofibrosarcoma   4 (5%)  4 (7%)  0 (6%) 
   fibrosarcoma   3 (4%)  2 (3%)  1 (6%) 
   MPNST   3 (4%)  2 (3%)  1 (6%) 
   epitheloid sarcoma   2 (3%)  1 (2%)  1 (6%) 
   myxoid chondrosarcoma   2 (3%)  2 3(%)  0 (0%) 
   angiosarcoma   2 (3%)  1 (2%)  1 (6%) 
   embryonal rhabdomyosarcoma   1 (1%)  0 (0%)  1 (6%) 
   others*   9x1 (10%)  9x1 (16%)  0 (0%) 
Metastases    
   No metastases  36 (49%)  31 (55%)  5 (29%) 
   Metastases at diagnosis STS  12 (17%)  11 (20%)  1 (6%) 
   Metastases during follow-up  25 (34%)  14 (25%)  11 (65%) 
Resection    
   R0  56 (77%)  44 (79%)  12 (70%) 
   R1  12 (16%)  9 (16%)  3 (18%) 
   R2  3 (4%)  2 (4%)  1 (6%) 
   No resection  2 (3%)  1 (2%)  1 (6%) 
 
Legend:  
* = well differentiated (lipoma like) liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, 
primitive neuroectodermal tumor (PNET), clear cell sarcoma, Ewing sarcoma, malignant myoepithelioma of soft 
tissue, pleomorphic rhabdomyosarcoma 
R0 = microscopically radical resection; R1 = macroscopically radical resection (but not microscopically radical), 
R2 = macroscopically irradical resection, MPNST = malignant peripheral nerve sheath tumor 
.  
117Chapter 8 
There were relatively more women in the group with an OPN than in the STS-only group. 
The median age at STS-diagnosis in the group with an OPN was also higher compared to the 
STS-only group. No significant differences could be found with respect to median tumor size, 
tumor grade, and performed surgery (R0, R1, R2) between the two groups, although in the 
group with an OPN there were relatively more pleomorphic undifferentiated sarcomas and 
myxoid liposarcomas. 
There were no cases where the treatment of the first malignancy (i.e. radiation therapy or 
chemo therapy) could be linked to the development of the second malignancy. (Table 1). 
The median age of STS patients with an OPN before the sarcoma was 60 (range 28-80) years 
and also 60 (range 33-73) years if the OPN was diagnosed after the STS, while the median 
age of STS in patients with only an STS was 52 (range 14-78) years. The median follow-up 
period in the group of patients with STS and OPN, calculated from the date of the STS-
diagnosis, was 48 (range 4-162) months; median follow-up period post-sarcoma OPNs 83 
(range 11-162) months, and median follow-up period pre-sarcoma OPNs 18 (range 4-113). Of 
the 17 patients with STS and an OPN, 7 patients (41%) are still alive with a median follow up 
of 113 (range 18-162) months. Two patients died of the OPN (colon carcinoma and malignant 
schwannoma located in the cervical spine) (12%) whereas six patients died of their STS 
(35%) and two patients died of metastases of either the STS or the OPN (one patient with 
rectal cancer and one patient with endometrial carcinoma and breast cancer). The 5-year 
overall survival rate in STS-only patients was 79 ± 13% compared to 50 ± 27% in patients 
with an STS and OPN (p = 0.049). In Figure 2 the overall survival of the non-metastasized 
STS-only patients is compared with the OPN-STS and STS-OPN groups. The OPN-STS 
group had a significantly shorter overall survival. The 5-year survival of the STS-only group 
(79 ± 13%) was not significantly different from the STS-OPN group (83 ± 17%) (p=0.46), 
whereas the 5-year survival rate of the OPN-STS group (13 ± 13%) was significantly 
decreased versus the STS-only group (P<0.0001) and the STS-OPN group (P= 0.009). The 
cause of death was the OPN in two cases (both in the STS-OPN group), the STS in 6 cases 
(five patients of the OPN-STS group and 1 patient whose STS and OPN were diagnosed 
simultaneously) and unknown in two cases. 
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Figure 2 Kaplan-Meier curve for overall survival in not-metastasized patients with only soft 
tissue sarcoma (STS-only) compared with not-metastasized patients with STS and another 
primary neoplasm (OPN). The group op patients with an OPN prior to STS are indicated as 
OPN-STS and the patients with an STS prior to an OPN are indicated as STS-OPN. The 
comparison STS-OPN versus STS-only was not significant (P=0.46). The comparison 
between OPN-STS versus STS-only was highly significant (P<0.0001) as well as the 
comparison between STS-OPN versus OPN-STS (P=0.009). (One patient with OPN and STS 
diagnosed simultaneously was classified as OPN-STS). 
 
 
Discussion  
Since the incidence of STS is low and the overall 5-years survival is 50-60%, data on the 
occurrence of OPN in patients with STS and its influence on survival are rare. The incidence 
of OPNs in patients with STS in this series was 23%, which is higher than the 16% incidence 
in 814 STS patients documented in the same period by the Comprehensive Cancer Center 
North Netherlands (CCCNN), the regional registry of cancer data in the northern part of The 
Netherlands. In the CCCNN series, 11% had an OPN prior to the STS and 5% had a OPN 
after STS (unpublished data). Our incidence figures are also significantly higher than those 
recently published by Merimsky et al. who found an OPN in 28 out of 375 STS cases (7.5%), 
half of which before and half which after diagnosis of STS (Table 3).
13 This might be due to 
selection criteria since we have included adult patients with large, merely high grade (88%) 
STS in the extremities. Another reason might be the fact that in this series no patients were 
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lost in follow-up and that we were able to question all survivors specifically about OPN’s in 
their past medical history.  
 
Table 3 Studies of STS and OPN in the literature 
 
Study  Current study  Merimsky
13 
Number of pts 73  375 
Definition of STS 
patients 
High grade STS of the 
extremities 
STS 
Incidence of OPN in % 23  7.5 
M:F ratio 2:3  Not  available 
% STS preceding OPN* 47  50 
% OPN preceding STS 53  50 
Most frequent 
OPN’s 
-adenoca breast  
-squamous cell ca head 
and neck 
-renal clear cell ca 
-colorectal adenoca 
-renal clear cell ca 
-STS 
-adenoca ca 
-colon ca 
Median age STS 
diagnosis 
60 (range 28-80)  47 (range 16-72 ) 
Median age OPN 
diagnosis 
53 (range 18-80)  68 (range 35-87 ) 
Median duration of 
follow-up (since STS 
diagnosis) 
48 (range 4-162)  51 (range 0-258 ) 
Overall survival if 1 st 
tumor is STS: median 
 (range) in months 
85 (11-162)  78 (5-258) 
Interval between STS 
and OPN: 
median (range) in 
months 
84 (0-145)  120 (0-252) 
Overall survival** if  
1 st tumor is OPN: 
 (range) in months 
76 (20-282)  102 (3-319) 
Interval between OPN 
and STS: 
median (range) in years 
68 (1-273)  84 (0-324) 
 
Legend:  
* = including patients whose STS and OPN were diagnosed simultaneously 
** = from the time of diagnosis of the first tumor 
 
Cohen et al. also report an incidence of OPN in STS patients.
19 These data can not be 
compared to our data in the same way as Merimsky’s, due to the selection of patients: Cohen 
included exclusively OPN’s after STS diagnosed in children and adolescents (< 18 years old) 
and documented an incidence rate of 1.8% (27/1499 patients) with a cumulative incidence of 
2%. This incidence rate was 12 times the expected incidence rate during the first 5 year.  
Many possible explanations exist for the occurrence of multiple primary neoplasms in cancer 
patients such as genetic predisposition, exposure to carcinogens, treatment modalities that 
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increase the likelihood of developing a new malignancy (e.g. radiotherapy and 
chemotherapy), immune- compromised state,
 and increased age. 
20-22 Four women out of 37 
(11%) developed breastcancer at a median age of 58 (range 51-73). This percentage is higher 
than expected on the basis of their age and population incidence alone (9.7% by age 74 in the 
general female population).
25 In the literature female sex was found to be an independent risk 
factor for the presence of an OPN.
23,24 No obvious explanations were found to explain the 
high occurrence of OPNs in these sarcoma patients. The progress in preoperative staging by 
various imaging techniques, such as spiral computed tomography (CT), magnetic resonance 
imaging (MRI), ultrasound and positron emission tomography (PET), can increase the chance 
to find asymptomatic OPNs at the time of the sarcoma is diagnosed. On the other hand 
asymptomatic OPNs are not diagnosed during sarcoma follow up since extensive 
radiodiagnostic follow up of sarcoma patients is not indicated. An explanation of the high 
incidence of a second primary malignancy might be the improved survival due to better 
combined treatment strategies of the first tumor, thereby adding lifeyears in which a second 
primary neoplasm can develop. More epidemiologic data is emerging, indicating that the risk 
of a second malignancy is about twice as high for survivors of various types of cancer as 
compared to the general population.
26,27 Currently, in the Netherlands 10% of all registered 
invasive cancers are diagnosed in patients that had a previous OPN.
25  In our study 4 out of 37 
women developed breast cancer, 3/73 cases had squamous cell carcinoma and 3/73 cases 
developed urinary tract carcinoma. This top three of most frequently diagnosed OPNs is the 
same as that in the CCCNN-data based on 814 STS patients and also comparable to the data 
of Merimsky et al. Other (case) reports also suggest that patients with STS are at increased 
risk of developing a second malignancy, most notably of the breast and kidney.
12,28,29  
Survival is significantly shortened if a OPN is diagnosed prior to the STS. The prognoses of 
OPNs that were diagnosed in the OPN-STS group did not significantly explain this difference 
in survival with the STS-OPN group. There were even more skin tumors, especially 
squamous cell carcinomas known for their favorable prognosis, diagnosed in the group with 
an OPN prior to STS. There was no significant difference in age at diagnosis in the STS-OPN 
group versus OPN-STS group. The presence of an OPN before an STS can either be an 
independent prognostic determinator that decreases survival due to it’s own adverse effect on 
survival, possibly triggered by the combined treatment strategy in the subsequent STS. The 
occurrence of multiple tumours in one patient may also be due to un underlying genetic cause, 
i.e. an increased susceptibility to develop malignancies. The presence of as yet unknown 
cancer susceptibility genes in the population might explain the increased incidence of multiple 
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primary’s in some cases and possibly also their reduced response to treatment and thereby 
their survival. Larger prospective studies are needed to verify these findings before further 
conclusions can be drawn for an individual patient with STS. Our data underline the need for 
thorough registration of follow-up data of cancer patients. 
The complete information concerning demographic and treatment factors and the long follow-
up period are the strengths of this retrospective cross-sectional study. Moreover, the fact that 
we only included locally advanced primary irresectable STS of the extremities makes our 
sample more homogeneous compared to most other studies.  
In summary, the incidence of OPNs in patients with a locally advanced soft tissue sarcoma in 
the limb is higher in this series than reported to date. The data show that patients with an OPN 
before a locally advanced STS have a significant shorter survival than patients diagnosed with 
only a soft tissue sarcoma.  
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Chapter 9 
 
Future perspectives Chapter 9 
Study the past if you would define the future (Confucius 551 BC-479 BC) 
 
Long-term research is important to gain genuine insights into the outcomes of cancer 
treatment. This is the case for sarcomas, as well as for other tumors, such as testicular cancer, 
breast cancer, colorectal tumors, tumors in children, and hematological malignancies. Long-
term research has become an important component not just of clinical cancer research such as 
treatment induced morbidity but also of, for example, (genetic) epidemiological research. 
  
Soft tissue sarcomas are a rare group of cancers accounting for circa 1% of all malignancies.
1 
The heterogeneity of sarcoma types and the rarity of cases have hampered evidence-based 
randomized double-blind studies concerning optimal treatment. In the mid-seventies, several 
important observations reshaped the approach to sarcoma treatment. Firstly, due to more 
insight in the growth pattern of sarcomas, the local recurrence rate after limb salvage 
treatment decreased to 10-15%.
2 Secondly, histology, tumor type, grade, and size were 
defined as predictors of survival independent of the surgical therapy. Thirdly, local recurrence 
was not necessarily associated with poor outcome, as more than 30% of patients could be 
salvaged by additional surgery.
2 Finally, a major change is the shift from surgical resection 
alone as the treatment of sarcomas to the use of multimodality treatment: surgery, radiation 
and/or chemotherapy.
3 
This long-term research, into the value of regional perfusion as an induction treatment for 
primarily non-resectable soft-tissue sarcomas of the extremities, has also provided a lot of 
information that has already contributed to the improvement of this cancer treatment and will 
lead to further improvements in the future. The central issue should be the reduction of short-
term and long-term complications caused by, on the one hand, extensive surgical resections 
and, on the other hand, the high radiation dosage. Tissue transposition and optimization of 
radiotherapy will be key elements in this endeavor. Years ago, we investigated the 
possibilities of intra-arterial chemotherapy in combination with radiotherapy.
4 Although this 
treatment was highly effective, the complications were severe.
5 Perfusion treatment in itself 
only causes minimal morbidity. Possibly, regional perfusion may be replaced by regional 
infusion, as is currently being developed for melanomas.
6,7 Using this technique, groin 
catheters are inserted percutaneously into the blood vessels. After isolation of the lower limb 
with a tourniquet, the intra-arterial infused chemotherapy will be manually flushed without 
using an oxygenation system. The major advantage of the minimally invasive infusion 
treatment is the possibility to be repeated and to evaluate it non-invasively with Positron 
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Emission Tomography (PET). If necessary, pre-operative radiation followed by surgery may 
be preferred to surgery followed by radiotherapy.  
  
There have been several breakthroughs in diagnostic imaging and treatment, resulting in 
improved limb salvage and survival rate, as summarized previously in this thesis. New 
technologies of high interest for the surgical oncologist are already available or will become 
available.  
Recently, spiral computed tomography (CT) was introduced, providing the surgeon with 
optimal three-dimensional images (3D-images) and further facilitating preoperative treatment 
planning. Computer-assisted navigation systems have become available, which are extremely 
useful in the intra-operative treatment planning of sarcomas located in or near the pelvic 
girdle or vertebral column. Improvements in the radiodiagnostics of soft tissue sarcoma have 
had a major impact on the staging and planning of surgical treatment.
8 Imaging provides the 
clinician with crucial information in the diagnosis, staging, treatment planning, treatment 
evaluation, and post-treatment assessment of patients with soft tissue sarcoma. Magnetic 
Resonance Imaging (MRI), including contrast-enhanced sequences, is usually preferred for 
evaluating the primary site in extremity sarcomas and lesions of the head and neck. CT is 
generally preferred for imaging of the chest, abdomen, and pelvis, either in the evaluation of 
the primary site in those regions or for identifying metastatic disease. The experienced 
radiologist can often suggest a specific diagnosis or narrow the differential diagnosis from the 
imaging characteristics, particularly with MRI. It is imperative that imaging be performed in a 
manner specific for the evaluation of soft tissue masses, and before biopsy or surgery, to 
provide the most accurate preoperative assessment and treatment planning. 
Although PET is not directly useful for diagnosing soft-tissue sarcomas, it may sometimes be 
helpful in the differential diagnosis of benign and malignant tumors. Its potential mainly lies 
in the area of therapy evaluation, and as such it is already being used with gastrointestinal 
stroma cell tumors.
9 Other areas of application might include Ewing’s sarcoma and 
rhabdomyosarcoma and the evaluation of new induction chemotherapy treatments. PET-MRI 
provides a very good insight into local tumor growth processes, the presence of metastases 
and therapy evaluation. Figure 1. In patients with advanced solid tumors, phase I studies are 
being performed to measure the effect of oral angiogenesis inhibitors like AG-013736 with 
dynamic contrast-enhanced MRI as a pharmacodynamic measure of response.
10 Using the 
biologic activity of tumors will optimalize diagnostic as well as therapeutic options in the 
future. 
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Sentinel node biopsy has become a tool for the staging and treatment of breast cancer and will 
probably soon be used with melanoma also, while research is being conducted into its 
relevance with gastrointestinal tumors and lung cancer.
11 Sentinel node biopsy may also be 
used for staging sarcomas that have a slightly higher risk of developing lymphogenic 
metastases, such as synovial sarcoma, epitheloid sarcoma, rhabdomyosarcoma, and clear cell 
sarcoma.  
 
The transition from conventional radiotherapy to three-dimensional conformal radiation 
therapy (3D-CRT) means a reduction in the volume of healthy tissue receiving a high dose in 
favour of the radiation target volume. The technique that is already being used with breast 
cancer, the simultaneous integrated boost, may in future also be applied to sarcomas. It 
involves applying more radiation to a small area, which reduces the overall treatment time. By 
contrast, the move from 3D-CRT to intensity modulated radiation therapy (IMRT) involves 
more fields, while the dose-volume histograms show that, as a consequence, a larger volume 
of normal tissue is exposed to lower doses. In addition, the number of monitor units is 
increased by a factor of 2 or 3, increasing the total body exposure, due to leakage radiation. 
Altogether, a disadvantage of IMRT is likely to be the almost double incidence of second 
malignancies compared with conventional radiotherapy from about 1% to 1.75% for patients 
surviving 10 years.
12 
The problem of radiotherapy has been, and will remain, a two-edged sword: although it is an 
important component of and for local tumor control, it may also induce secondary tumors and, 
in the long term, may also lead to fibrosis, with reduced limb function as the ultimate 
outcome. 
What we have learnt by now is that reconstructive plastic surgery should be used on a much 
wider scale. Reconstructive plastic surgery procedures through tissue transfer and 
microvascular surgical techniques play a key role in coverage of major defects and prevention 
of wound-healing problems, and reduces the side effects of radiation treatment. 
 
Sarcomas are an interesting tumor model. They give the word “radical” a new dimension. 
“Radical” from a purely surgical point of view, with “radical” excision of the root or source 
of a morbid process, appears to be highly important in the improvement of patient survival 
and the prevention of local recurrence. In the case of sarcomas, this has led to very extensive 
surgery, major amputations, and unique methods of reconstruction. 
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An example of one of the first successful “radical” operations, a hemipelvectomy, was 
reported by Charles Girard in 1895, for a recurrent sarcoma.
13 Pringle stated in 1916 that this 
procedure “entails the greatest mutilation for which surgery is responsible”.
14 Nowadays these 
very extensive resections are preceded by more accurate preoperative assessment and 
followed by complex reconstructive procedures. This is shown in Figure 2.  
 
Figure 1 PET-MRI provides a very good insight into local tumor growth processes and 
metastases as illustrated here in an upper leg with a locally advanced extremity sarcoma 
before and after isolated hyperthermic limb perfusion with TNFα and Melphalan.1“Radical” 
also becomes a more abstract term referring to a fundamental shift in our paradigms on cancer 
biology and the outcome of the patient, both oncologic and functional. 
 
 
 
 
Figure 2 En bloc breast and chest wall resection for a high grade sarcoma.  
(A)  Preoperative view of an angiosarcoma located in the left breast and thorax 
(B)  The surgical defect, including a major portion of the chest wall  
(C)  Reconstruction of the chest wall defect with polypropylene mesh, omental plasty and 
split skin graft. 
 
A B  C 
 
 
 
 
  
 
 
131Chapter 9 
A patient with a sarcoma located in the chest underwent chest wall resection with subsequent 
reconstruction. Without doubt, the most radical of all potential sarcoma surgeries is 
translumbar amputation or hemicorporectomy, which was performed for the first time in 
1962.
15 
This leads us to the other reason why “radical” is an interesting model. Sarcomas are an 
interesting tumor model because they also cause radical changes in other areas than surgery, 
due to their remarkably aggressive growth and metastasis pattern. In these cases, “radical” 
means “departing markedly from the usual or customary”. The treatment of what used to be 
classified as leiomyosarcoma of the intestines but is now named gastrointestinal stroma tumor 
(GIST) in accordance with new insights into the condition, for example, made the cover of 
Time Magazine (volume 157, no 21, 2001). The selective tyrosine kinase inhibitor Imatinib, 
the new “target drug”, heralded the “new war against cancer”.  
Angiogenesis inhibition remains a promising approach for new drug development in cancer 
therapy. In fact blocking vascular endothelial growth factor (VEGF) has already been shown 
to have potent antivascular effects and significant clinical activity as evidenced by an 
improvement in overall survival when combined with standard chemotherapy e.g. in 
colorectal cancer.
16,17 Beside that, there are also trials with Ecteinascidin-743 (ET-743; also 
known as trabectedin and Yondelis), an isolated, purified, and synthesized extract of the 
Caribbean marine tunicate Ecteinascidia turbinata. ET-743 would inhibit cell proliferation 
and be potent against a variety of soft tissue sarcoma cell lines, even those resistant to many 
other cytotoxic agents.
18 
With the improved treatment of aggressive cancers such as soft tissue sarcomas, the number 
of cancer survivors is increasing gradually and they reach a higher age. This has several 
implications which may also lead to further insight into (genetic) cancer epidemiology.  
First, these patients often appear to be at increased risk of developing other malignancies later 
in life. This may either be due to chance occurrence thanks to increased life expectancy, or to 
environmental factors that also caused the first cancer or to long-term carcinogenicity of the 
therapy that was given for the first cancer. However, second malignancies might also occur 
due to the fact that the initial cancer arose as part of a genetic cancer predisposition. It can be 
expected that “new” hereditary cancer syndromes with only moderately increased cancer 
risks, will be delineated in the near future, if survivors of childhood cancer are monitored 
adequately. It will, however, need large datasets and long-term follow-up to establish these 
tentative cancer risk genes. 
132Future perspectives 
 
 
The second implication of improved cancer treatment and survival is that more patients will 
reach adulthood. Since in the treatment of cancer in children and young adults much attention 
is given to preserving fertility, these cancer survivors are now more often able to have 
children themselves. This may lead to a second way to recognize the possible genetic nature 
of their cancer (syndrome): if subsequently the same or related malignancies are diagnosed in 
their offspring. Long term follow-up data will be of great value here as well. 
The fact that increased life expectancy due to improved treatment enables the occurrence of 
subsequent cancers in the same patient, is most clear in cases with ‘early onset’ cancers, e.g. 
retinoblastoma and soft tissue sarcoma. These types of cancer are however relatively rare in 
the general population. The same effect of improved prognosis can be expected in common 
cancers that are diagnosed at later age, such as colon cancer or breast cancer. Since these 
types of cancer are much more frequent, the contribution of second and third cancers in this 
population to general cancer incidence may become substantial. It is through longevity that 
we will be able to recognize underlying genetic predispositions to late-onset types of cancer in 
this population. These may be “high risk” genes that come to clinical expression at later age, 
but they may also be “moderate risk” genes with an gradually increasing age-related 
penetrance. In the view of increasing life expectancy in the general population, the 
contribution of such genes to the total cancer incidence and the implications in general 
practice and health care are hard to predict and deserve further research. 
Since many high-grade tumors morphologically manifest themselves as undifferentiated 
tumors, the identification of chromosomal aberrations may be important for the final 
diagnosis and classification. With the help of micro-array analysis, which allows the 
simultaneous study of the expression of thousands of genes, it may be possible to realize a 
new classification, better diagnostics, and more effective therapies in the near future.  
 
In essence, the new “radical” treatment for sarcomas involves radical resection, but also 
complex reconstruction and limb salvage techniques. Major contributions to this treatment 
approach include microvascular plastic surgery techniques, an increased emphasis on 
functionality, the development of prosthetic materials, neurovascular reconstruction, down-
staging with isolated limb perfusion, and the concept of limb remodelling and replantation. 
The development of new kinase inhibitors and new angiogenese inhibitors might change in 
the near future the treatment approach and outcome of locally advanced and disseminated soft 
tissue sarcomas. 
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“Radical” also becomes a more abstract term referring to a fundamental shift in our paradigms 
on cancer biology and the outcome of the patient, both oncologic and functional. 
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 Chapter 10 
Summary 
 
Chapter 1 
The outline and aim of this thesis are described in this chapter. The following questions will 
be answered in the various chapters: 
- Treatment options for radiation-induced sarcoma: what are the challenges in the treatment? 
- What is the role of surgery in the multidisciplinary treatment of soft tissue sarcoma? 
- During which periods, and through what causes, are patients at risk of losing an extremity 
with a locally advanced soft tissue sarcoma treated with isolated limb perfusion, surgery and 
radiotherapy? 
- Is adjuvant radiotherapy indicated after isolated limb perfusion and resection for patients 
with a primarily irresectable soft tissue sarcoma in an extremity? 
- What are the potentials of biological imaging in the prediction of long-term outcome of 
patients with a soft tissue sarcoma of the extremity treated with isolated limb perfusion? 
- Do soft tissue sarcoma perfusion survivors differ from the general population in terms of 
quality of life and do post traumatic stress symptoms occur that should be taken into 
account in the longer term? 
- Is the incidence of other primary tumors increased in patients with locally advanced soft 
tissue sarcoma of the extremities and does this affect long-term survival? 
 
Chapter 2  
Radiation-induced sarcomas are rare but extremely aggressive tumors that arise from a 
previous radiation site, often after a long period of time. The radiation was delivered to treat a 
either malignant or benign disease. 
Between 1987 and 2003, 27 patients were diagnosed with radiation-induced sarcoma. The 
median post-radiation period was 8 (range 3-41) years. Median radiation dose was 50 (range 
16-70) Gy. Five-year tumor-free survival rate and overall survival rate were 27 and 30%, 
respectively. Local recurrence rate after microscopic radical resection (=R0) was 54%. In the 
group as a whole, 41% of the patients developed distant metastases. Patients who had 
undergone R0 resection had a significantly better survival rate than patients who had 
undergone a microscopically positive resection (p=0.026). 
Radiation-induced sarcomas tend to recur locally and develop distant metastases. Radical 
resection is the only procedure for improving patient survival. Even in a palliative setting 
radical surgery may contribute to improve the quality of life. 
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Chapter 3 
The current treatment options of soft tissue sarcomas are described in this chapter. Combined 
modality treatment strategies are used in which the extend of local resection and the role of 
adjuvant radiation treatment are well defined. The optimal sequence of radiation and surgery 
remains complex. The introduction of hyperthermic isolated limb perfusion with Tumor 
Necrosis Factor alpha (TNFα) and melphalan was a breakthrough in limb salvage fom 
primarily irresectable soft tissue sarcomas. In the combined modality treatment, surgery still 
is the cornerstone of successful soft tissue sarcoma treatment. 
 
Chapter 4 
The long term limb salvage rate and the three time periods at risk for amputation of a limb 
with locally advanced soft tissue sarcoma after hyperthermic isolated limb perfusion with 
Tumor Necrosis Factor alpha (TNFα) and melphalan are described. 73 patients (36 male, 37 
female; median age 54 (range 14 – 80) years) with biopsy proven soft tissue sarcoma 
underwent 78 perfusions followed by delayed surgical resection, with or without adjuvant 
radiation. A total of 21 amputations (28%) were performed. Overall 1, 5 and 10 years limb 
salvage was 80.1 ± 4.8, 68.2 ± 6.5% and 60.6 ± 9.2% respectively. The first period was within 
1½ year after perfusion due to massive necrosis or recurrent disease (n=17). The second time 
period was within five years with two amputations performed for late local recurrence. The 
third episode occurred ten years after perfusion, two amputations performed for critical leg 
ischemia. Another two patients developed a pathological fracture of the femur due to radiation 
osteonecrosis. All four patients received post-perfusion radiotherapy. 
 
Chapter 5 
Can radiotherapy be given in combination with regional perfusion treatment for primary non-
resectable sarcomas of the extremities and is adjuvant radiotherapy indicated after isolated 
limb perfusion and resection of a soft tissue sarcoma? 
Between 1991 and 2003, 73 patients with a median age of 54 (range 14-80) years with a 
primary non-resectable soft tissue sarcoma were treated with isolated limb perfusion with 
Tumor Necrosis Factor alpha (TNFα) and melphalan. After a median period of 8 (range 2-15) 
weeks, the residual tumor mass was resected. Adjuvant external beam radiotherapy (EBRT) 
was given when the resection margins were marginally radically free (R0) or microscopically 
positive (R1). The aim of the study was the evaluation of the value of adjuvant radiotherapy. 
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Local recurrence was scored and calculated with the Kaplan-Meier method and the Log-rank 
test. After resection of the residual tumor mass, 58% of the patients were given EBRT 
(EBRT+ group), while 42% did not receive EBRT (EBRT- group). The median follow-up 
was 28 (range 2-159) months. There was significantly less local recurrence in the EBRT+ 
group than in the EBRT- group (p<0.0001). When only R0 resections in the non-metastasized 
patients were factored in, the difference remained significant (p=0.0003). In the EBRT- 
group, R1 or R2 resections resulted in earlier local recurrence than R0 resections (p=0.0475). 
Twelve patients presented with distant metastases at the time of the isolated limb perfusion 
(16%). During the follow-up, 25 patients (41%) developed distant metastases after an interval 
of nine months. The overall one-, five-, and ten-year survival rates were 83.1 ± 4.4%, 61.4 ± 
6.4% and 47.5 ± 7.5%, respectively. Adjuvant radiotherapy as part of the combined modality 
treatment of soft tissue sarcoma of the extremities with isolated limb perfusion improves local 
tumor control. It is indicated when the resection margins are marginally free or 
microscopically positive, and seems to be beneficial even after a so-called R0 resection. 
 
Chapter 6 
Little is known about the potentials of biological imaging with 18F-fluorodeoxyglucose 
(FDG) uptake in Positron Emission Tomography (PET) and its role in long-term predictions 
for patients with a primary non-resectable soft tissue sarcoma of the extremities. The patients 
in the study underwent isolated limb perfusion with Tumor Necrosis Factor alpha and 
melphalan, with ‘tumor kill’ as the objective: reduction of the tumor facilitating tumor 
resection. A group of 13 patients was given two FDG- PET scans: one before and one after 
islated limb perfusion, after which tumor resection followed. Univariate analysis showed that 
the overall survival in this selected group of 13 patients was longer for those whose maximum 
standardized uptake value (SUVmax) of FDG after perfusion was low than for those whose 
SUVmax was high (144 versus 33 months; p=0.0004). The multivariate analysis did not show 
a significant difference between the two groups, but there was a trend towards a difference in 
overall survival (p=0.08). 
Biological imaging seems a valuable instrument to gain insight into the effects of the 
treatment on the tumor, although it is currently not an ‘absolute predictor’ of the treatment 
outcome. 
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Chapter 7 
The study evaluates the quality of life and post traumatic stress symptoms (PTSS) in patients 
with a soft tissue sarcoma who were treated with isolated limb perfusion followed by 
resection and radiotherapy. The treatment objective was limb salvage, even though the tumor 
seemed primarily non-resectable. Surviving patients were asked to fill out questionnaires. The 
average period after perfusion was 7 (range 1-13) years. The response rate (39/41 patients) 
was 98%. The following validated questionnaires were used: the RAND 36 and the Impact of 
Event Scale (IES). No differences were found in mean scores between the sarcoma group and 
a group from the general population, except that the sarcoma patients reported poorer physical 
functioning. Patients who had undergone an amputation following ILP exhibited significantly 
worse physical and social functioning and more role limitations due to physical and emotional 
problems than sarcoma patients whose limbs had been saved. 
Eleven patients (28%) had a PTSS-score of 0, while eight patients (20.5%) had a score of 
>26. With such a high score, psychological counselling is recommended. The limb had not 
been amputated in this group of eight patients. Patients who indicated that the treatment mode 
had been chosen by the physician instead of by themselves or in consultation with the 
physician exhibited significantly poorer social functioning and more role limitations and 
intrusion. Greater satisfaction with the treatment was related to better social functioning, more 
vitality, better health perception, less intrusion, less avoidance, and less stress response 
symptoms. 
 
Chapter 8 
The purpose was to investigate the incidence of other primary neoplasms in patients with a 
locally advanced soft tissue sarcoma of the extremities and their effect on survival. Therefore 
a retrospective cohort of 73 patients, median age 54 (range 14-80) years diagnosed with 
locally advanced soft tissue sarcoma, all treated by isolated limb perfusion and delayed 
surgical resection was studied. Medical records were examined for clinical characteristics of 
the soft tissue sarcoma and other primary neoplasms, therapeutic interventions, morbidity and 
survival. 
Seventeen patients of the 73 treated with isolated limb perfusion (23%) had another primary 
neoplasm: 8 other primary neoplasms before soft tissue sarcoma-diagnosis (47%), 1 
synchronously, 1 between two other primary neoplasms, and 7 patients had another primary 
neoplasms after soft tissue sarcoma-diagnosis (41%). The median follow-up period after soft 
tissue sarcoma-diagnosis was 48 (4-162) months. The 5-year survival of the group with only a 
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non-metastasized soft tissue sarcoma (79 ± 13%) was not significantly different from the 
group with a soft tissue sarcoma before another primary neoplasms-diagnosis group (83 ± 
17%) (p=0.46). The 5-year survival rate of the group with another primary neoplasms before 
soft tissue sarcoma-diagnosis (13 ± 13%) was however significantly decreased versus the 
group with only a soft tissue sarcoma (P<0.0001). The most frequent types of other primary 
neoplasms were breast cancer, squamouscell carcinoma and urinary tract (kidney and bladder) 
cancer. 
The conclusion is that patients with locally advanced soft tissue sarcoma have a high risk to 
be diagnosed with another primary neoplasm. The overall survival in non-metastasized soft 
tissue sarcoma patients is significantly decreased if patients had another primary neoplasm 
before a soft tissue sarcoma. 
 
Chapter 9 
Perspectives about future and recent breakthroughs in diagnostic imaging and treatment of 
soft tissue sarcomas are described in this chapter such as three-dimensional images, PET-MRI 
combination, sentinel node biopsy for sarcomas, regional infusion, computer-assisted 
navigation systems to perform surgery, microvascular surgical reconstructive techniques, 
intensity modulated radiation therapy (IMRT), angiogenese and kinase inhibitors and new 
insights in (genetic) cancer epidemiology. 
 
Conclusion 
In the combined modality treatment of soft tissue sarcomas is surgery the cornerstone of 
successful treatment. Hyperthermic isolated limb perfusion with Tumor Necrosis Factor alpha 
(TNFα) and melphalan was a breakthrough in limb salvage for primarily irresectable soft 
tissue sarcomas. After this treatment, there are still three periods at risk for amputation due to 
massive necrosis, recurrent disease and critical leg ischemia. Adjuvant radiotherapy is 
indicated when resection margins are marginally free or microscopically positive, and seems 
to be beneficial even after microscopically negative resections. Even though ‘soft tissue 
sarcoma- survivors’ quality of life (QoL) was only different from a reference group in 
physical functioning, one fifth of the patients suffered from post traumatic stress symptoms 
(PTSS). An amputation, the physicians’ decision rather than the patients’ decision for the 
perfusion treatment and a low satisfaction with the performed treatment negatively influenced 
QoL. Patients with locally advanced soft tissue sarcoma have a high risk to be diagnosed with 
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another primary neoplasm. The overall survival in non-metastasized soft tissue sarcoma 
patients is significantly decreased if patients had another primary neoplasm before an soft 
tissue sarcoma. Biological imaging seems a valuable instrument to gain insight into the effects 
of the treatment on the tumor. Other ‘radical’ shifts in paradigms on cancer biology and the 
outcome of the patient both oncologic and functional will be the future of sarcoma treatment. 
A ‘radical’ operation will nevertheless remain the first step in a successful cancer treatment, 
more and more in a ‘combinded modality’ setting with pre-or postoperative radiotherapy 
and/or (neo)adjuvant chemotherapy. 
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Samenvatting 
 
Hoofdstuk 1 
De achtergronden en het doel van dit proefschrift worden in dit hoofdstuk beschreven. De 
volgende vraagstellingen in de achtereenvolgende hoofdstukken zullen worden samengevat: 
-  Behandelingsmogelijkheden van het radiatiesarcoom: waar ligt de uitdaging in de 
behandeling? 
- Wat is de rol van chirurgie in de multidisciplinaire behandeling van het weke-delen 
sarcoom? 
- Wat zijn de risicovolle tijdsperiodes en de oorzaken om een extremiteit met een uitgebreid 
lokaal weke-delen sarcoom te verliezen na geïsoleerde regionale perfusie, resectie en 
radiotherapie? 
- Is er indicatie voor adjuvante radiotherapie na geïsoleerde regionale perfusie en resectie 
voor patiënten met een primair irresectabel weke-delen sarcoom van een extremiteit? 
- Wat zijn de mogelijkheden van ‘biological imaging’ bij het voorspellen van resultaten op 
lange termijn voor patiënten met een weke-delen sarcoom in de extremiteiten die behandeld 
werden met geïsoleerde perfusie? 
- Verschilt de kwaliteit van het leven van de ‘soft tissue sarcoma perfusion survivors’ van de 
algemene bevolking en is er sprake van posttraumatische stress responssymptomen, waar op 
langere termijn rekening mee moet worden gehouden? 
- Is er een verhoogde incidentie van andere primaire tumoren bij patiënten met een uitgebreid 
lokaal sarcoom van de extremiteiten en heeft dit gevolgen op de langetermijnoverleving? 
 
Hoofdstuk 2 
Radiatiesarcomen zijn zeldzame, maar bijzonder agressieve tumoren die ontstaan in een 
eerder bestralingsveld, vaak na een lang tijdsinterval. Deze bestraling werd gegeven om een al 
dan niet kwaadaardige aandoening te behandelen. 
Tussen 1987 en 2003 werd bij 27 patiënten de diagnose radiatiesarcoom gesteld. Dat was 
gemiddeld (mediaan) 8 (spreiding 3-41) jaar na de bestraling. De mediane bestralingsdosis 
bedroeg 50 (spreiding 16-70) Gy. De vijfjaars ziektevrije overleving en de algehele 
overleving bedroeg respectievelijk 27 en 30 %. De kans op lokaal recidief na een 
microscopisch radicale resectie (=R0 resectie) bedroeg 54 %. In de hele groep ontwikkelde 41 
% van de patiënten afstandsmetastasen. Patiënten die een R0 resectie ondergingen, hadden 
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een significant betere overleving dan patiënten met een niet-microscopisch vrije resectie 
(p=0.026). 
Radiatiesarcomen hebben een grote tendens om lokaal te recidiveren en metastasen op afstand 
te ontwikkelen. Een radicale resectie is de enige kans om de overleving van de patiënten te 
verbeteren. Zelfs in een palliatieve setting kan radicale chirurgie bijdragen tot een verbetering 
van de kwaliteit van leven. 
 
Hoofdstuk 3 
De huidige behandelingsopties van het weke-delen sarcoom worden in dit hoofdstuk 
beschreven. In de gecombineerde modaliteitbehandeling strategieën zijn het belang van de 
lokale resectie en adjuvante radiotherapie duidelijk aangetoond. De optimale volgorde van 
radiotherapie en chirurgie blijft nog steeds een complexe zaak. Het invoeren van geïsoleerde 
regionale perfusie met Tumor Necrosis Factor alpha (TNFα) en melphalan was een doorbraak 
voor het behoud van de extremiteit bij het primair irresectabele weke-delen sarcoom. In de 
gecombineerde behandeling blijft chirurgie nog steeds een hoeksteen voor succesvolle 
behandeling van kwaadaardige tumoren van de weke-delen. 
 
Hoofdstuk 4 
De langetermijnresultaten van extremiteitsparende behandeling en de drie risicovolle 
tijdsperioden voor amputatie van een extremiteit met een uitgebreid lokaal weke-delen 
sarcoom die een hyperthermische geïsoleerde regionale perfusie met Tumor Necrosis Factor 
alpha (TNFα) en melphalan onderging, worden beschreven. 73 patiënten (36 mannen, 37 
vrouwen; mediane leeftijd van 54 (spreiding 14-80) jaar) met een histologisch bewezen weke-
delen sarcoom, ondergingen 78 perfusies, gevolgd door chirurgische resectie én al of niet 
aanvullende bestraling. In totaal werden 21 amputaties (28 %) verricht. De 1, 5 en 10 ‘limb 
salvage rate’ was respectievelijk 80.1 ± 4.8, 68.2 ± 6.5 % en 60.6 ± 9.2 %. De eerste 
risicovolle periode voor amputatie viel binnen 1.5 jaar na de perfusie ten gevolge van 
uitgebreide necrose of lokaal recidief (n=17). De tweede periode viel binnen een tijdsperiode 
van vijf jaar, waarin twee amputaties werden verricht wegens laatijdig lokaal recidief. In de 
derde episode, tien jaar na perfusie, werden twee amputaties verricht wegens ernstige 
ischemische schade van de extremiteit. Twee andere patiënten ontwikkelden een patholo-
gische fractuur ten gevolge van osteonecrose. Deze vier patiënten hadden allen radiotherapie 
gekregen na perfusie en resectie.  
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Hoofdstuk 5  
Kan radiotherapie in de regionale perfusiebehandeling van patiënten met een primair 
irresectabel sarcoom van de extremiteiten worden gegeven en wat is de plaats van adjuvante 
radiotherapie na geïsoleerde regionale perfusie en resectie van een weke-delen sarcoom? 
Van 1991 tot 2003 werden 73 patiënten met een mediane leeftijd van 54 (spreiding 14-80) 
jaar met een primair niet resectabel weke-delen sarcoom behandeld met geïsoleerde regionale 
perfusie met Tumor Necrosis Factor alpha (TNFα) en melphalan. Na een gemiddelde 
(mediane) periode van 8 (spreiding 2-15) weken werd de overgebleven tumor gereseceerd. 
Adjuvante radiotherapie (external beam radiotherapy, EBRT) werd in geval van krap radicaal 
vrije (R0) of microscopisch positieve (R1) resectiemarges gegeven. Het doel van de studie 
was de waarde van adjuvante radiotherapie te onderzoeken. Lokale recidieven werden 
gescoord en berekend met de Kaplan-Meier-methode en de Log-rank-test. Nadat de 
overgebleven tumor was gereseceerd, kregen 58 % van de patiënten bestraling (bestraling+ 
groep) en 42 % van de patiënten kregen geen bestraling (bestraling- groep). De gemiddelde 
(mediane) follow-up was 28 (spreiding 2-159) maanden. Er waren significant minder lokale 
recidieven in de bestraling+ groep vergeleken met de bestraling- groep (p<0.0001). Wanneer 
alleen R0-resecties in de niet-gemetastaseerde patiënten in beschouwing werden genomen 
bleef het verschil significant aanwezig (P=0.0003). In de bestraling- groep resulteerde een 
microscopisch niet radicale (R1) -resectie of macroscopisch niet radicale (R2) -resectie in een 
sneller optreden van lokaal recidief vergeleken met een resectie met vrije sneevlakken (R0-
resectie) (p=0.0475). Twaalf patiënten presenteerden zich met metastasen op afstand ten tijde 
van de geïsoleerde regionale perfusie (16 %). Gedurende de follow-up ontwikkelden 25 
patiënten (41 %) metastasen op afstand na een interval van negen maanden. De één, vijf- en 
tienjaars overleving was respectievelijk 83.1 ± 4.4 %, 61.4 ± 6.4 % and 47.5 ± 7.5 %. In de 
gecombineerde modaliteitsbehandeling van weke-delen sarcoom van de extremiteiten met 
geïsoleerde regionale perfusie verbetert adjuvante radiotherapie de lokale tumor controle. 
Adjuvante radiotherapie is geïndiceerd als de resectiemarges krap zijn of microscopisch niet 
vrij en lijkt eveneens een meerwaarde te hebben na een microscopisch vrije resectie. 
 
Hoofdstuk 6  
Er is weinig bekend over de mogelijkheden van ‘biological imaging’ met 18F-
Fluorodeoxyglucose (FDG)-uptake met behulp van Positron Emissie Tomografie (PET) en de 
rol hiervan bij langetermijnvoorspellingen voor patiënten met een primair irresectabel weke-
delen sarcoom van de extremiteiten. De patiënten ondergingen een geïsoleerde regionale 
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perfusie met Tumor Necrosis Factor alpha en melphalan met als doel ‘tumor kill’: verkleinen 
van de tumor en het vereenvoudigen van de resectie. Een groep van dertien patiënten kreeg 
twee FDG- PET scans: een vóór en een ná geïsoleerde regionale perfusie en voorafgaand aan 
de resectie van de tumor. De algehele overleving in deze geselecteerde groep van dertien 
patiënten was in de univariaat analyse langer indien de maximum gestandaardiseerde uptake 
waarde (=SUVmax) van de FDG-uptake na perfusie laag was in vergelijking met de groep 
waarbij de SUVmax hoog was (144 versus 33 maanden; p= 0.0004). Bij de 
multivariaatanalyse was er geen significant verschil tussen beide groepen, wel een trend voor 
een verschil in algehele overleving (p=0.08). 
Biologische beeldvorming lijkt een waardevol instrument om inzichten te krijgen in de 
effecten van behandeling op de tumor zonder daarbij op dit moment een ‘absolute 
voorspeller’ te zijn van de uiteindelijke uitkomst van de behandeling. 
 
Hoofdstuk 7  
De kwaliteit van leven en de posttraumatische stress responssymptomen (PTSS) bij een groep 
patiënten die met een weke-delen sarcoom werden behandeld met geïsoleerde regionale 
perfusie, gevolgd door resectie en bestraling werden onderzocht. Het doel van de behandeling 
was de extremiteit te behouden, niettegenstaande de tumor primair irresectabel leek. Het 
behoud van de extremiteit slaagde bij het merendeel van de onderzochte patiënten (77 %). 
Negenendertig nog in leven zijnde patiënten werden gevraagd vragenlijsten in te vullen. De 
gemiddelde (mediane) tijd na perfusie bedroeg bij hen 7 (spreiding 1-13) jaar. De respons rate 
bedroeg 98 %. Er werd gebruik gemaakt van gevalideerde vragenlijsten: de RAND 36 en de 
Impact of Event Scale (IES). Er werden geen verschillen gevonden in de gemiddelde scores 
tussen de bestudeerde ‘sarcoomgroep’ en een referentiegroep, behalve dat de ‘sarcoomgroep’ 
fysiek slechter functioneerde. Patiënten die een amputatie ondergingen, functioneerden zowel 
fysiek als sociaal significant slechter en ze hadden meer fysieke en emotionele rolbeperkingen 
dan sarcoompatiënten waarbij de extremiteit gespaard kon blijven.  
Elf patiënten (28 %) hadden een PTSS-score van nul, acht patiënten (20.5 %) een score >26. 
Bij deze hoge score wordt psychologische ondersteuning geadviseerd. Bij geen van deze acht 
patiënten was een extremiteit geamputeerd. Patiënten die aangaven dat de keuze van 
behandeling gemaakt was door hun arts in plaats van door henzelf of in samenspraak, 
functioneerden achteraf sociaal significant slechter en hadden meer rolbeperkingen en 
intrusie. Een grotere tevredenheid met de behandeling was gerelateerd met beter sociaal 
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functioneren, meer vitaliteit, een betere gezondheidsperceptie, minder intrusie, minder 
vermijdingsgedrag en minder stress responssymptomen. 
 
Hoofdstuk 8 
Het opzet was de incidentie van andere primaire tumoren te onderzoeken bij patiënten met 
een uitgebreid lokaal weke-delen sarcoom van de extremiteiten en het effect van de andere 
primaire tumor op de overleving. Daarom werd een retrospectieve cohort van 73 patiënten, 
gediagnosticeerd met een uitgebreid lokaal weke-delen sarcoom op de gemiddelde (mediane) 
leeftijd van 54 (spreiding 14-80) jaar en behandeld met geïsoleerde regionale perfusie van de 
extremiteit gevolgd door chirurgische resectie, bestudeerd. Medische dossiers werden 
nagekeken op klinische karakteristieken van het weke-delen sarcoom en de andere primaire 
tumor, de uitgevoerde behandeling, morbiditeit en overleving. 
Zeventien patiënten van de 73 die behandeld waren met geïsoleerde regionale perfusie (23 %) 
hadden een andere primaire tumor: 8 hadden een andere primaire tumor vóór de diagnose van 
het weke-delen sarcoom (47 %), 1 synchroon, 1 had een weke-delen sarcoom tussen twee 
andere primaire tumoren in, en 7 hadden een andere primaire tumor na de diagnose van het 
weke-delen sarcoom (41 %). De mediane follow-up periode na de diagnose van het weke-
delen sarcoom was 48 (4-162) maanden. De 5-jaars overleving van groep met een niet-
gemetastaseerd weke-delen sarcoom zonder een andere primaire tumor (79 ± 13 %) was niet 
significant verschillend van de groep die een weke-delen sarcoom vóór de andere primaire 
tumor hadden (83 ± 17 %) (p=0.46). De 5-jaarsoverleving van de groep met een andere 
primaire tumor vóór de weke-delen sarcoom (13 ± 13 %) daarentegen was significant minder 
versus de groep met alleen een weke-delen sarcoom (P<0.0001). De frequentst voorkomende 
vormen andere primaire tumor waren borstkanker, plaveiselcelcarcinoom en tumoren van de 
urinewegen (nier en blaas). 
De conclusie is dat patiënten met een uitgebreid lokaal weke-delen sarcoom een hoog risico 
hebben om gediagnosticeerd te worden met een andere primaire tumor. De overleving in niet-
gemetastaseerde weke-delen sarcoom-patiënten was significant minder als patiënten al een 
andere primaire tumor hadden vóór de diagnose van het weke-delen sarcoom. 
 
Hoofdstuk 9 
Perspectieven over toekomstige en recente doorbraken in beeldvorming en behandeling van 
het weke-delen sarcoom worden in dit hoofdstuk beschreven zoals driedimensionele 
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beeldvorming, PET-MRI combinatie, schildwachtklierbiopsie voor weke-delen sarcomen, 
regionale infusie, computer geassisteerde navigatie systemen tijdens chirurgische ingrepen, 
microvasculaire reconstructieve chirurgische technieken, ‘intensity modulated radiation 
therapy’ (IMRT), angiogenese en kinase inhibitoren en nieuwe inzichten in (genetische) 
kankerepidemiologie. 
 
Conclusie 
In de gecombineerde behandeling van weke-delen sarcomen is chirurgie de hoeksteen van een 
succesvolle behandeling. Hyperthermische geïsoleerde perfusie van een extremiteit met 
Tumor Necrosis Factor alpha (TNFα) en melphalan was een doorbraak voor het behoud van 
de extremiteit bij primair irresectabele weke-delen sarcomen. Na deze behandeling zijn er nog 
drie risicovolle tijdsperioden voor amputatie ten gevolge van uitgebreide necrose, lokaal 
recidief en ernstige ischemische schade van een extremiteit. Adjuvante radiotherapie is 
aangewezen wanneer de resectiemarges krap zijn of microscopisch niet vrij en lijkt zelfs een 
meerwaarde te hebben na een microscopisch vrije resectie. Alhoewel de levenskwaliteit van 
de in leven zijnde patiënten die een weke-delen sarcoom hebben gehad alleen in fysiek 
functioneren verschilt van een referentiegroep, lijdt een vijfde van hen aan posttraumatische 
stress responssymptomen (PTSS). Een amputatie, de behandelingskeuze voor de perfusie door 
de arts eerder dan door de patiënt en lage tevredenheid over de uitgevoerde behandeling 
beïnvloedden de kwaliteit van leven negatief. Patiënten met een uitgebreid lokaal weke-delen 
sarcoom lopen een hoog risico om gediagnosticeerd te worden met een andere primaire 
tumor. De overleving van patiënten met een niet-gemetastaseerd weke-delen sarcoom was 
significant minder als patiënten al een andere primaire tumor vóór de diagnose van het weke-
delen sarcoom hadden. 
Biologische beeldvorming lijkt een waardevol instrument om inzicht te krijgen in de effecten 
van de tumorbehandeling. Andere ‘radicale’ verschuivingen in paradigma’s van de 
kankerbiologie en de gevolgen voor de patiënt, zowel op oncologisch als functioneel gebied, 
zullen in de toekomst de behandeling van weke-delen sarcomen bepalen. Een ‘radicale’ 
operatie zal niettemin de eerste stap in een succesvolle kankerbehandeling blijven, meer en 
meer in een ‘combined modality’ setting met pre- of postoperatieve radiotherapie en/of 
(neo)adjuvante chemotherapie. 
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Plukker en Dr. J. de Vries voor cruciale chirurgisch-oncologische inzichten die ze mij 
toevertrouwden. 
 
Via een sarcomenpoli kreeg mijn onderzoek meer houvast. Voor deze poli was de hulp van 
Jan Loonstra, Prof. Dr. J.H.B. Geertzen, Eke Sijtsema en Miranda Hollander onontbeerlijk. 
Ik bedank ook de patiënten die hebben meegewerkt aan dit onderzoek. Een groot deel van de 
prospectief vergaarde data van deze ‘sarcomenpoli’ werd nog niet in dit proefschrift 
opgenomen. Dat volgt nog.  
 
De samenwerking met de afdelingen pathologie, radiotherapie, medische oncologie, 
psychologie, nucleaire geneeskunde en klinische genetica verliep aangenaam en was 
verrijkend. Vooral Dr. A.J. Suurmeijer, Dr. E. Pras, Dr. W.T.A.Van der Graaf, Dr. J.E.H.M. 
Hoekstra-Weebers, Dr. P.L. Jager en Dr. J.C. Oosterwijk waren daar verantwoordelijk voor. 
 
Ook bedank ik Prof. Dr. J. Oldhoff en Prof. Dr. H. Schraffordt Koops. Zij hebben de eerste 
stappen in Groningen gezet in de behandeling van sarcomen met geïsoleerde regionale 
perfusie. Daarnaast Prof. dr. F.J. Lejeune voor zijn baanbrekend werk op het gebied van de 
toepassing van TNF bij de regionale perfusie en zijn adviezen ten tijde van zijn visiting 
professorship in Groningen in 2004. Het was dankzij hun pionierswerk dat dit 
langetermijnonderzoek kon plaatsvinden. De dwerg op de schouder van reuzen krijgt vaak 
uitstekend (in)zicht. 
 
Een gemeenschappelijke chivo-kamer is niet voor alle aspecten de ideale plaats om parttime-
onderzoek te doen, maar het is wel leuk. Ik bedank mijn medechivo’s en fellows, Han 
Hegeman, Jan Willem Daemen, Annelies Kemper, Jorrit Harbers, Pieter Lubbert, Edwin van 
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der Zaag, Koen Reijnders, Marco Waleboer en Johannes Wegdam voor hun collegialiteit en 
hun mooie verhalen uit ‘the real world’. Ook de andere stafleden en assistenten maakten mijn 
Groningse periode waardevol en ook erg aangenaam. 
 
Anderen die ik wil bedanken zijn Esther Bastiaannet, Lucas Been en Marten Kapma voor hun 
bijdrage in het onderzoek. Tevens bedank ik de chirurgische secretaresses, de telefonistes en 
de mensen achter de ICT-helplijn van het UMCG voor hun kundigheid waarmee ze me met 
persisterende vriendelijkheid hielpen in opspeuracties naar personen en oplossingen voor 
computerraadsels. 
 
De leden van de beoordelingscommissie, bestaande uit Prof. Dr. J.H.B. Geertzen, Prof. Dr. 
Th. Wiggers en Prof. Dr. I. De Wever, wil ik graag bedanken voor de tijd en aandacht die zij 
hebben vrijgemaakt voor de beoordeling van dit proefschrift. 
 
Mijn paranimfen Stephanie Breukink en Bibi Hansson bedank ik. Zij hebben al bewezen dat 
ze goed kunnen feestvieren. Ik hoop dat ze de traditie kunnen voortzetten op 19 april. 
 
Klassiek bij een dankwoord hoort ook de dank voor de liefelijke steun van je levensgezel die 
je thee en koekjes bracht tijdens je ietwat asociaal schrijfgezwoeg. Wel, dit deel is er niet. Het 
scheelt dat ik boven een supermarkt woonde en de aanvoer van (meer dan) thee en koekjes 
niet echt lastig was. Maar het zou onterecht zijn al mijn vrienden te vergeten die afwisselend 
en soms op onnavolgbare en onvoorspelbare wijze mijn leven binnen struikelen en er vaak 
een leuke meerwaarde aan geven. Ik hoef hen niet op te sommen. Ze kennen hun eigen naam 
wel. 
 
Mijn ouders wil ik enorm bedanken omdat ze mij - ondanks de vreemde oorden waar ik 
naartoe trok en de wat merkwaardige uitdagingen die ik aanging - steeds ten volle hebben 
gesteund en vertrouwd. Zonder hen was ik er niet, in de dubbele betekenis van het woord. 
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